

CITATION REPORT

List of articles citing

Accuracy of clinical diagnosis of idiopathic Parkinson's disease: a clinico-pathological study of 100 cases

DOI: 10.1136/jnnp.55.3.181

Journal of Neurology, Neurosurgery and Psychiatry,
1992, 55, 181-4.

Source: <https://exaly.com/paper-pdf/23363988/citation-report.pdf>

Version: 2024-04-24

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
2258	The dopaminergic response in multiple system atrophy. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 1992 , 55, 1009-13	5.5	118
2257	Hereditary Lewy-body parkinsonism and evidence for a genetic etiology of Parkinson's disease. 1992 , 2, 309-20		20
2256	Lack of pyramidal tract signs in Parkinson's disease. 1992 , 340, 125		1
2255	Parkinson's disease: one illness or many syndromes?. 1992 , 339, 1263-4		8
2254	Growth hormone response to clonidine in central and peripheral primary autonomic failure. 1992 , 340, 263-6		38
2253	Diffuse Lewy body disease presenting with supranuclear gaze palsy, parkinsonism, and dementia: a case report. 1992 , 7, 355-8		67
2252	Idiopathic torsion dystonia. 1992 , 7, 387-8		5
2251	The oxidant stress hypothesis in Parkinson's disease: evidence supporting it. 1992 , 32, 804-12		803
2250	Letters to the editor. 1993 , 8, 527-531		
2249	The detection of preclinical Parkinson's disease: what is the role of positron emission tomography?. 1993 , 8, 271-7		43
2248	Striatonigral degeneration with neurofibrillary tangles. 1993 , 86, 405-10		7
2247	Selective anosmia in Parkinson's disease?. 1993 , 341, 435-436		66
2246	Functional imaging in relation to parkinsonian syndromes. 1993 , 115, 1-17		81
2245	Possible time-dependent sensitization to xenobiotics: self-reported illness from chemical odors, foods, and opiate drugs in an older adult population. 1993 , 48, 315-27		44
2244	Accuracy of clinical diagnosis of idiopathic Parkinson's disease. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 1993 , 56, 938-9	5.5	33
2243	Accuracy of clinical diagnosis of idiopathic Parkinson's disease.. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 1993 , 56, 939-939	5.5	
2242	Herpes simplex encephalitis in a patient with complex partial epilepsy: confirmation by the polymerase chain reaction with necropsy studies. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 1993 , 56, 937-8	5.5	1

2241	Significance of parkinsonian manifestations in essential tremor. 1993 , 20, 114-7		110
2240	Differential diagnosis of Parkinson's disease, multiple system atrophy, and Steele-Richardson-Olszewski syndrome: discriminant analysis of striatal 18F-dopa PET data. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 1994 , 57, 278-84	5.5	127
2239	HMPAO SPECT in Parkinson's disease before and after levodopa: correlation with dopaminergic responsiveness. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 1994 , 57, 180-5	5.5	27
2238	Parkinson's disease. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 1994 , 57, 672-81	5.5	314
2237	Motor response to levodopa in patients with parkinsonian motor fluctuations: a follow-up study over three years. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 1994 , 57, 430-4	5.5	27
2236	Does selegiline delay progression of Parkinson's disease? A critical re-evaluation of the DATATOP study. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 1994 , 57, 217-20	5.5	52
2235	Multiple system atrophy: natural history, MRI morphology, and dopamine receptor imaging with 123IBZM-SPECT. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 1994 , 57, 1047-56	5.5	152
2234	Signs of Madness: Towards a Cognitive Account of the Clinical Features of Schizophrenia. 1994 , 47, 497-516		2
2233	Genetic factors in the etiology of idiopathic Parkinson's disease. 1994 , 8, 1-37		27
2232	Cerebrospinal fluid ferritin levels of patients with Parkinson's disease, Alzheimer's disease, and multiple system atrophy. 1994 , 7, 109-14		32
2231	Immunoreactivity profile of hippocampal CA2/3 neurites in diffuse Lewy body disease. 1994 , 87, 269-76		130
2230	Hypokinesia of associated movement in Parkinson's disease: a symptom in early stages of the disease. 1994 , 241, 517-21		15
2229	Early onset Parkinson's disease: are juvenile- and young-onset different?. 1994 , 9, 539-44		35
2228	Case 2, 1994: parkinsonism and cognitive impairment. 1994 , 9, 679-86		3
2227	Comparison of clinical state, retrospective informant interview and the neuropathologic diagnosis of alzheimer's disease. 1994 , 9, 233-236		26
2226	Autosomal dominant Lewy body parkinsonism in a four-generation family. 1994 , 35, 59-64		146
2225	Alzheimer's disease and Lewy body disease: a comparative clinicopathological study. 1994 , 35, 81-8		149
2224	Oxidative stress: free radical production in neural degeneration. 1994 , 63, 37-122		406

2223	Diagnosis and treatment of Parkinson's disease in the elderly. 1994 , 9, 583-9	5
2222	Striatal, Accumbent, and Nigral Degeneration with Rosenthal Fibers, Presenting as Shy-Drager Syndrome. 1994 , 14, 67-71	
2221	Platelet morphology in Parkinson's disease: an electron microscopic study. 1994 , 122, 84-9	16
2220	Positron emission tomography and central neurotransmitter systems in movement disorders. 1994 , 8, 503-17	6
2219	Stability of cell size and nucleolar size in Lewy body containing neurons of substantia nigra in Parkinson's disease. 1994 , 637, 339-41	43
2218	Striatonigral degeneration: iron deposition in putamen correlates with the slit-like void signal of magnetic resonance imaging. 1994 , 21, 311-8	50
2217	Positron emission tomography: applications to the investigation of movement disorders. 1994 , 24, 433-40	
2216	Magnetic resonance imaging of neurodegenerative diseases. 1994 , 4, 146-58	11
2215	Autonomic failure, depression and anxiety in Parkinson's disease. 1995 , 166, 789-92	52
2214	The results, indications, and physiology of posteroventral pallidotomy for patients with Parkinson's disease. 1995 , 36, 1118-25; discussion 1125-7	169
2213	Apolipoprotein E genotype and Lewy body disease. 1995 , 45, 97-103	82
2212	Olfactory function in atypical parkinsonian syndromes. 1995 , 91, 247-50	192
2211	A prospective study of depression in French patients with Parkinson's disease. The Depar study. 1995 , 2, 455-61	2
2210	Differentiation of multiple system atrophy from idiopathic Parkinson's disease using proton magnetic resonance spectroscopy. 1995 , 37, 204-10	154
2209	Concentrations of amyloid beta protein in cerebrospinal fluid of patients with Alzheimer's disease. 1995 , 37, 277-9	81
2208	The subacute levodopa test for evaluating long-duration response in Parkinson's disease. 1995 , 38, 389-95	52
2207	Abnormal vestibuloocular reflex cancellation in multiple system atrophy and progressive supranuclear palsy but not in Parkinson's disease. 1995 , 10, 163-70	17
2206	Patterns of regional cerebral blood flow in corticobasal degeneration studied using HMPAO SPECT; comparison with Parkinson's disease and normal controls. 1995 , 10, 179-87	88

2205	Does levodopa therapy delay death in Parkinson's disease? A review of the evidence. 1995 , 10, 250-6		63
2204	Screening Parkinson's disease: a validated questionnaire of high specificity and sensitivity. 1995 , 10, 643-9		59
2203	Parkinsonism and dilatation of the perivascular spaces (lat cribl) of the striatum: a clinical, magnetic resonance imaging, and pathological study. 1995 , 10, 754-60		30
2202	Localized proton NMR spectroscopy in the striatum of patients with idiopathic Parkinson's disease: a multicenter pilot study. 1995 , 33, 589-94		84
2201	Parkinson's disease--medical education and psychosocial aspects. 1995 , 26, 71-9		28
2200	CSF somatostatin increase in patients with early parkinsonian syndrome. 1995 , 9, 189-96		8
2199	Progression of motor and cognitive impairment in Parkinson's disease. 1995 , 242, 535-40		22
2198	The classification and nomenclature of autonomic disorders--ending chaos, resolving conflict and hopefully achieving clarity. 1995 , 5, 307-10		39
2197	[Treatment of Parkinson disease]. 1995 , 53, 1-10		2
2196	Magnetic resonance spectroscopic study of parkinsonism related to boxing. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 1995 , 58, 688-91	5.5	38
2195	The impact of genetic and environmental factors on the pathobiology of Alzheimer's disease: a multifactorial disorder?. 1995 , 7, 361-383		2
2194	Which factors predict cognitive decline in Parkinson's disease?. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 1995 , 58, 51-5	5.5	46
2193	Clinicopathological study of 35 cases of multiple system atrophy. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 1995 , 58, 160-6	5.5	169
2192	Magnetic resonance spectroscopic study of parkinsonism related to boxing. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 1995 , 59, 561-2	5.5	2
2191	The relation between bradykinesia and excitability of the motor cortex assessed using transcranial magnetic stimulation in normal and parkinsonian subjects. 1995 , 97, 169-78		39
2190	Is there a genetic susceptibility to idiopathic parkinsonism?. 1995 , 1, 73-84		6
2189	Apomorphine in patients with Parkinson's disease. 1995 , 49, 197-209		36
2188	Contingent negative variation and movement-related cortical potentials in parkinsonism. 1995 , 95, 346-9		43

2187	Concurrence of Alzheimer's disease, Parkinson's disease, diffuse Lewy body disease, and amyotrophic lateral sclerosis. 1995 , 128, 219-24	29
2186	Levodopa-induced local cerebral blood flow changes in Parkinson's disease and related disorders. 1995 , 128, 212-8	33
2185	Parkinson's disease and the environment in early life. 1995 , 132, 201-6	54
2184	A clinical and genetic study of familial cases of Parkinson's disease. 1995 , 133, 164-72	23
2183	'Lewy body disease': clinico-pathological correlations in 18 consecutive cases of Parkinson's disease with and without dementia. 1995 , 97, 13-22	66
2182	Movement-related potential measures of different modes of movement selection in Parkinson's disease. 1996 , 140, 67-74	24
2181	The GTP-cyclohydrolase I gene in atypical parkinsonian patients: a clinico-genetic study. 1996 , 141, 27-32	18
2180	Prevalence of parkinsonian signs and associated mortality in a community population of older people. 1996 , 334, 71-6	537
2179	Lewy bodies are located preferentially in limbic areas in diffuse Lewy body disease. 1996 , 212, 111-4	66
2178	The human homologue of the weaver mouse gene in familial and sporadic Parkinson's disease. 1996 , 72, 877-9	20
2177	Age-standardized incidence and prevalence of Parkinson's disease in a Swedish community. 1996 , 49, 637-41	77
2176	Proton magnetic resonance spectroscopy of the striatum in Parkinson's disease patients with motor response fluctuations. 1996 , 2, 63-7	15
2175	Midbrain neuropathology in idiopathic Parkinson's disease and diffuse Lewy body disease. 1996 , 3, 52-60	82
2174	Oxidative stress: Free radical production in neural degeneration. 1996 , 425-509	0
2173	Parkinson's disease. 1996 , 85, 528-9	
2172	Consensus statement on the definition of orthostatic hypotension, pure autonomic failure and multiple system atrophy. 1996 , 6, 125-6	273
2171	Comparison of cerebral atrophy evaluated by MRI in Parkinson's disease and multiple system atrophy. 1996 , 3, 429-437	
2170	Prevalence of a history of shaking in persons 65 years of age and older: diagnostic and functional correlates. 1996 , 11, 63-9	68

2169	Reliability of patient completion of the historical section of the Unified Parkinson's Disease Rating Scale. 1996 , 11, 185-92		68
2168	Occupation, education, and Parkinson's disease: a case-control study in an Italian population. 1996 , 11, 201-6		32
2167	Clinical course of patients with idiopathic Parkinson's disease. 1996 , 11, 236-42		85
2166	Basal ganglia iron content in Parkinson's disease measured with magnetic resonance. 1996 , 11, 243-9		78
2165	Sympathetic skin response and R-R interval variability in multiple system atrophy and idiopathic Parkinson's disease. 1996 , 11, 268-72		53
2164	Case 1, 1996: rapidly progressive parkinsonism, incontinence, impotency, and levodopa-induced moaning in a patient with multiple myeloma. 1996 , 11, 298-310		18
2163	Quantitative gait analysis in patients with vascular parkinsonism. 1996 , 11, 501-8		60
2162	Dietary lipids and antioxidants in Parkinson's disease: a population-based, case-control study. 1996 , 39, 89-94		230
2161	Dynamic properties of horizontal and vertical eye movements in parkinsonian syndromes. 1996 , 39, 368-77	157	
2160	Abnormalities of smooth eye and head movement control in Parkinson's disease. 1996 , 39, 749-60		55
2159	Serotonin and the extrapyramidal system âa neurological perspective. 1996 , 11, S95-S102		6
2158	Mitochondrial NADH dehydrogenase and CYP2D6 genotypes in Lewy-body parkinsonism. 1996 , 44, 174-83		38
2157	Tremor and voluntary repetitive movement in Parkinson's disease: comparison before and after L-dopa with positron emission tomography. 1996 , 107, 453-62		27
2156	Patient characteristics, MRI examination, and dopaminergic drug response in clinical possible Parkinson's disease. 1996 , 9, 157-63		
2155	Motor response to acute dopaminergic challenge with apomorphine and levodopa in Parkinson's disease: implications for the pathogenesis of the on-off phenomenon. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 1996 , 60, 634-7	5.5	60
2154	Effects of intravenous L-dopa on P300 and regional cerebral blood flow in parkinsonism. 1996 , 85, 147-54		25
2153	Frequency of the apolipoprotein E epsilon 4 allele in a case-control study of early onset Parkinson's disease. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 1996 , 61, 347-51	5.5	22
2152	Neuropsychological and psychiatric differences between Alzheimer's disease and Parkinson's disease with dementia. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 1996 , 61, 381-7	5.5	57

2151	How far are we in understanding the cause of Parkinson's disease?. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 1996 , 61, 4-16	5.5	46
2150	Tachykinins, neurotrophism and neurodegenerative diseases: a critical review on the possible role of tachykinins in the aetiology of CNS diseases. 1996 , 7, 187-214		26
2149	Olfactory dysfunction in Parkinson's disease. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 1997 , 62, 436-46	5.5	268
2148	Parkinson's disease. 1997 , 73, 257-64		16
2147	Motor and cognitive function in Lewy body dementia: comparison with Alzheimer's and Parkinson's diseases. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 1997 , 62, 243-52	5.5	137
2146	Prevalence of orthostatic hypotension in Parkinson's disease. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 1997 , 63, 584-9	5.5	243
2145	Parkinson's Disease. 1997 , 216-245		6
2144	Disturbed striatoprefrontal mediated visual behaviour in moderate to severe parkinsonian patients. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 1997 , 63, 296-9	5.5	37
2143	Measurement environment for diagnosing the Parkinson's disease.		
2142	Electrophysiological analysis of cognitive slowing in Parkinson's disease. 1997 , 149, 47-56		38
2141	Dementia with lewy bodies: a study of post-synaptic dopaminergic receptors with iodine-123 iodobenzamide single-photon emission tomography. 1997 , 24, 609-14		53
2140	Parkinson's disease. 1997 , 20, 769-90		28
2139	Use of apomorphine in parkinsonian patients with neuropsychiatric complications to oral treatment. 1997 , 3, 103-7		47
2138	Point of view: Dementia in Parkinson's disease. 1997 , 3, 151-8		12
2137	Association of slow acetylator genotype for N-acetyltransferase 2 with familial Parkinson's disease. 1997 , 350, 1136-9		110
2136	Identification of Spanish familial Parkinson's disease and screening for the Ala53Thr mutation of the alpha-synuclein gene in early onset patients. 1997 , 235, 57-60		61
2135	Association of the mitochondrial tRNAA4336G mutation with Alzheimer's and Parkinson's diseases. 1997 , 23, 315-321		54
2134	SPECT findings in Alzheimer's disease and Parkinson's disease with dementia. 1997 , 4, 231-236		

2133	Is the SF-36 health survey questionnaire suitable as a self-report measure of the health status of older adults with Parkinson's disease?. 1997 , 6, 213-6	27
2132	Mitochondrial DNA polymorphisms in pathologically proven Parkinson's disease. 1997 , 244, 262-5	45
2131	Is seborrhea a sign of autonomic impairment in Parkinson's disease?. 1997 , 104, 1295-304	44
2130	Psychoses: diagnosis and treatment in the elderly. 1997 , 1997, 53-70	5
2129	Is there a genetic susceptibility locus for Parkinson's disease on chromosome 22q13?. 1997 , 41, 813-7	30
2128	Short-term levodopa test assessed by movement time accurately predicts dopaminergic responsiveness in Parkinson's disease. 1997 , 12, 103-6	38
2127	Prevalence of Parkinson's disease in Junĭ, Buenos Aires Province, Argentina. 1997 , 12, 197-205	65
2126	Clinical and pharmacological differences in early- versus late-onset Parkinson's disease. 1997 , 12, 277-84	52
2125	Dopa-responsive, nonprogressive juvenile parkinsonism: report of a case. 1997 , 12, 453-6	8
2124	Sleep benefit in Parkinson's disease. 1997 , 12, 506-8	63
2123	The 'common deletion' is not increased in parkinsonian substantia nigra as shown by competitive polymerase chain reaction. 1997 , 12, 639-45	21
2122	Proton magnetic resonance spectroscopy in Steele-Richardson-Olszewski syndrome. 1997 , 12, 767-71	80
2121	Postprandial hypotension and parkinsonian state in Parkinson's disease. 1997 , 12, 877-84	46
2120	Unilateral parkinsonism following a large infarct in the territory of the lenticulostriate arteries. 1997 , 12, 1086-90	32
2119	Apolipoprotein E genotyping in patients with neurodegenerative diseases. 1997 , 30, 405-11	5
2118	Concentration-response relationship of levodopa in patients at different stages of Parkinson's disease. 1998 , 64, 183-91	36
2117	Ala30Pro mutation in the gene encoding alpha-synuclein in Parkinson's disease. 1998 , 18, 106-8	3295
2116	Olfactory evoked responses and identification tests in neurological disease. 1998 , 855, 608-15	70

2115	Low dosage clozapine effects on L-dopa induced dyskinesias in parkinsonian patients. 1998 , 97, 295-9	39
2114	EEG findings in patients with vascular parkinsonism. 1998 , 98, 243-7	14
2113	Early detection of Parkinson's disease through automatic movement evaluation. 1998 , 17, 81-8	12
2112	Genetic dissection of familial Parkinson's disease. 1998 , 4, 438-44	25
2111	The role of spectroscopy in parkinsonism. 1998 , 13, 2-4	1241
2110	Depression in classic versus akinetic-rigid Parkinson's disease. 1998 , 13, 29-33	178
2109	Ropinirole in the treatment of early Parkinson's disease: a 6-month interim report of a 5-year levodopa-controlled study. 056 Study Group. 1998 , 13, 39-45	234
2108	Genetic aspects of Parkinson's disease. 1998 , 13, 203-11	35
2107	Late components of the event-related potentials and their topography in Parkinson's disease. 1998 , 13, 262-7	22
2106	Differential diagnosis of parkinsonism with [18F]fluorodeoxyglucose and PET. 1998 , 13, 268-74	92
2105	123I-beta-CIT and 123I-IBZM-SPECT scanning in levodopa-naive Parkinson's disease. 1998 , 13, 438-45	39
2104	Do visual-evoked potentials and spatiotemporal contrast sensitivity help to distinguish idiopathic Parkinson's disease and multiple system atrophy?. 1998 , 13, 446-52	20
2103	Confirmation of the antidyskinetic effect of posteroventral pallidotomy by means of an intraoperative apomorphine test. 1998 , 13, 533-5	5
2102	Normal frontal perfusion in patients with frozen gait. 1998 , 13, 677-83	36
2101	Parkinsonism with HIV infection. 1998 , 13, 684-9	119
2100	An akinetic-rigid syndrome, depression, and stereotypies in a young man. 1998 , 13, 835-44	5
2099	Simplified neuropathological diagnosis of dementia with Lewy bodies. 1998 , 24, 195-201	25
2098	Analysis of the alpha-synuclein G209A mutation in familial Parkinson's disease. 1998 , 351, 37-8	48

2097	Methodological and research issues in the evaluation of biological diagnostic markers for Alzheimer's disease. 1998 , 19, 121-3	6
2096	Increased cerebrospinal fluid levels of neurofilament protein in progressive supranuclear palsy and multiple-system atrophy compared with Parkinson's disease. 1998 , 13, 70-7	124
2095	Movement quality of repetitive self-paced single joint rapid arm movements on Parkinson's disease: acute effect of 1-dopa. 1998 , 4, 31-7	4
2094	Mutation in the alpha-synuclein gene and sporadic Parkinson's disease, Alzheimer's disease, and dementia with lewy bodies. 1998 , 153, 164-6	24
2093	Genetic and environmental risk factors in Parkinson's disease. 1998 , 100, 15-26	58
2092	Differentiation of idiopathic Parkinson's disease from striatonigral degeneration and progressive supranuclear palsy using iodine-123 meta-iodobenzylguanidine myocardial scintigraphy. 1998 , 155, 60-7	221
2091	Clinical pharmacology of dopamine agonists in Parkinson's disease. 1998 , 13, 381-9	18
2090	Utility of the apolipoprotein E genotype in the diagnosis of Alzheimer's disease. Alzheimer's Disease Centers Consortium on Apolipoprotein E and Alzheimer's Disease. 1998 , 338, 506-11	449
2089	Genetic epidemiology of Parkinson's disease. 1998 , 11, 98-106	30
2088	Verbal fluency task affects gait in Parkinson's disease with motor freezing. 1998 , 11, 181-5	109
2087	Clinical and genetic aspects of progressive supranuclear palsy. 1998 , 11, 107-14	26
2086	Neuropsychological prediction of dementia in Parkinson's disease. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 1998 , 64, 178-83	5.5 149
2085	Cognitive Impairment Without Dementia in Parkinson's Disease. 1998 , 343-350	
2084	Diagnosis and Epidemiology of Parkinson's Disease. 1998 , 3, 23-35	1
2083	A new approach to the genetic analysis of nervous system diseases: retrospective genotyping of archival brains. 1998 , 117, 307-13	1
2082	Continuous Spinal Anesthesia for Hip Surgery in a Patient with Shy-Drager Syndrome. 1998 , 87, 396-399	10
2081	Continuous spinal anesthesia for hip surgery in a patient with Shy-Drager syndrome. 1998 , 87, 396-9	10
2080	Increased basal ganglia iron in striatonigral degeneration: in vivo estimation with magnetic resonance. 1998 , 25, 44-7	29

2079	Neuropathology of Movement Disorders. 1998 , 9, 237-262		20
2078	Targeted expression of a toxin gene to D1 dopamine receptor neurons by cre-mediated site-specific recombination. 1998 , 18, 9845-57		58
2077	Etiology of parkinsonism in a Brazilian movement disorders clinic. 1998 , 56, 171-5		25
2076	Genetics, drugs and environmental factors in Parkinson's disease. A case-control study. 1999 , 57, 347-55		33
2075	Mechanisms underlying gait disturbance in Parkinson's disease: a single photon emission computed tomography study. 1999 , 122 (Pt 7), 1271-82		232
2074	Improvement of levodopa induced dyskinesias by thalamic deep brain stimulation is related to slight variation in electrode placement: possible involvement of the centre median and parafascicularis complex. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 1999 , 67, 308-14	5.5	88
2073	Evidence for cortical dysfunction in clinically non-demented patients with Parkinson's disease: a proton MR spectroscopy study. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 1999 , 67, 20-6	5.5	49
2072	Effect of interstimulus interval on visual P300 in Parkinson's disease. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 1999 , 67, 497-503	5.5	18
2071	The sydney multicentre study of Parkinson's disease: progression and mortality at 10 years. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 1999 , 67, 300-7	5.5	256
2070	Historical and clinical features of psychogenic tremor: a review of 70 cases. 1999 , 26, 190-5		89
2069	Differential diagnosis of parkinsonism. 1999 , 26 Suppl 2, S1-4		5
2068	Proprioceptive regulation of voluntary ankle movements, demonstrated using muscle vibration, is impaired by Parkinson's disease. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 1999 , 67, 504-10	5.5	67
2067	Impairment of EEG desynchronisation before and during movement and its relation to bradykinesia in Parkinson's disease. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 1999 , 66, 442-6	5.5	38
2066	(123)I-metaiodobenzylguanidine myocardial scintigraphy in Parkinson's disease. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 1999 , 67, 189-94	5.5	257
2065	Progressive supranuclear palsy (Steele-Richardson-Olszewski disease). 1999 , 75, 579-84		27
2064	Acute and chronic effects of anteromedial globus pallidus stimulation in Parkinson's disease. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 1999 , 67, 315-22	5.5	30
2063	Silver staining method for demonstrating Lewy bodies in Parkinson's disease and argyrophilic oligodendrocytes in multiple system atrophy. 1999 , 87, 111-5		26
2062	MRI evaluation of brain iron in earlier- and later-onset Parkinson's disease and normal subjects. 1999 , 17, 213-22		187

2061	Mitochondrial myopathies and encephalomyopathies. 1999 , 29, 886-98	31
2060	Exercise test in Parkinson's disease. 1999 , 9, 129-34	21
2059	New, selective catechol-O-methyltransferase inhibitors as therapeutic agents in Parkinson's disease. 1999 , 81, 1-36	78
2058	Magnetic resonance imaging-based volumetry differentiates idiopathic Parkinson's syndrome from multiple system atrophy and progressive supranuclear palsy. 1999 , 45, 65-74	232
2057	Enhanced lateral premotor activity during paradoxical gait in Parkinson's disease. 1999 , 45, 329-36	184
2056	Increased susceptibility to sporadic Parkinson's disease by a certain combined alpha-synuclein/apolipoprotein E genotype. 1999 , 45, 611-7	245
2055	A data-driven approach to the study of heterogeneity in idiopathic Parkinson's disease: identification of three distinct subtypes. 1999 , 14, 10-20	117
2054	Nutritional and occupational factors influencing the risk of Parkinson's disease: a case-control study in southeastern Sweden. 1999 , 14, 28-37	192
2053	Apomorphine induces changes in GPi spontaneous outflow in patients with Parkinson's disease. 1999 , 14, 45-9	97
2052	The vulnerability of nigral neurons to Parkinson's disease is unrelated to their intrinsic capacity for dopamine synthesis: an in situ hybridization study. 1999 , 14, 206-18	28
2051	Worsening of levodopa-induced dyskinesias by motor and mental tasks. 1999 , 14, 242-5	33
2050	Parkinsonism associated with Sjögren's syndrome: three cases and a review of the literature. 1999 , 14, 262-8	41
2049	Bradykinesia and impairment of EEG desynchronization in Parkinson's disease. 1999 , 14, 423-9	87
2048	Phosphorus magnetic resonance spectroscopy in multiple system atrophy and Parkinson's disease. 1999 , 14, 430-5	58
2047	Prevalence of Parkinson's disease in lower Aragon, Spain. 1999 , 14, 596-604	36
2046	Evolution of motor fluctuations in Parkinson's disease: a longitudinal study over 6 years. 1999 , 14, 605-11	40
2045	Motor cortex activation in Parkinson's disease: dissociation of electrocortical and peripheral measures of response generation. 1999 , 14, 790-9	44
2044	Environmental risk factors in Parkinson's disease. 1999 , 14, 928-39	92

2043	Neuroendocrine responses to levodopa in multiple system atrophy (MSA). 1999 , 14, 981-7	20
2042	Evaluation of a screening questionnaire for genetic studies of Parkinson's disease. 1999 , 88, 539-543	74
2041	Dopaminergic Dysfunction in Parkinsonism: New Lessons from Imaging. 1999 , 5, 333-340	7
2040	Parkinson's disease--a multifactorial neurodegenerative disorder. 1999 , 56, 113-25	30
2039	Central motor conduction time in Parkinson's disease. 1999 , 6, 17-19	3
2038	Astrocytes and microglia in the substantia nigra and caudate-putamen in Parkinson's disease. 1999 , 5, 115-22	26
2037	Genetic predisposition plays a role in nigral cell death in Parkinson's disease. 1999 , 5, 169-72	1
2036	Event-related potentials reveal memory deficits in Parkinson's disease. 1999 , 8, 165-72	17
2035	Neurogenetic correlates of Parkinson's disease: apolipoprotein-E and cytochrome P450 2D6 genetic polymorphism. 1999 , 266, 149-51	37
2034	The Ile93Met mutation in the ubiquitin carboxy-terminal-hydrolase-L1 gene is not observed in European cases with familial Parkinson's disease. 1999 , 270, 1-4	67
2033	Exclusion of dominant mutations within the FTDP-17 locus on chromosome 17 for Parkinson's disease. 1999 , 272, 140-2	2
2032	Apolipoprotein E polymorphisms and Parkinson's disease. 1999 , 277, 83-6	17
2031	[Genetics of Parkinson disease]. 1999 , 20, 709-14	4
2030	Atypical parkinsonism in the French West Indies. 1999 , 354, 1473	1
2029	Possible relation of atypical parkinsonism in the French West Indies with consumption of tropical plants: a case-control study. Caribbean Parkinsonism Study Group. 1999 , 354, 281-6	197
2028	Unilateral pallidotomy in Parkinson's disease: a randomised, single-blind, multicentre trial. 1999 , 354, 1665-9	135
2027	Clinical disorders of the autonomic nervous system associated with orthostatic intolerance: an overview of classification, clinical evaluation, and management. 1999 , 22, 798-810	87
2026	Clinical manifestations of Parkinson's disease. 1999 , 83, 327-47	24

2025	Visual event-related potential changes at two different tasks in nondemented Parkinson's disease. 1999 , 164, 139-47	18
2024	Pathologic heterogeneity in clinically diagnosed corticobasal degeneration. 1999 , 53, 795-800	392
2023	Single-photon emission computed tomography of the dopamine transporter in parkinsonism. 1999 , 9, 223-8	9
2022	Towards neurotransplantation in multiple system atrophy: clinical rationale, pathophysiological basis, and preliminary experimental evidence. 2000 , 9, 279-88	35
2021	The effect of amantadine on levodopa-induced dyskinesias in Parkinson's disease: a double-blind, placebo-controlled study. 2000 , 23, 82-5	118
2020	[123I] beta-CIT binding and SPET compared with clinical diagnosis in parkinsonism. 2000 , 21, 417-24	10
2019	Correlation between tapping and inserting of pegs in Parkinson's disease. 2000 , 27, 311-5	48
2018	The utility of neuroSPECT imaging in the investigation of dementia and parkinsonism. 2000 , 17, 96-99	0
2017	Anal sphincter EMG does not distinguish between multiple system atrophy and Parkinson's disease. 2000 , 23, 731-4	47
2016	Quantitative electromyography of the external anal sphincter in Parkinson's disease and multiple system atrophy. 2000 , 23, 1250-6	51
2015	A single nucleotide polymorphism of dopamine transporter gene is associated with Parkinson's disease. 2000 , 47, 528-531	35
2014	Parkin is associated with actin filaments in neuronal and nonneuronal cells. 2000 , 48, 737-744	63
2013	The dopamine D2 receptor gene is a susceptibility locus for Parkinson's disease. 2000 , 15, 127-31	104
2012	Objective quantification of resting and activated parkinsonian rigidity: a comparison of angular impulse and work scores. 2000 , 15, 48-55	47
2011	Pallidotomy and quality of life in patients with Parkinson's disease: an early study. 2000 , 15, 65-70	46
2010	Postural and action myoclonus in patients with parkinsonian type multiple system atrophy. 2000 , 15, 77-83	54
2009	Motor unit changes in sporadic idiopathic Parkinson's disease. 2000 , 15, 238-43	16
2008	Accurate differentiation of parkinsonism and essential tremor using visual assessment of [I]-FP-CIT SPECT imaging: The [I]-FP-CIT study group. 2000 , 15, 503-510	551

2007	Chronic effects of dopaminergic replacement on cognitive function in Parkinson's disease: a two-year follow-up study of previously untreated patients. 2000 , 15, 613-26		134
2006	Disruption of spatial organization and interjoint coordination in Parkinson's disease, progressive supranuclear palsy, and multiple system atrophy. 2000 , 15, 627-40		26
2005	The Bradykinesia Akinesia Incoordination Test (BRAIN TEST), an objective and user-friendly means to evaluate patients with parkinsonism. 2000 , 15, 641-7		40
2004	The effect of exercise on pharmacokinetics and pharmacodynamics of levodopa. 2000 , 15, 862-8		39
2003	5-HT _{2C} receptor binding is increased in the substantia nigra pars reticulata in Parkinson's disease. 2000 , 15, 1064-9		57
2002	Dilated perivascular spaces in the putamen and pallidum in patients with Parkinson's disease scheduled for pallidotomy: a comparison between MRI findings and clinical symptoms and signs. 2000 , 15, 1139-44		28
2001	[¹²³ I]beta-CIT SPECT in multiple system atrophy, progressive supranuclear palsy, and corticobasal degeneration. 2000 , 15, 1158-67		172
2000	Basal ganglia metabolite concentrations in idiopathic Parkinson's disease and multiple system atrophy measured by proton magnetic resonance spectroscopy. 2000 , 7, 661-5		51
1999	Juvenile parkinsonism: a heterogeneous entity. 2000 , 7, 467-71		11
1998	Loss of dopamine uptake sites and dopamine D ₂ receptors in striatonigral degeneration. 2000 , 852, 228-32		10
1997	Lack of autonomic nervous dysfunction in progressive supranuclear palsy, a study of blood pressure variability. 2000 , 10, 309-12		13
1996	Hallucinations, REM sleep, and Parkinson's disease: a medical hypothesis. 2000 , 55, 281-8		397
1995	Systematic review of acute levodopa and apomorphine challenge tests in the diagnosis of idiopathic Parkinson's disease. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2000 , 69, 590-4	5.5	52
1994	Cognitive impairment in Parkinson's disease. 2000 , 12, 281-289		11
1993	Immunocytochemical, ultrastructural and neurochemical evidences on synaptogenesis and dopamine release of rat chromaffin cells co-cultured with striatal neurons. 2000 , 59, 170-4		2
1992	Cortical dysfunction in non-demented Parkinson's disease patients: a combined (³¹ P)-MRS and (¹⁸ F)FDG-PET study. 2000 , 123 (Pt 2), 340-52		185
1991	Pharmacological treatment of Parkinson's disease. 2000 , 76, 602-10		26
1990	Mismatch between electrophysiologically defined and ventriculography based theoretical targets for posteroventral pallidotomy in Parkinson's disease. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2000 , 69, 787-91	5.5	10

1989	Progressive supranuclear palsy. 2000 , 76, 333-6		25
1988	Progression of Hoehn and Yahr stages in Parkinsonian disorders: a clinicopathologic study. 2000 , 55, 888-91		92
1987	Neuropsychological follow up in patients with Parkinson's disease, striatonigral degeneration-type multisystem atrophy, and progressive supranuclear palsy. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2000 , 69, 313-8	5.5	89
1986	What clinical features are most useful to distinguish definite multiple system atrophy from Parkinson's disease?. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2000 , 68, 434-40	5.5	176
1985	Parkinsonism and Epilepsy: Case Report and Reappraisal of an Old Question. 2000 , 1, 128-130		17
1984	Proton magnetic resonance spectroscopy of patients with parkinsonism. 2000 , 52, 589-95		68
1983	Test-retest reliability of an epidemiological instrument for Parkinson's disease. 2000 , 53, 863-5		8
1982	Levodopa in plasma correlates with body weight of parkinsonian patients. 2000 , 6, 171-173		46
1981	Construction of freezing of gait questionnaire for patients with Parkinsonism. 2000 , 6, 165-170		517
1980	Levodopa motor complications in Parkinson's disease. 2000 , 23, S2-7		333
1979	Goal-directed secondary motor tasks: their effects on gait in subjects with Parkinson disease. 2000 , 81, 110-6		156
1978	Neuropsychiatric aspects of Parkinson's disease. 2000 , 41, 15-23		78
1977	Reduced striatal dopamine transporters in idiopathic rapid eye movement sleep behaviour disorder. Comparison with Parkinson's disease and controls. 2000 , 123 (Pt 6), 1155-60		332
1976	Prospects for the treatment of Parkinson's disease using neural grafts. 2000 , 1, 889-902		10
1975	Efectividad y seguridad de la palidotomía posteroventral en el tratamiento de la enfermedad de Parkinson avanzada. 2000 , 114, 205-208		
1974	VOIDING DYSFUNCTION AND PARKINSON'S DISEASE: URODYNAMIC ABNORMALITIES AND URINARY SYMPTOMS. 2000 , 164, 1640-1643		165
1973	The effect of transcranial magnetic stimulation on reaction time in progressive supranuclear palsy. 2000 , 111, 2008-13		16
1972	Parkinson's disease impairs the ability to change set quickly. 2000 , 175, 57-70		115

1971	Differentiation of Parkinson's disease and multiple system atrophy in early disease stages by means of I-123-MIBG-SPECT. 2000 , 175, 3-12	199
1970	Short-term motor improvement after sub-threshold 5-Hz repetitive transcranial magnetic stimulation of the primary motor hand area in Parkinson's disease. 2000 , 178, 91-4	129
1969	Choice reaction time after levodopa challenge in parkinsonian patients. 2000 , 181, 98-103	24
1968	Delay of simple reaction time after levodopa intake. 2001 , 112, 2133-7	23
1967	Pharmacokinetic-pharmacodynamic relationship of levodopa with and without tolcapone in patients with Parkinson's disease. 2001 , 40, 383-93	31
1966	Risk factors of Parkinson's disease in Indian patients. 2001 , 190, 49-55	100
1965	Single photon emission CT and positron emission tomography in the evaluation of neurologic disease. 2001 , 39, 1007-33	10
1964	[Genetics in Parkinson's disease: toward a new nosological era]. 2001 , 116, 614-6	
1963	The frissonnant mutant mouse, a model of dopamino-sensitive, inherited motor syndrome. 2001 , 8, 447-58	10
1962	Plasma von Willebrand factor activities in vascular Parkinsonism: comparison with Parkinson's disease. 2001 , 10, 227-30	2
1961	Levodopa responsive Parkinsonism in adults with Angelman Syndrome. 2001 , 8, 421-2	34
1960	Olanzapine for the treatment of psychosis in patients with Parkinson's disease and dementia. 2001 , 42, 477-81	34
1959	A comparison of (18)F-dopa PET and inversion recovery MRI in the diagnosis of Parkinson's disease. 2001 , 56, 1195-200	69
1958	Comparative analysis of the gait disorder of normal pressure hydrocephalus and Parkinson's disease. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2001 , 70, 289-97	5.5 224
1957	Recognition memory in normal aging and Parkinson's disease: behavioral and electrophysiologic measures. 2001 , 11, 23-32	21
1956	Tolcapone increases plasma catecholamine levels in patients with Parkinson's disease. 2001 , 7, 93-96	13
1955	Familial occurrence of Parkinson's disease in a community-based case-control study. 2001 , 7, 297-303	14
1954	Contributions of PET and SPECT to the understanding of the pathophysiology of Parkinson's disease. 2001 , 31, 321-40	50

1953	Parkinson's disease: clinical features, epidemiology and genetics. 2001 , 19, 565-78, vi	26
1952	Lumping and splitting the Parkinson Plus syndromes: dementia with Lewy bodies, multiple system atrophy, progressive supranuclear palsy, and cortical-basal ganglionic degeneration. 2001 , 19, 607-27, vi	30
1951	[Sporadic and familial Parkinson's disease: comparative study]. 2001 , 116, 601-4	1
1950	Syncope resulting from autonomic insufficiency syndromes associated with orthostatic intolerance. 2001 , 85, 457-72	20
1949	Health-related quality of life and healthcare utilisation in patients with Parkinson's disease: impact of motor fluctuations and dyskinesias. 2001 , 19, 1013-38	89
1948	5: Movement disorders I: parkinsonism and the akinetic-rigid syndromes. 2001 , 174, 357-63	2
1947	Striatal dopamine transporter binding in early to moderately advanced Parkinson's disease: monitoring of disease progression over 2 years. 2001 , 22, 721-5	56
1946	Imaging of the dopaminergic system in parkinsonism with SPET. 2001 , 22, 819-27	30
1945	Methylphenidate increases the motor effects of L-Dopa in Parkinson's disease: a pilot study. 2001 , 24, 208-13	37
1944	The -141C Ins/Del polymorphism of the dopamine D2 receptor gene is not associated with either migraine or Parkinson's disease. 2001 , 11, 49-52	34
1943	Chapter 9 Clinical Trials in Parkinson's Disease. 2001 , 173-199	
1942	The optimal imaging time for [99Tcm]TRODAT-1/SPET in normal subjects and patients with Parkinson's disease. 2001 , 22, 151-4	26
1941	CYP2D6*4 polymorphism is not associated with Parkinson's disease and has no protective role against Alzheimer's disease in the Korean population. 2001 , 55, 373-7	22
1940	Systematic review of proton magnetic resonance spectroscopy of the striatum in parkinsonian syndromes. 2001 , 8, 573-7	73
1939	Parkinson's and migraine. 2001 , 21, 706-7	1
1938	Mutations in the alpha-synuclein gene in Parkinson's disease among Indians. 2001 , 103, 120-2	22
1937	Vascular parkinsonism: a distinct, heterogeneous clinical entity. 2001 , 104, 63-7	94
1936	Cardiovascular effects of domperidone in patients with Parkinson's disease treated with apomorphine. 2001 , 104, 92-6	12

1935	Phenotypic characterisation of autosomal recessive PARK6-linked parkinsonism in three unrelated Italian families. 2001 , 16, 999-1006	57
1934	CYP2D6 polymorphism in Parkinson's disease: the Rotterdam Study. 2001 , 16, 290-3	13
1933	Cardiovascular reflex testing contributes to clinical evaluation and differential diagnosis of Parkinsonian syndromes. 2001 , 16, 217-25	67
1932	69-year-old man with gait disturbance and Parkinsonism. 2001 , 16, 548-61	1
1931	The tau A0 allele in Parkinson's disease. 2001 , 16, 442-7	51
1930	Association of REM sleep behavior disorder and neurodegenerative disease may reflect an underlying synucleinopathy. 2001 , 16, 622-30	489
1929	Effect of sleep deprivation on motor performance in patients with Parkinson's disease. 2001 , 16, 616-21	27
1928	Novel observations with FDOPA-PET imaging after early nigrostriatal damage. 2001 , 16, 838-48	33
1927	Gastric emptying time and gastric motility in patients with Parkinson's disease. 2001 , 16, 1041-7	218
1926	Rigidity decreases resting tremor intensity in Parkinson's disease: A [(123)I]beta-CIT SPECT study in early, nonmedicated patients. 2001 , 16, 1033-40	19
1925	Clinical features of parkinsonian patients with the alpha-synuclein (G209A) mutation. 2001 , 16, 1007-13	78
1924	Parkinson's disease is not associated with the combined β synuclein/apolipoprotein E susceptibility genotype. 2001 , 49, 665-668	64
1923	Metabolic enzyme expression in dopaminergic neurons in Parkinson's disease: an in situ hybridization study. 2001 , 50, 142-9	14
1922	Case-Control study of the extended tau gene haplotype in Parkinson's disease. 2001 , 50, 658-61	48
1921	Stroke and idiopathic Parkinson's disease: does a shortage of dopamine offer protection against stroke?. 2001 , 16, 119-23	41
1920	Loss of olfaction in de novo and treated Parkinson's disease: possible implications for early diagnosis. 2001 , 16, 41-6	224
1919	The auditory startle reaction in parkinsonian disorders. 2001 , 16, 62-71	89
1918	Quality of life in Parkinson's disease: Greek translation and validation of the Parkinson's disease questionnaire (PDQ-39). 2001 , 10, 159-63	27

1917	Do P1 and N1 evoked by the ERP task reflect primary visual processing in Parkinson's disease?. 2001 , 102, 1-9		23
1916	Differential expression and tissue distribution of parkin isoforms during mouse development. 2001 , 130, 173-81		29
1915	Neural transplantation therapies for Parkinson's and Huntington's diseases. 2001 , 6, 575-582		4
1914	Outcome of unilateral pallidotomy in advanced Parkinson's disease: cohort study of 32 patients. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2001 , 71, 375-82	5.5	31
1913	Association of single-nucleotide polymorphisms of the tau gene with late-onset Parkinson disease. 2001 , 286, 2245-50		135
1912	Barriers to treatment: the unique challenges for physicians providing dementia care. 2001 , 14, 188-98		20
1911	Clinical phenotype in patients with alpha-synuclein Parkinson's disease living in Greece in comparison with patients with sporadic Parkinson's disease. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2001 , 70, 662-5	5.5	50
1910	Prospective study of hallucinations and delusions in Parkinson's disease. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2001 , 70, 734-8	5.5	228
1909	Effects of levodopa on pulmonary function in Parkinson's disease. 2001 , 119, 387-93		63
1908	Bilateral pallidotomy for treatment of Parkinson's disease induced corticobulbar syndrome and psychic akinesia avoidable by globus pallidus lesion combined with contralateral stimulation. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2001 , 71, 611-4	5.5	53
1907	Prevalence and correlates of parkinsonism in patients with primary depression. 2001 , 57, 553-5		13
1906	Failed suppression of direct visuomotor activation in Parkinson's disease. 2001 , 13, 31-43		129
1905	Effect of levodopa on orthostatic and postprandial hypotension in elderly Parkinsonian patients. 2001 , 56, M749-55		36
1904	Demography and Epidemiology of Age-Associated Neuronal Impairment. 2001 , 31-50		2
1903	Anosmia in dementia is associated with Lewy bodies rather than Alzheimer's pathology. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2001 , 70, 739-43	5.5	92
1902	The Parkinson's Disease Activities of Daily Living Scale: a new simple and brief subjective measure of disability in Parkinson's disease. 2001 , 15, 241-6		72
1901	The genetic basis of Parkinson's disease. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2002 , 73, 363-70	5.5	47
1900	Incidence and prediction of falls in Parkinson's disease: a prospective multidisciplinary study. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2002 , 72, 721-5	5.5	431

1899	Two large British kindreds with familial Parkinson's disease: a clinico-pathological and genetic study. 2002 , 125, 44-57		22
1898	Guadeloupean parkinsonism: a cluster of progressive supranuclear palsy-like tauopathy. 2002 , 125, 801-11		137
1897	Global attentional-executive sequelae following surgical lesions to globus pallidus interna. 2002 , 125, 562-74		43
1896	14-3-3 proteins in Lewy bodies in Parkinson disease and diffuse Lewy body disease brains. 2002 , 61, 245-53		119
1895	Where does parkinson disease pathology begin in the brain?. 2002 , 61, 413-26		508
1894	Dissociation of habit-learning in Parkinson's and cerebellar disease. 2002 , 14, 493-9		58
1893	Differentiation of dementia with Lewy bodies from Alzheimer's disease using a dopaminergic presynaptic ligand. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2002 , 73, 134-40	5.5	204
1892	Differentiating multiple system atrophy from Parkinson's disease: contribution of striatal and midbrain MRI volumetry and multi-tracer PET imaging. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2002 , 73, 517-23	5.5	164
1891	Neuroimaging in dementia with Lewy bodies: metabolism, neurochemistry, and morphology. 2002 , 15, 200-9		31
1890	Expression polymorphism of the blood-brain barrier component P-glycoprotein (MDR1) in relation to Parkinson's disease. 2002 , 12, 529-34		168
1889	Motor circuitry re-organization after pallidotomy in Parkinson disease: a neurophysiological study of the Bereitschaftspotential, contingent negative variation, and N30. 2002 , 19, 553-61		10
1888	Motor response to apomorphine in patients with Parkinson's disease with long-duration response to levodopa. 2002 , 25, 119-21		1
1887	Clinical aspects of Parkinson disease. 2002 , 15, 457-60		52
1886	Parkinsonian syndromes and differential diagnosis. 2002 , 15, 461-6		10
1885	Tapping and peg insertion after levodopa intake in treated and de novo parkinsonian patients. 2002 , 29, 73-7		20
1884	Neuromelanin in the human brain: a review and atlas of pigmented cells in the substantia nigra. 2002 , 110, 257-369		16
1883	Body weight influences pharmacokinetics of levodopa in Parkinson's disease. 2002 , 25, 79-82		54
1882	Increased red blood cell polyamines in ALS and Parkinson's disease. 2002 , 177, 515-20		38

1881	Expression of MMP-2, MMP-9, and MMP-1 and their endogenous counterregulators TIMP-1 and TIMP-2 in postmortem brain tissue of Parkinson's disease. 2002 , 178, 13-20	102
1880	Lewy body-free nigral degeneration--a case report. 2002 , 198, 97-100	3
1879	Abnormalities of rate-corrected QT intervals in Parkinson's disease-a comparison with multiple system atrophy and progressive supranuclear palsy. 2002 , 199, 31-7	51
1878	The nature of the autonomic dysfunction in multiple system atrophy. 2002 , 200, 1-10	42
1877	Neurophysiological correlate of clinical signs in Parkinson's disease. 2002 , 113, 792-805	62
1876	The accuracy of diagnosis of parkinsonian syndromes in a specialist movement disorder service. 2002 , 125, 861-70	933
1875	Olfactory function in Parkinsonian syndromes. 2002 , 9, 521-4	130
1874	PARK3 influences age at onset in Parkinson disease: a genome scan in the GenePD study. 2002 , 70, 1089-95	81
1873	Age at onset in two common neurodegenerative diseases is genetically controlled. 2002 , 70, 985-93	262
1872	Genome screen to identify susceptibility genes for Parkinson disease in a sample without parkin mutations. 2002 , 71, 124-35	150
1871	Neurodegeneration, parkinsonian syndromes and autonomic failure. 2002 , 96, 50-8	10
1870	Dual SPECT of dopamine system using [99mTc]TRODAT-1 and [123I]IBZM in normal and 6-OHDA-lesioned formosan rock monkeys. 2002 , 29, 561-7	33
1869	Motor unit number estimates in idiopathic Parkinson's disease. 2002 , 8, 161-4	22
1868	Quantification of the dopaminergic response in Parkinson's disease. 2002 , 8, 181-6	19
1867	Apomorphine delays simple reaction time in Parkinsonian patients. 2002 , 8, 357-60	10
1866	Kinetic tremor during tracking movements in patients with Parkinson's disease. 2002 , 8, 361-8	7
1865	Parkinson's genetics--creating exciting new insights. 2002 , 8, 459-64	4
1864	Idiopathic Parkinson's disease(s) may follow subclinical episodes of perivenous demyelination. 2002 , 59, 762-9	4

1863	Parkinson's genetics: molecular insights for the new millennium. 2002 , 23, 503-14	17
1862	The tau H1 haplotype is associated with Parkinson's disease in the Norwegian population. 2002 , 322, 83-6	61
1861	Metabolic alterations in Parkinson's disease after thalamotomy, as revealed by 1H MR spectroscopy. 2002 , 3, 180-8	11
1860	Frontal atrophy correlates with behavioural changes in progressive supranuclear palsy. 2002 , 125, 789-800	115
1859	Intact artificial grammar learning in patients with cerebellar degeneration and advanced Parkinson's disease. 2002 , 40, 1534-40	51
1858	Selective changes in the levels of nicotinic acetylcholine receptor protein and of corresponding mRNA species in the brains of patients with Parkinson's disease. 2002 , 956, 358-66	50
1857	Progressive supranuclear palsy: where are we now?. 2002 , 1, 359-69	120
1856	Age at onset of Parkinson disease and apolipoprotein E genotypes. 2002 , 107, 156-61	51
1855	Park6-linked parkinsonism occurs in several european families. 2002 , 51, 14-18	81
1854	Combined effect of age and severity on the risk of dementia in Parkinson's disease. 2002 , 51, 722-9	163
1853	Applications of neural network analyses to in vivo 1H magnetic resonance spectroscopy of Parkinson disease patients. 2002 , 16, 13-20	23
1852	Clinical-pathological study of levodopa complications. 2002 , 17, 289-96	106
1851	Combination of dopamine transporter and D2 receptor SPECT in the diagnostic evaluation of PD, MSA, and PSP. 2002 , 17, 303-12	159
1850	Phenotypic variability in a large kindred (Family LA) with deletions in the parkin gene. 2002 , 17, 424-6	26
1849	Trunk movement in Parkinson's disease during rising from seated position. 2002 , 17, 274-82	40
1848	Do risk factors for Alzheimer's disease predict dementia in Parkinson's disease? An exploratory study. 2002 , 17, 250-7	48
1847	Field validation of a method for population screening of parkinsonism. 2002 , 17, 258-64	13
1846	Bilateral pallidotomy in Parkinson's disease: a retrospective study. 2002 , 17, 533-8	51

1845	Repairing the brain in Parkinson's disease: where next?. 2002 , 17, 233-41	27
1844	[123I]beta-CIT SPECT distinguishes vascular parkinsonism from Parkinson's disease. 2002 , 17, 518-23	82
1843	Diagnosing Parkinson's disease using videotaped neurological examinations: validity and factors that contribute to incorrect diagnoses. 2002 , 17, 513-7	26
1842	Accuracy of acute levodopa challenge for clinical prediction of sustained long-term levodopa response as a major criterion for idiopathic Parkinson's disease diagnosis. 2002 , 17, 795-8	63
1841	Parkinsonism in multiple system atrophy: natural history, severity (UPDRS-III), and disability assessment compared with Parkinson's disease. 2002 , 17, 701-9	61
1840	Genetics of parkinsonism. 2002 , 17, 645-56	87
1839	Clinical correlates of the pathology underlying parkinsonism: a population perspective. 2002 , 17, 910-6	62
1838	Effect of medication on EMG patterns in individuals with Parkinson's disease. 2002 , 17, 950-60	56
1837	Survival duration of Parkinson's disease patients living in Greece who carry the G209A alpha-synuclein mutation. 2002 , 17, 847-8	4
1836	Diagnosing multiple system atrophy with greater accuracy: combined analysis of the clonidine-growth hormone test and external anal sphincter electromyography. 2002 , 17, 1242-7	19
1835	Motor response to levodopa and the evolution of motor fluctuations in the first decade of treatment of Parkinson's disease. 2002 , 17, 1227-34	49
1834	An imaging study of parkinsonism among African-Caribbean and Indian London communities. 2002 , 17, 1321-8	13
1833	Parkinson's disease and dementia with Lewy bodies: one disease or two?. 2002 , 17, 1161-5	56
1832	Memory and executive function impairment predict dementia in Parkinson's disease. 2002 , 17, 1221-6	189
1831	Application of the International Cooperative Ataxia Scale rating in multiple system atrophy. 2002 , 17, 1248-54	41
1830	Can SPET imaging of dopamine uptake sites replace PET imaging in Parkinson's disease? For. 2002 , 29, 711-4	51
1829	Influence of benzodiazepines on antiparkinsonian drug treatment in levodopa users. 2002 , 105, 8-12	6
1828	Anti-GM1 ganglioside antibodies in Parkinson's disease. 2002 , 106, 54-7	48

1827	Vascular parkinsonism--neuropathological findings. 2002 , 105, 414-5	12
1826	Lack of association between an estrogen receptor 1 gene polymorphism and Parkinson's disease with dementia. 2002 , 106, 128-30	14
1825	Beta-CIT-SPECT combined with UPDRS appears to distinguish different parkinsonian conditions. 2002 , 105, 5-7	5
1824	L-Dopa decreases cutaneous nociceptive inhibition of motor activity in Parkinson's disease. 2002 , 105, 196-201	35
1823	Start of a selective serotonin reuptake inhibitor (SSRI) and increase of antiparkinsonian drug treatment in patients on levodopa. 2002 , 54, 168-70	36
1822	Parkinson's disease mimicking senile dementia of the Alzheimer type: a clinicopathological study of four autopsy cases. 2002 , 22, 77-84	10
1821	The differential diagnosis of Parkinson's disease. 2002 , 9 Suppl 3, 23-30	165
1820	Drug prescribing patterns in Parkinson's disease: a pharmacoepidemiological survey in a cohort of ambulatory patients. 2002 , 11, 149-57	41
1819	Comparison of striatal dopamine D2 receptors in Parkinson's disease and progressive supranuclear palsy patients using [123I] iodobenzofuran single-photon emission computed tomography. 2002 , 12, 316-24	20
1818	Clinical and neuropathological correlates of Lewy body disease. 2003 , 105, 341-50	78
1817	Magnetization transfer changes of grey and white matter in Parkinson's disease. 2003 , 45, 224-30	37
1816	Alpha-synuclein pathology in Parkinson's and Alzheimer's disease brain: incidence and topographic distribution--a pilot study. 2003 , 106, 191-201	139
1815	Genes and parkinsonism. 2003 , 2, 221-8	85
1814	A linkage study of candidate loci in familial Parkinson's Disease. 2003 , 3, 6	14
1813	Deep brain stimulation of the subthalamic nucleus does not increase the striatal dopamine concentration in parkinsonian humans. 2003 , 18, 41-8	128
1812	Systematic review of incidence studies of Parkinson's disease. 2003 , 18, 19-31	362
1811	Cerebrospinal fluid Abeta42 is reduced in multiple system atrophy but normal in Parkinson's disease and progressive supranuclear palsy. 2003 , 18, 186-90	110
1810	Prevalence of PD and other types of parkinsonism in three elderly populations of central Spain. 2003 , 18, 267-274	151

1809	Increased daytime sleepiness in Parkinson's disease: a questionnaire survey. 2003 , 18, 319-323	57
1808	Reliability of reported age at onset for Parkinson's disease. 2003 , 18, 275-279	27
1807	Dopamine D2 receptor TaqIA and TaqIB polymorphisms in Parkinson's disease. 2003 , 18, 593-5	27
1806	Double-blind, placebo-controlled study to evaluate the efficacy and safety of botulinum toxin type A in the treatment of drooling in parkinsonism. 2003 , 18, 685-8	153
1805	Parkinson's disease is associated with hippocampal atrophy. 2003 , 18, 784-90	245
1804	Movement Disorders Society Scientific Issues Committee report: SIC Task Force appraisal of clinical diagnostic criteria for Parkinsonian disorders. 2003 , 18, 467-86	835
1803	Diagnostic accuracy of progressive supranuclear palsy in the Society for Progressive Supranuclear Palsy brain bank. 2003 , 18, 1018-26	143
1802	Voxel-based morphometry detects cortical atrophy in the Parkinson variant of multiple system atrophy. 2003 , 18, 1132-8	135
1801	Two-year follow-up of subthalamic deep brain stimulation in Parkinson's disease. 2003 , 18, 1332-7	217
1800	Unclassifiable parkinsonism in two European tertiary referral centres for movement disorders. 2003 , 18, 1123-31	25
1799	Diagnostic potential of acoustic startle reflex, acoustic blink reflex, and electro-oculography in progressive supranuclear palsy: a prospective study. 2003 , 18, 1273-9	25
1798	Parkinson's syndrome associated with neurofibrillary degeneration and tau pathologic findings. 2003 , 18 Suppl 6, S28-33	52
1797	Impact of genetic analysis on Parkinson's disease research. 2003 , 18 Suppl 6, S96-8	16
1796	Role of dopamine transporter imaging in the diagnosis of atypical tremor disorders. 2003 , 18 Suppl 7, S22-7	36
1795	Dopamine transporter imaging and SPECT in diagnostic work-up of Parkinson's disease: a decision-analytic approach. 2003 , 18 Suppl 7, S52-62	27
1794	Sweating dysfunction in Parkinson's disease. 2003 , 18, 1459-63	124
1793	Role of dopamine transporter imaging in routine clinical practice. 2003 , 18, 1415-23	183
1792	Monoamine oxidase B polymorphism, cigarette smoking and risk of Parkinson's disease: a study in an Asian population. 2003 , 120B, 58-62	26

1791	Subthalamic nucleus stimulation affects a frontotemporal network: a PET study. 2003 , 54, 445-50	131
1790	Familial aggregation of early- and late-onset Parkinson's disease. 2003 , 54, 507-13	85
1789	Effects of rivastigmine on the quantitative EEG in demented Parkinsonian patients. 2003 , 107, 252-5	37
1788	Rivastigmine (Exelon) for dementia in patients with Parkinson's disease. 2003 , 108, 368-73	61
1787	Involvement of precerebellar nuclei in multiple system atrophy. 2003 , 29, 60-76	70
1786	Orthostatic hypotension: causes, classification, and treatment. 2003 , 26, 892-901	31
1785	Camptocormia as a form of dystonia in Parkinson's disease. 2003 , 10, 107-8	33
1784	Clinical characteristics of the alpha-synuclein mutation (G209A)-associated Parkinson's disease in comparison with other forms of familial Parkinson's disease in Greece. 2003 , 10, 281-6	22
1783	Pramipexole and pergolide in the treatment of depression in Parkinson's disease: a national multicentre prospective randomized study. 2003 , 10, 399-406	184
1782	Therapeutic effect of repetitive transcranial magnetic stimulation on motor function in Parkinson's disease patients. 2003 , 10, 567-72	119
1781	Alzheimer's disease and Parkinson's disease. 2003 , 348, 1356-64	929
1780	Enfermedad de Parkinson: concepto, etiopatogenia, manifestaciones clínicas, historia natural, complicaciones, diagnóstico diferencial. 2003 , 8, 5081-5088	
1779	Movement disorders. 2003 , 87, 771-91, vii	4
1778	[18F]fluorodopa uptake in the upper brainstem measured with positron emission tomography correlates with decreased REM sleep duration in early Parkinson's disease. 2003 , 105, 262-9	36
1777	Dose-dependent protective effect of coffee, tea, and smoking in Parkinson's disease: a study in ethnic Chinese. 2003 , 216, 163-7	150
1776	Paired transcranial magnetic stimulation for the early diagnosis of corticobasal degeneration. 2003 , 114, 272-8	29
1775	Echogenicity of the substantia nigra in relatives of patients with sporadic Parkinson's disease. 2003 , 18, 416-22	91
1774	Alpha synuclein promoter and risk of Parkinson's disease: microsatellite and allelic size variability. 2003 , 336, 70-2	56

1773	Intravenous amantadine sulphate application improves the performance of complex but not simple motor tasks in patients with Parkinson's disease. 2003 , 339, 25-8	32
1772	Strong association between Saitohin gene polymorphism and tau haplotype in the Polish population. 2003 , 348, 163-6	21
1771	Imaging studies in movement disorders. 2003 , 33, 105-13	16
1770	Significant linkage of Parkinson disease to chromosome 2q36-37. 2003 , 72, 1053-7	138
1769	Neuroleptic malignant syndrome-like, or--dopaminergic malignant syndrome--due to levodopa therapy withdrawal. Clinical features in 11 patients. 2003 , 9, 175-8	40
1768	Selegiline in the treatment of Parkinson's disease: its impact on orthostatic hypotension. 2003 , 9, 221-4	17
1767	The prevalence of Parkinson's disease in British Columbia, Canada, estimated by using drug tracer methodology. 2003 , 9, 233-8	26
1766	Early sensory information processes are enhanced on visual oddball and S1-S2 tasks in Parkinson's disease: a visual event-related potentials study. 2003 , 9, 329-40	17
1765	Current status of Parkinson's disease treatment in Korea. 2003 , 9 Suppl 2, S99-104	7
1764	Mutation at the SCA17 locus is not a common cause of parkinsonism. 2003 , 9, 317-20	12
1763	Neuropsychological changes after subthalamic nucleus stimulation: a 12 month follow-up in nine patients with Parkinson's disease. 2003 , 10, 73-9	54
1762	Cutaneous sympathetic function and cardiovascular function in patients with progressive supranuclear palsy and Parkinson's disease. 2003 , 10, 101-6	20
1761	Trastornos del movimiento. Concepto, epidemiología y clasificación. 2003 , 8, 5075-5080	
1760	Levodopa-induced response fluctuations in patients with Parkinson's disease: strategies for management. 2003 , 17, 475-89	32
1759	Amantadine for dyskinesia in Parkinson's disease. 2003 , CD003467	39
1758	Rationale for current therapies in Parkinson's disease. 2003 , 4, 1747-61	41
1757	Autonomic nervous system testing may not distinguish multiple system atrophy from Parkinson's disease. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2003 , 74, 56-60	5.5 56
1756	Deep brain stimulation of the subthalamic nucleus: effectiveness in advanced Parkinson's disease patients previously reliant on apomorphine. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2003 , 74, 170-4	5.5 25

1755	Tremor in Parkinson's disease and serotonergic dysfunction: an 11C-WAY 100635 PET study. 2003 , 60, 601-5		241
1754	[[123I]]beta-CIT SPECT is a useful method for monitoring dopaminergic degeneration in early stage Parkinson's disease. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2003 , 74, 294-8	5.5	77
1753	Cognitive and behavioural effects of chronic stimulation of the subthalamic nucleus in patients with Parkinson's disease. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2003 , 74, 175-82	5.5	152
1752	Detecting scaling in the period dynamics of multimodal signals: application to Parkinsonian tremor. 2003 , 67, 031903		25
1751	Amantadine in Parkinson's disease. 2003 , CD003468		34
1750	Detection of pathologic prion protein in the olfactory epithelium in sporadic Creutzfeldt-Jakob disease. 2003 , 348, 711-9		125
1749	Occipital hypoperfusion in Parkinson's disease without dementia: correlation to impaired cortical visual processing. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2003 , 74, 419-22	5.5	95
1748	High-dose ropinirole in advanced Parkinson's disease with severe dyskinesias. 2003 , 26, 146-50		31
1747	99mTc-TRODAT-1 SPECT in healthy and 6-OHDA lesioned parkinsonian monkeys: comparison with 18F-FDOPA PET. 2003 , 24, 77-83		8
1746	Therapies for depression in Parkinson's disease. 2003 , CD003465		49
1745	Progressive supranuclear palsy. 2003 , 64, 585-8		2
1744	[Acoustic analysis of prosody in females with Parkinson's disease: comparison with normal controls]. 2003 , 61, 999-1003		22
1743	[Acoustic analysis of prosody in females with Parkinson's disease: effect of L-dopa]. 2003 , 61, 995-8		14
1742	Uma revisão sobre depressão como fator de risco na Doenã de Parkinson e seu impacto na cognião. 2004 , 26, 52-60		4
1741	Avaliaão da doenã de Parkinson pela ressonãncia magnãtica. 2004 , 37, 83-90		1
1740	Subthalamic nucleus deep brain stimulation in a patient with levodopa-responsive multiple system atrophy. Case report. 2004 , 100, 553-6		41
1739	Sexual dysfunction in Parkinson's disease. 2004 , 30, 95-105		123
1738	Tau gene and Parkinson's disease: a case-control study and meta-analysis. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2004 , 75, 962-5	5.5	100

1737	Striatal dopamine transporter in dementia with Lewy bodies and Parkinson disease: a comparison. 2004 , 62, 1568-72	112
1736	The cognitive ability of an incident cohort of Parkinson's patients in the UK. The CamPaIGN study. 2004 , 127, 550-60	523
1735	Postural abnormalities to multidirectional stance perturbations in Parkinson's disease. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2004 , 75, 1245-54	5.5 184
1734	Psychiatric comorbidity in a population of Parkinson's disease patients. 2004 , 11, 315-20	155
1733	Pergolide mesylate can improve sexual dysfunction in patients with Parkinson's disease: the results of an open, prospective, 6-month follow-up. 2004 , 11, 483-8	28
1732	A registry-based, case-control investigation of Parkinson's disease with and without cognitive impairment. 2004 , 11, 347-51	10
1731	Genetic testing in spinocerebellar ataxia in Taiwan: expansions of trinucleotide repeats in SCA8 and SCA17 are associated with typical Parkinson's disease. 2004 , 65, 209-14	73
1730	Polymorphism in candidate genes: implications for the risk and treatment of idiopathic Parkinson's disease. 2004 , 4, 291-306	26
1729	Subthalamic nucleus stimulation restores glucose metabolism in associative and limbic cortices and in cerebellum: evidence from a FDG-PET study in advanced Parkinson's disease. 2004 , 24, 7-16	170
1728	Effect of intention and visual fixation disengagement on prosaccades in Parkinson's disease patients. 2004 , 42, 624-32	18
1727	Learning of ambiguous versus hybrid sequences by patients with Parkinson's disease. 2004 , 42, 1350-7	29
1726	Functional brain imaging in the differential diagnosis of Parkinson's disease. 2004 , 3, 284-90	57
1725	Neuroprotection and pharmacotherapy for motor symptoms in Parkinson's disease. 2004 , 3, 466-74	57
1724	Diagnostic issues in non-AD dementias. 2004 , 3, 363-374	1
1723	Sound lateralization in Parkinson's disease. 2004 , 21, 335-41	21
1722	Imaging of brain function using SPECT. 2004 , 19, 113-23	35
1721	The scientific basis for the current treatment of Parkinson's disease. 2004 , 55, 41-60	143
1720	Oxidative basis of manganese neurotoxicity. 2004 , 1012, 129-41	105

1719	Manganese-induced parkinsonism and Parkinson's disease. 2004 , 1012, 209-23	354
1718	Parkinson's disease: clinical aspects. 2004 , 318, 115-20	88
1717	Orofacial apraxia in corticobasal degeneration, progressive supranuclear palsy, multiple system atrophy and Parkinson's disease. 2004 , 251, 1317-23	38
1716	Significance of 123I-MIBG scintigraphy as a pathophysiological indicator in the assessment of Parkinson's disease and related disorders: it can be a specific marker for Lewy body disease. 2004 , 18, 453-61	114
1715	Reproducibility of dopamine transporter density measured with 123I-FPCIT SPECT in normal control and Parkinson's disease patients. 2004 , 18, 609-16	26
1714	Dopamine transporter SPECT using fast kinetic ligands: 123I-FP-beta-CIT versus 99mTc-TRODAT-1. 2004 , 31, 1119-27	43
1713	Usefulness of brain 99mTc-TRODAT-1 SPET for the evaluation of Parkinson's disease. 2004 , 31, 155-61	55
1712	Differential response in choice reaction time following apomorphine based on prior dopaminergic treatment. 2004 , 109, 348-54	5
1711	The effect of vascular disease on late onset Parkinson's disease. 2004 , 11, 231-5	47
1710	parkin mutation analysis in clinic patients with early-onset Parkinson [corrected] disease. 2004 , 129A, 44-50	40
1709	The new mutation, E46K, of alpha-synuclein causes Parkinson and Lewy body dementia. 2004 , 55, 164-73	2025
1708	A functional polymorphism regulating dopamine beta-hydroxylase influences against Parkinson's disease. 2004 , 55, 443-6	48
1707	The gene responsible for PARK6 Parkinson's disease, PINK1, does not influence common forms of parkinsonism. 2004 , 56, 329-35	32
1706	Exercise-induced dystonia as a preceding symptom of familial Parkinson's disease. 2004 , 19, 228-30	28
1705	Assessing quality of life in Parkinson's disease: can a short-form questionnaire be useful?. 2004 , 19, 308-12	35
1704	Cerebrospinal fluid Abeta42 levels in multiple system atrophy. 2004 , 19, 238-40; author reply 240-1	30
1703	Non-subtype-selective opioid receptor antagonism in treatment of levodopa-induced motor complications in Parkinson's disease. 2004 , 19, 554-60	60
1702	Cerebrospinal fluid analysis differentiates multiple system atrophy from Parkinson's disease. 2004 , 19, 571-9	76

1701	Punding in Parkinson's disease: its relation to the dopamine dysregulation syndrome. 2004 , 19, 397-405	444
1700	Measurements of transcallosally mediated cortical inhibition for differentiating parkinsonian syndromes. 2004 , 19, 518-28	66
1699	Clinicopathological investigation of vascular parkinsonism, including clinical criteria for diagnosis. 2004 , 19, 630-40	273
1698	Evaluation of the role of Nurr1 in a large sample of familial Parkinson's disease. 2004 , 19, 649-55	33
1697	Atypical parkinsonism and Annonaceae consumption in New Caledonia. 2004 , 19, 603-4	32
1696	Parkinson's disease-like presentation of multiple system atrophy with poor response to STN stimulation: a clinicopathological case report. 2004 , 19, 973-7	33
1695	Impact of dopamine transporter SPECT using 123I-lobflupane on diagnosis and management of patients with clinically uncertain Parkinsonian syndromes. 2004 , 19, 1175-82	224
1694	Comparison of diffusion-weighted imaging and [123I]IBZM-SPECT for the differentiation of patients with the Parkinson variant of multiple system atrophy from those with Parkinson's disease. 2004 , 19, 1438-45	78
1693	Distribution, type, and origin of Parkin mutations: review and case studies. 2004 , 19, 1146-57	194
1692	Levodopa treatment does not affect low-dose apomorphine test in patients with Parkinson's disease. 2004 , 19, 1511-5	8
1691	Nurr1 mutational screen in Parkinson's disease. 2004 , 19, 1503-5	17
1690	Smoking and Parkinson's disease. 1994 , 9, 207-12	33
1689	Treatment benefit and daily drug costs associated with treating Parkinson's disease in a Parkinson's disease clinic. 2004 , 18, 105-11	18
1688	[Utility of dopamine transporter imaging (123-I Ioflupane SPECT) in the assessment of movement disorders]. 2004 , 23, 245-52	4
1687	Mutations in the glucocerebrosidase gene and Parkinson's disease in Ashkenazi Jews. 2004 , 351, 1972-7	456
1686	Cardiac 123I-MIBG scintigraphy can assess the disease severity and phenotype of PD. 2004 , 220, 105-11	75
1685	Noradrenergic mechanisms in neurodegenerative diseases: a theory. 2004 , 45, 38-78	319
1684	Association of variations in monoamine oxidases A and B with Parkinson's disease subgroups. 2004 , 83, 454-60	21

1683	Hand rhythmic tapping and timing in Parkinson's disease. 2004 , 10, 143-8	49
1682	Association of a variation in the promoter region of the brain-derived neurotrophic factor gene with familial Parkinson's disease. 2004 , 10, 213-9	30
1681	Visual object recognition deficits in early Parkinson's disease. 2004 , 10, 227-33	30
1680	Caribbean parkinsonism and other atypical parkinsonian disorders. 2004 , 10 Suppl 1, S19-26	4
1679	Parkinson's disease and thyroid dysfunction. 2004 , 10, 381-3	35
1678	Diagnostic accuracy of [99mTc]TRODAT-1 SPECT imaging in early Parkinson's disease. 2004 , 10, 375-9	46
1677	Comparison of magnetic resonance imaging in subtypes of multiple system atrophy. 2004 , 10, 363-8	61
1676	Differential involvement and heterogeneous phosphorylation of tau isoforms in progressive supranuclear palsy. 2004 , 121, 95-101	18
1675	The E318G substitution in PSEN1 gene is not connected with Alzheimer's disease in a large Polish cohort. 2004 , 357, 167-70	10
1674	Chronic levodopa intake increases levodopa plasma bioavailability in patients with Parkinson's disease. 2004 , 363, 284-7	27
1673	Genetic analysis of DJ-1 in a cohort Parkinson's disease patients of different ethnicity. 2004 , 367, 109-12	23
1672	Paraoxonase 1 (PON1) gene polymorphisms and Parkinson's disease in a Finnish population. 2004 , 367, 168-70	20
1671	Transient arrest of psychogenic tremor induced by contralateral ballistic movements. 2004 , 370, 135-9	54
1670	Analysis of MDR1 haplotypes in Parkinson's disease in a white population. 2004 , 372, 240-4	40
1669	Post-stroke movement disorders: report of 56 patients. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2004 , 75, 1568-74	5.5 164
1668	Abnormalities of prepulse inhibition do not depend on blink reflex excitability: a study in Parkinson's disease and Huntington's disease. 2004 , 115, 1527-36	67
1667	Differentiation of idiopathic Parkinson's disease, multiple system atrophy, progressive supranuclear palsy, and healthy controls using magnetization transfer imaging. 2004 , 21, 229-35	131
1666	Trace of diffusion tensor differentiates the Parkinson variant of multiple system atrophy and Parkinson's disease. 2004 , 21, 1443-51	127

1665	Plasma homocysteine levels in pergolide-treated Parkinson disease patients. 2004 , 27, 163-5	3
1664	Mood disorders in early Parkinson's disease. 2004 , 17, 191-196	9
1663	Vascular parkinsonism. 2004 , 17, 49-54	32
1662	[Drug-induced parkinson syndromes]. 2004 , 59, 105-12	27
1661	Morning glory sign: a particular MR finding in progressive supranuclear palsy. 2004 , 3, 125-32	65
1660	Association of N-acetyl transferase 2 gene polymorphism and slow acetylator phenotype with young onset and late onset Parkinson's disease among Indians. 2005 , 15, 731-5	13
1659	Evaluation of epidemiologic and animal data associating pesticides with Parkinson's disease. 2005 , 47, 1059-87	59
1658	The relation between visual hallucinations and visual evoked potential in Parkinson disease. 2005 , 28, 79-82	19
1657	How genetics research in Parkinson's disease is enhancing understanding of the common idiopathic forms of the disease. 2005 , 18, 706-11	56
1656	Quetiapine for insomnia in Parkinson disease: results from an open-label trial. 2005 , 28, 185-7	70
1655	Effects of aging on the regularity of physiological tremor. 2005 , 93, 3064-74	77
1654	Clinical, diagnostic, genetic and management issues in dementia with Lewy bodies. 2005 , 109, 343-54	13
1653	Causes and consequences of Parkinson's disease. 2005 , 7, 158-161	2
1652	N-isopropyl-p- 123I iodoamphetamine single photon emission computed tomography study of Parkinson's disease with dementia. 2005 , 44, 1046-50	12
1651	Cognitive performance in people with Parkinson's disease and mild or moderate depression: effects of dopamine agonists in an add-on to L-dopa therapy. 2005 , 12, 9-15	28
1650	Tyrosinase exacerbates dopamine toxicity but is not genetically associated with Parkinson's disease. 2005 , 93, 246-56	84
1649	The Treatment of Patients with Parkinson's Disease: Who Cares?. 2005 , 5, 66-67	
1648	Differential progression of proprioceptive and visual information processing deficits in Parkinson's disease. 2005 , 21, 239-48	59

1647	Relationships among impairment, disability, handicap, burden of care, economic expenses, event-related potentials and regional cerebral blood flow in Parkinson's disease. 2005 , 5, 189-201	
1646	Growth hormone response to arginine test distinguishes multiple system atrophy from Parkinson's disease and idiopathic late-onset cerebellar ataxia. 2005 , 62, 428-33	20
1645	PARK11 is not linked with Parkinson's disease in European families. 2005 , 13, 193-7	21
1644	Can Alzheimer's type pathology influence the clinical phenotype of Parkinson's disease?. 2005 , 111, 353-9	25
1643	Three-dimensional stereotactic surface projection study of orthostatic hypotension and brain perfusion image in Parkinson's disease. 2005 , 112, 36-41	14
1642	The prevalence of PD in a nutritionally deficient rural population in China. 2005 , 112, 29-35	15
1641	A review of studies describing the use of acetyl cholinesterase inhibitors in Parkinson's disease dementia. 2005 , 111, 403-9	10
1640	Progressive supranuclear palsy: a systematic review. 2005 , 20, 179-86	40
1639	Memory for time intervals is impaired in left hemi-Parkinson patients. 2005 , 43, 1163-7	26
1638	Lack of evidence for a genetic association between FGF20 and Parkinson's disease in Finnish and Greek patients. 2005 , 5, 11	35
1637	Parkin mutation dosage and the phenomenon of anticipation: a molecular genetic study of familial parkinsonism. 2005 , 5, 4	7
1636	Medical healthcare use in Parkinson's disease: survey in a cohort of ambulatory patients in Italy. 2005 , 5, 26	16
1635	Dementia in Parkinson's disease: a post-mortem study in a population of brain donors. 2005 , 20, 418-22	37
1634	Clinical and positron emission tomography of Parkinson's disease caused by LRRK2. 2005 , 57, 453-6	88
1633	Multiple regions of alpha-synuclein are associated with Parkinson's disease. 2005 , 57, 535-41	206
1632	Transcranial ultrasound shows nigral hypoechogenicity in restless legs syndrome. 2005 , 58, 630-4	172
1631	Common variants of LRRK2 are not associated with sporadic Parkinson's disease. 2005 , 58, 905-8	47
1630	Three-dimensional gait biomechanics in Parkinson's disease: evidence for a centrally mediated amplitude regulation disorder. 2005 , 20, 40-50	171

1629	Impact of the motor complications of Parkinson's disease on the quality of life. 2005 , 20, 224-30	387
1628	Pilot association study of the beta-glucocerebrosidase N370S allele and Parkinson's disease in subjects of Jewish ethnicity. 2005 , 20, 100-3	71
1627	Sydney Multicenter Study of Parkinson's disease: non-L-dopa-responsive problems dominate at 15 years. 2005 , 20, 190-9	799
1626	Novel parkin mutations detected in patients with early-onset Parkinson's disease. 2005 , 20, 424-431	51
1625	Force control and disease severity in Parkinson's disease. 2005 , 20, 441-450	52
1624	FP-CIT and MIBG scintigraphy in early Parkinson's disease. 2005 , 20, 552-61	89
1623	Mosapride citrate, a novel 5-HT4 agonist and partial 5-HT3 antagonist, ameliorates constipation in parkinsonian patients. 2005 , 20, 680-6	150
1622	Patient-perceived involvement and satisfaction in Parkinson's disease: effect on therapy decisions and quality of life. 2005 , 20, 616-9	83
1621	Progressive supranuclear palsy-like phenotype associated with bilateral hypoxic-ischemic striopallidal lesions. 2005 , 20, 755-7	11
1620	Does cigarette smoking provide clinically significant neuroprotection among patients diagnosed with Parkinson's disease?. 2005 , 20, 641-2	3
1619	Rimantadine in Parkinson's disease patients experiencing peripheral adverse effects from amantadine: report of a case series. 2005 , 20, 873-7	21
1618	Identifying and distinguishing cases of parkinsonism and Parkinson's disease using ICD-9 CM codes and pharmacy data. 2005 , 20, 964-70	50
1617	Emergency hospital admissions in idiopathic Parkinson's disease. 2005 , 20, 1104-8	133
1616	Bilateral stimulation of nucleus subthalamicus in advanced Parkinson's disease: no effects on, and of, autonomic dysfunction. 2005 , 20, 976-81	30
1615	Mutation of the Parkin gene in a Persian family: clinical progression over a 40-year period. 2005 , 20, 887-90	4
1614	Three-dimensional stereotactic surface projection study of freezing of gait and brain perfusion image in Parkinson's disease. 2005 , 20, 1272-7	51
1613	Atypical unclassifiable parkinsonism on Guadeloupe: an environmental toxic hypothesis. 2005 , 20 Suppl 12, S114-8	28
1612	Validity of a modified Parkinson's disease screening questionnaire in India: effects of literacy of participants and medical training of screeners and implications for screening efforts in developing countries. 2005 , 20, 1550-6	11

1611	Abnormal sleep architecture is an early feature in the E46K familial synucleinopathy. 2005 , 20, 1310-5	33
1610	Suboptimal medication adherence in Parkinson's disease. 2005 , 20, 1502-7	155
1609	Corticobasal degeneration and Parkinson's disease assessed by HmPaO SPECT: the utility of factorial discriminant analysis. 2005 , 20, 1431-8	12
1608	Effect of levodopa on pain threshold in Parkinson's disease: a clinical and positron emission tomography study. 2005 , 20, 1557-63	300
1607	Osteoporosis in Parkinson's disease. 2005 , 20, 1636-40	35
1606	Differences in [^{99m} Tc]TRODAT-1 SPECT binding to dopamine transporters in patients with multiple system atrophy and Parkinson's disease. 2005 , 32, 302-7	28
1605	Early-stage [¹²³ I]beta-CIT SPECT and long-term clinical follow-up in patients with an initial diagnosis of Parkinson's disease. 2005 , 32, 689-95	27
1604	Does subthalamic nucleus stimulation affect the frontal limbic areas? A single-photon emission computed tomography study using a manual anatomical segmentation method. 2005 , 27, 389-94	13
1603	[Postmortal diagnosis of Parkinson's disease]. 2005 , 26, 214-20	1
1602	[Medication treatment for Parkinson's disease]. 2005 , 76, 1547-57; quiz 1558	0
1601	Parkinsonism with excessive daytime sleepiness--a narcolepsy-like disorder?. 2005 , 252, 139-45	105
1600	Progression of parkinsonism in multiple system atrophy. 2005 , 252, 91-6	47
1599	High frequency stimulation of the subthalamic nucleus is efficacious in Parkin disease. 2005 , 252, 208-11	32
1598	Association study of the G258S transferrin gene polymorphism and Parkinson's disease in the Spanish population. 2005 , 252, 1269-70	9
1597	Different clinical and evolutional patterns in late idiopathic and vascular parkinsonism. 2005 , 252, 1045-9	43
1596	Development and evaluation of the Parkinson Psychosis Questionnaire A screening-instrument for the early diagnosis of drug-induced psychosis in Parkinson's disease. 2005 , 252, 1060-6	44
1595	Factors associated with drug-induced visual hallucinations in Parkinson's disease. 2005 , 252, 1223-8	68
1594	Effect of bilateral subthalamic nucleus stimulation on balance and finger control in Parkinson's disease. 2005 , 252, 1487-94	29

1593	Imaging of dopamine transporters and D2 receptors in vascular parkinsonism: a report of four cases. 2005 , 112, 1355-61		18
1592	Quality of life and gender identity in Parkinson's disease. 2005 , 112, 1511-22		22
1591	Brain SPECT imaging in multiple system atrophy. 2005 , 112, 1635-45		42
1590	Metaiodobenzylguanidine (MIBG) uptake in Parkinson's disease also decreases at thyroid. 2005 , 19, 225-9		23
1589	Low-frequency MEG activity and MRI evaluation in Parkinson's disease. 2005 , 18, 59-63		22
1588	Exclusion of PINK1 as candidate gene for the late-onset form of Parkinson's disease in two European populations. 2005 , 4, 10		6
1587	¹²³ I ioflupane (Datscan®) presynaptic nigrostriatal imaging in patients with movement disorders. 2005 , 48, 115-126		4
1586	Approach to the patient presenting with parkinsonism. 2005 , 551-560		
1585	Depression in Parkinson's disease: study of 60 cases. 2005 , 63, 766-71		16
1584	Testing association between LRRK2 and Parkinson's disease and investigating linkage disequilibrium. 2006 , 43, e9		29
1583	New and reliable MRI diagnosis for progressive supranuclear palsy. 2005 , 64, 2050-5		273
1582	"Applause sign" helps to discriminate PSP from FTD and PD. 2005 , 64, 2132-3		100
1581	Conséquences fonctionnelles de la sclérose en plaques et de la maladie de Parkinson. 2005 , 527-531		1
1580	Disease progression continues in patients with advanced Parkinson's disease and effective subthalamic nucleus stimulation. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2005 , 76, 1217-21	5.5	112
1579	Neurocardiogenic syncope and related disorders of orthostatic intolerance. 2005 , 111, 2997-3006		137
1578	Population genetic approaches to neurological disease: Parkinson's disease as an example. 2005 , 360, 1573-8		3
1577	Amino-truncated beta-amyloid ₄₂ peptides in cerebrospinal fluid and prediction of progression of mild cognitive impairment. 2005 , 51, 1650-60		73
1576	How useful is [¹²³ I]beta-CIT SPECT in clinical practice?. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2005 , 76, 1211-6	5.5	46

1575	Cardiac 123I-MIBG scintigraphy in patients with drug induced parkinsonism. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2006 , 77, 372-4	5.5	39
1574	Apomorphine: an overview of clinical use. 2005 , 1, 193-202		1
1573	A systematic review of nutritional risk factors of Parkinson's disease. 2005 , 18, 259-82		35
1572	Depression in Parkinson's disease: loss of dopamine and noradrenaline innervation in the limbic system. 2005 , 128, 1314-22		757
1571	Motor Deficits, Exercise, and Parkinson's Disease. 2005 , 57, 79-101		6
1570	Voxel-wise analysis of [123I]beta-CIT SPECT differentiates the Parkinson variant of multiple system atrophy from idiopathic Parkinson's disease. 2005 , 128, 1605-12		102
1569	Relationship between impulsive sensation seeking traits, smoking, alcohol and caffeine intake, and Parkinson's disease. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2006 , 77, 317-21	5.5	134
1568	Differential impairment of spatial location memory in Huntington's disease. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2005 , 76, 1516-9	5.5	32
1567	The sepiapterin reductase gene region reveals association in the PARK3 locus: analysis of familial and sporadic Parkinson's disease in European populations. 2006 , 43, 557-62		32
1566	Heterogeneity of Parkinson's disease in the early clinical stages using a data driven approach. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2005 , 76, 343-8	5.5	367
1565	Clinical deficits correlate with regional cerebral atrophy in progressive supranuclear palsy. 2005 , 128, 1259-66		125
1564	Alpha-synuclein lesions in normal aging, Parkinson disease, and Alzheimer disease: evidence from the Baltimore Longitudinal Study of Aging (BLSA). 2005 , 64, 156-62		108
1563	A common LRRK2 mutation in idiopathic Parkinson's disease. 2005 , 365, 415-6		283
1562	[Utility of 123-I ioflupane SPECT in the assessment of patients with Parkinsonian syndrome and cerebral vasculopathy]. 2005 , 24, 392-403		4
1561	Clinical practice. Diagnosis and initial management of Parkinson's disease. 2005 , 353, 1021-7		227
1560	Abnormal head nociceptive withdrawal reaction to facial nociceptive stimuli in Parkinson's disease. 2005 , 116, 2091-8		30
1559	Executive dysfunction in Parkinson's disease is associated with altered pallidal-frontal processing. 2005 , 25, 588-99		67
1558	FDG PET in the differential diagnosis of parkinsonian disorders. 2005 , 26, 912-21		315

1557	Identification of a novel LRRK2 mutation linked to autosomal dominant parkinsonism: evidence of a common founder across European populations. 2005 , 76, 672-80	453
1556	Genetics of Parkinson's disease. 2005 , 37, 86-96	64
1555	Type and frequency of mutations in the LRRK2 gene in familial and sporadic Parkinson's disease*. 2005 , 128, 3000-11	217
1554	Simultaneous measurement of beta-amyloid(1-42), total tau, and phosphorylated tau (Thr181) in cerebrospinal fluid by the xMAP technology. 2005 , 51, 336-45	358
1553	Unaltered alpha-synuclein blood levels in juvenile Parkinsonism with a parkin exon 4 deletion. 2005 , 374, 189-91	14
1552	Impaired gastric emptying of a solid test meal in patients with Parkinson's disease using ¹³ C-sodium octanoate breath test. 2005 , 375, 170-3	120
1551	Analysis of SCA-2 and SCA-3 repeats in Parkinsonism: evidence of SCA-2 expansion in a family with autosomal dominant Parkinson's disease. 2005 , 382, 191-4	29
1550	Voxel based comparison of glucose metabolism in the differential diagnosis of the multiple system atrophy using statistical parametric mapping. 2005 , 52, 211-9	36
1549	Neurodegenerative disorders mimicking progressive supranuclear palsy: a report of three cases. 2005 , 12, 941-5	7
1548	Trunk sway measurements during stance and gait tasks in Parkinson's disease. 2005 , 22, 240-9	110
1547	Brain 3D-SSP SPECT analysis in dementia with Lewy bodies, Parkinson's disease with and without dementia, and Alzheimer's disease. 2005 , 107, 396-403	53
1546	Atypical parkinsonism on Guadeloupe, comparison with the parkinsonism-dementia complex of Guam, and environmental toxic hypotheses. 2005 , 19, 407-13	16
1545	Direction-specific postural instability in subjects with Parkinson's disease. 2005 , 193, 504-21	269
1544	Parkinsonian action tremor: interference with object manipulation and lacking levodopa response. 2005 , 194, 151-60	24
1543	Administration of selegiline is not associated with visual hallucinations in advanced Parkinson's disease patients. 2005 , 11, 265-6; author reply 267	2
1542	Visual event-related potentials under different interstimulus intervals in Parkinson's disease: relation to motor disability, WAIS-R, and regional cerebral blood flow. 2005 , 11, 209-19	11
1541	Early-onset Parkinson's disease in a Chinese population: 99mTc-TRODAT-1 SPECT, Parkin gene analysis and clinical study. 2005 , 11, 173-80	29
1540	Quality of life in patients with Parkinson's disease. 2005 , 11, 221-6	117

1539	Brain perfusion differences between Parkinson's disease and multiple system atrophy with predominant parkinsonian features. 2005 , 11, 227-32	20
1538	Psychometric characteristics of the Parkinson's disease questionnaire (PDQ-39)--Ecuadorian version. 2005 , 11, 297-304	21
1537	The long-lasting improvement of sexual dysfunction in patients with advanced, fluctuating Parkinson's disease induced by pergolide: evidence from the results of an open, prospective, one-year trial. 2005 , 11, 509-12	24
1536	Prevalence of parkin gene mutations and variations in idiopathic Parkinson's disease. 2005 , 11, 341-7	13
1535	Balance and fear of falling in Parkinson's disease. 2005 , 11, 427-33	93
1534	Correlates of excessive daytime sleepiness in Parkinson's disease. 2005 , 11, 441-8	23
1533	Cause, seasonality of death and co-morbidities in progressive supranuclear palsy (PSP). 2005 , 11, 459-63	20
1532	The LRRK2 I2012T, G2019S, and I2020T mutations are rare in Taiwanese patients with sporadic Parkinson's disease. 2005 , 11, 521-2	59
1531	Activating transcription factor 2 expression in the adult human brain: association with both neurodegeneration and neurogenesis. 2005 , 133, 437-51	41
1530	Rigidity and bradykinesia reduce interlimb coordination in Parkinsonian gait. 2005 , 86, 183-9	59
1529	Metaiodobenzylguanidine (MIBG) scintigraphy at various parts of the body in Parkinson's disease and multiple system atrophy. 2005 , 119, 56-60	13
1528	[Application of 123I-FP-CIT in the clinical practice in Parkinsonism patients]. 2005 , 24, 224-33	2
1527	[SPECT with 123I-IBZM: utility in differential diagnosis of degenerative Parkinsonisms and establishment of quantification method]. 2005 , 24, 234-43	3
1526	[Dopaminergic neurotransmission image in Parkinsonian syndromes]. 2005 , 24, 255-76	5
1525	[Gait analysis in Parkinson's disease and response to dopaminergic treatment]. 2005 , 124, 50-2	5
1524	Comparison of age of onset and development of motor complications between smokers and non-smokers in Parkinson's disease. 2005 , 231, 35-9	23
1523	Role of [18F]-dopa-PET imaging in assessing movement disorders. 2005 , 43, 93-106	25
1522	Characterization of proteome of human cerebrospinal fluid. 2006 , 73, 29-98	27

1521	Validity and utility of a LRRK2 G2019S mutation test for the diagnosis of Parkinson's disease. 2006 , 10, 221-7	13
1520	A case-control association study of the 12 single-nucleotide polymorphisms implicated in Parkinson disease by a recent genome scan. 2006 , 78, 1090-2; author reply 1092-4	37
1519	Conflicting results regarding the semaphorin gene (SEMA5A) and the risk for Parkinson disease. 2006 , 78, 1082-4; author reply 1092-4	49
1518	Comparison of region-of-interest analysis and human observers in the diagnosis of Parkinson's disease using [^{99m} Tc]TRODAT-1 and SPECT. 2006 , 51, 575-85	21
1517	Achtergronden en behandeling van Lewy body dementie. 2006 , 31, 108-114	
1516	Progression of putaminal degeneration in multiple system atrophy: a serial diffusion MR study. 2006 , 31, 240-5	84
1515	Low frequency rTMS of the SMA transiently ameliorates peak-dose LID in Parkinson's disease. 2006 , 117, 1917-21	76
1514	Parkinsonian syndromes. 2006 , 22, 827-42, vi	9
1513	Brain SPECT analysis by 3D-SSP and phenotype of Parkinson's disease. 2006 , 241, 67-72	24
1512	Differential patterns of dopamine transporter loss in the basal ganglia of progressive supranuclear palsy and Parkinson's disease: analysis with [(123)I]IPT single photon emission computed tomography. 2006 , 244, 103-9	30
1511	The range and nature of sleep dysfunction in untreated Parkinson's disease (PD). A comparative controlled clinical study using the Parkinson's disease sleep scale and selective polysomnography. 2006 , 248, 158-62	87
1510	Are dementia and depression in Parkinson's disease related?. 2006 , 248, 138-42	36
1509	Vascular parkinsonism--an update. 2006 , 248, 185-91	55
1508	Effects of acute tryptophan depletion on cognition, memory and motor performance in Parkinson's disease. 2006 , 248, 259-65	12
1507	Complex I polymorphisms, bigenomic heterogeneity, and family history in Virginians with Parkinson's disease. 2006 , 247, 224-30	20
1506	Effects of transcranial direct current stimulation on working memory in patients with Parkinson's disease. 2006 , 249, 31-8	481
1505	A randomized trial of deep-brain stimulation for Parkinson's disease. 2006 , 355, 896-908	2015
1504	Broadening a classic clinical triad: The hypokinetic motor disorder of normal pressure hydrocephalus also affects the hand. 2006 , 198, 81-7	25

1503	Camptocormia or Pisa syndrome in multiple system atrophy. 2006 , 108, 699-704	36
1502	The effect of depression on motor function and disease severity of Parkinson's disease. 2006 , 108, 465-9	45
1501	LRRK2: a common pathway for parkinsonism, pathogenesis and prevention?. 2006 , 12, 76-82	78
1500	Analysis of the PINK1 gene in a cohort of patients with sporadic early-onset parkinsonism in Taiwan. 2006 , 394, 33-6	36
1499	Absence/rarity of commonly reported LRRK2 mutations in Indian Parkinson's disease patients. 2006 , 409, 83-8	56
1498	Hyperhomocysteinemia and methylenetetrahydrofolate reductase polymorphism in patients with Parkinson's disease. 2006 , 404, 56-60	47
1497	Association study of sporadic Parkinson's disease genetic risk factors in patients from Russia by APEX technology. 2006 , 405, 212-6	11
1496	Mutations in DJ-1 are rare in familial Parkinson disease. 2006 , 408, 209-13	37
1495	The diagnosis of manganese-induced parkinsonism. 2006 , 27, 340-6	183
1494	A rapid method for mass screening for parkinsonism. 2006 , 27, 357-61	13
1493	Vigilance troubles in Parkinson's disease: a subjective and objective polysomnographic study. 2006 , 7, 448-53	59
1492	The effects of visual rhythms and optic flow on stride patterns of patients with Parkinson's disease. 2006 , 12, 21-7	42
1491	Parkin mutations in familial and sporadic Parkinson's disease among Indians. 2006 , 12, 239-45	31
1490	Wisconsin Card Sorting Test and brain perfusion imaging in Parkinson's disease. 2006 , 12, 273-8	9
1489	Does cardiac metaiodobenzylguanidine (MIBG) uptake in Parkinson's disease correlate with major autonomic symptoms?. 2006 , 12, 284-8	48
1488	Anticipation of onset age in familial Parkinson's disease without SCA gene mutations. 2006 , 12, 309-13	2
1487	Disruptions of the fornix fiber in Parkinsonian patients with excessive daytime sleepiness. 2006 , 12, 319-22	21
1486	Parkinson's disease and family history. 2006 , 12, 399-409	39

1485	LRRK2 G2019S mutation and Parkinson's disease: a clinical, neuropsychological and neuropsychiatric study in a large Italian sample. 2006 , 12, 410-9	85
1484	Progression patterns of neuronal loss and Lewy body pathology in the substantia nigra in Parkinson's disease. 2006 , 12, S92-S98	17
1483	Lewy body disease: thalamic cholinergic activity related to dementia and parkinsonism. 2006 , 27, 433-8	56
1482	[Neuroimaging of the dopamine transporter in Parkinsons disease: first study using [99mTc]-TRODAT-1 and SPECT in Brazil]. 2006 , 64, 628-34	20
1481	[Comparison study of executive functions in Parkinson's disease and degenerative cerebellar disease's patients]. 2006 , 64, 814-23	2
1480	Syndromic approach to Parkinson's disease: role of functional imaging. 2006 , 2, 83-91	
1479	Parkinson's disease and dopamine transporter neuroimaging: a critical review. 2006 , 124, 168-75	41
1478	Diagnosis and treatment of Parkinson disease: molecules to medicine. 2006 , 116, 1744-54	461
1477	Quality of life in a Brazilian sample of patients with Parkinson's disease and their caregivers. 2006 , 28, 209-11	22
1476	Clinical Implications of Cardiac-MIBG SPECT in the Differentiation of Parkinsonian Syndromes. 2006 , 2, 51-7	26
1475	Olfaction in Parkinsonian Syndromes. 279-295	
1474	Paralysie supranucléaire progressive (maladie de Steele-Richardson-Olszewski). 2006 , 3, 1-11	
1473	Relationship of apolipoprotein E and age at onset to Parkinson disease neuropathology. 2006 , 65, 116-23	74
1472	Rater-blinded, prospective comparison: quetiapine versus clozapine for Parkinson's disease psychosis. 2006 , 29, 331-7	110
1471	Two-year follow-up in 150 consecutive cases with normal dopamine transporter imaging. 2006 , 27, 933-7	88
1470	A novel P755L mutation in LRRK2 gene associated with Parkinson's disease. 2006 , 17, 1859-62	15
1469	Challenging the serotonergic system in Parkinson disease patients: effects on cognition, mood, and motor performance. 2006 , 29, 276-85	18
1468	Non-motor aspects of Parkinson's disease. 2006 , 11, 541-54	36

1467	Effect of step-synchronized vibration stimulation of soles on gait in Parkinson's disease: a pilot study. 2006 , 3, 9	72
1466	Verbal fluency in Parkinson's disease: results of a 2-min fluency test. 2006 , 18, 38-41	4
1465	Longitudinal metric properties of disability rating scales for Parkinson's disease. 2006 , 9, 386-93	35
1464	The effect of ischemic cerebrovascular disease on the clinical characteristics of Parkinson's disease. A post-mortem study. 2006 , 13, 96-7	3
1463	Placebo-controlled trial of riluzole in multiple system atrophy. 2006 , 13, 1146-8	25
1462	Overactive bladder in Parkinson's disease: alteration of brainstem raphe detected by transcranial sonography. 2006 , 13, 1291-7	15
1461	LRRK2 mutations in a clinic-based cohort of Parkinson's disease. 2006 , 13, 1298-301	6
1460	Parkin gene variations in late-onset Parkinson's disease: comparison between Norwegian and German cohorts. 2006 , 113, 9-13	21
1459	Dietary factors and smoking as risk factors for PD in a rural population in China: a nested case-control study. 2006 , 113, 278-81	20
1458	Depression in Parkinson's disease -- a review. 2006 , 113, 1-8	165
1457	A systematic review of depression and mental illness preceding Parkinson's disease. 2006 , 113, 211-20	215
1456	Features associated with the development of hallucinations in Parkinson's disease. 2006 , 114, 239-43	38
1455	The validity of a hyperventilation test for an investigation of autonomic failure: assessment in patients with multiple system atrophy and Parkinson's disease. 2006 , 60, 1542-7	6
1454	Clinical Lewy body syndromes. 2000 , 920, 1-8	33
1453	Predictors of gastric emptying in Parkinson's disease. 2006 , 18, 369-75	130
1452	Comprehensive analysis of the LRRK2 gene in sixty families with Parkinson's disease. 2006 , 14, 322-31	134
1451	Chromosome 5 and Parkinson disease. 2006 , 14, 1106-10	4
1450	Parkinson's disease and brain mitochondrial dysfunction: a functional phosphorus magnetic resonance spectroscopy study. 2006 , 26, 283-90	83

1449	[(11)C]d-threo-methylphenidate PET in patients with Parkinson's disease and essential tremor. 2006 , 113, 187-93	35
1448	Analysis of the polymorphic prion protein gene codon 129 in idiopathic Parkinson's disease. 2006 , 113, 331-7	14
1447	Kinematic analysis of dopaminergic effects on skilled handwriting movements in Parkinson's disease. 2006 , 113, 609-23	85
1446	Kinetic tremor in Parkinson's disease--an underrated symptom. 2006 , 113, 845-53	44
1445	Possible impact of dopamine SPECT on decision-making for drug treatment in Parkinsonian syndrome. 2006 , 113, 1177-90	30
1444	The plasma alpha-synuclein levels in patients with Parkinson's disease and multiple system atrophy. 2006 , 113, 1435-9	177
1443	Pharmacokinetic behaviour of levodopa and 3-O-methyldopa after repeat administration of levodopa/carbidopa with and without entacapone in patients with Parkinson's disease. 2006 , 113, 1441-8	44
1442	Brain perfusion effects of cholinesterase inhibitors in Parkinson's disease with dementia. 2006 , 113, 1787-90	17
1441	Feasibility of 2-deoxy-2-[18F]fluoro-D-glucose- A85380-PET for imaging of human cardiac nicotinic acetylcholine receptors in vivo. 2006 , 95, 105-9	21
1440	Feasibility of 2-deoxy-2-[18F]fluoro-D-glucose- A85380-PET for imaging of human cardiac nicotinic acetylcholine receptors in vivo. 2006 , 95, 354-354	1
1439	The place of perceptual analysis of dysarthria in the differential diagnosis of corticobasal degeneration and Parkinson's disease. 2006 , 253, 92-7	9
1438	Levodopa availability improves with progression of Parkinson's disease. 2006 , 253, 1221-6	23
1437	End-of-dose deterioration in non ergolinic dopamine agonist monotherapy of Parkinson's disease. 2006 , 253, 1633-9	20
1436	Myocardial 123I-MIBG scintigraphy in patients with PSP, CBD and MSA. 2006 , 253, iii35-iii40	10
1435	Early-onset Parkinson's disease caused by a novel parkin mutation in a genetic isolate from north-eastern Brazil. 2006 , 7, 13-9	15
1434	A common missense variant in the LRRK2 gene, Gly2385Arg, associated with Parkinson's disease risk in Taiwan. 2006 , 7, 133-8	216
1433	Genetic susceptibility to Parkinson's disease among South and North Indians: I. Role of polymorphisms in dopamine receptor and transporter genes and association of DRD4 120-bp duplication marker. 2006 , 7, 223-9	19
1432	Quantitative simultaneous (99m)Tc-ECD/123I-FP-CIT SPECT in Parkinson's disease and multiple system atrophy. 2006 , 33, 87-92	44

1431	Comparative non-radioactive RT-PCR assay: an approach to study the neurosteroids biosynthetic pathway in humans. 2006 , 153, 290-8	6
1430	Initial treatment of Parkinson's disease. 2006 , 8, 224-35	11
1429	Preclinical diagnosis of Parkinson's disease: are we there yet?. 2006 , 6, 295-301	41
1428	Response to 4-month treatment with reboxetine in Parkinson's disease patients with a major depressive episode. 2006 , 28, 59-64	30
1427	Brain dopamine and kinematics of graphomotor functions. 2006 , 25, 492-509	43
1426	The impact of normal aging and Parkinson's disease on response preparation in task-switching behavior. 2006 , 1114, 173-82	22
1425	The diagnosis of Parkinson's disease. 2006 , 5, 75-86	476
1424	Non-motor symptoms of Parkinson's disease: diagnosis and management. 2006 , 5, 235-45	1757
1423	Rapid-eye-movement sleep behaviour disorder as an early marker for a neurodegenerative disorder: a descriptive study. 2006 , 5, 572-7	752
1422	Case-control studies in the genomic era: a clinician's guide. 2006 , 5, 701-7	41
1421	The mystery of motor asymmetry in Parkinson's disease. 2006 , 5, 796-802	245
1420	Selective nicotinic acetylcholine receptor subunit deficits identified in Alzheimer's disease, Parkinson's disease and dementia with Lewy bodies by immunoprecipitation. 2006 , 23, 481-9	99
1419	Patients with Parkinson's disease learn to control complex systems-an indication for intact implicit cognitive skill learning. 2006 , 44, 2445-51	23
1418	Association of HFE common mutations with Parkinson's disease, Alzheimer's disease and mild cognitive impairment in a Portuguese cohort. 2006 , 6, 24	62
1417	The frequency and validity of self-reported diagnosis of Parkinson's Disease in the UK elderly: MRC CFAS cohort. 2006 , 6, 29	12
1416	A common genetic factor for Parkinson disease in ethnic Chinese population in Taiwan. 2006 , 6, 47	66
1415	Neuropathology, tremor and electromyogram in rats exposed to manganese phosphate/sulfate mixture. 2006 , 26, 419-26	10
1414	Orthostatic hypotension in Parkinson's disease: association with cognitive decline?. 2006 , 21, 778-83	85

1413	Presence of an APOE4 allele results in significantly earlier onset of Parkinson's disease and a higher risk with dementia. 2006 , 21, 45-9	73
1412	HS1-BP3 gene variant is common in familial essential tremor. 2006 , 21, 306-9	23
1411	Nigral degeneration and striatal dopaminergic dysfunction in idiopathic and Parkin-linked Parkinson's disease. 2006 , 21, 299-305	17
1410	Inhibition of catechol-O-methyltransferase contributes to more stable levodopa plasma levels. 2006 , 21, 332-6	41
1409	REM sleep behavior disorder, hallucinations, and cognitive impairment in Parkinson's disease. 2006 , 21, 462-6	96
1408	Subthalamic nucleus influences spatial orientation in extra-personal space. 2006 , 21, 354-61	13
1407	Parkinson's disease and LRRK2: frequency of a common mutation in U.S. movement disorder clinics. 2006 , 21, 519-23	70
1406	No correlation between the clinical severity of autonomic symptoms (SCOPA-AUT) and electrophysiological test abnormalities in advanced Parkinson's disease. 2006 , 21, 430-1	13
1405	Quantitative study of salivary secretion in Parkinson's disease. 2006 , 21, 660-7	98
1404	Hereditary spastic paraplegia associated with dopa-responsive parkinsonism. 2006 , 21, 716-7	14
1403	Parkinsonism and Parkinson's disease in the elderly: a community-based survey in Brazil (the Bambu study). 2006 , 21, 800-8	144
1402	Blood donations, iron stores, and risk of Parkinson's disease. 2006 , 21, 835-8	30
1401	Topography of putaminal degeneration in multiple system atrophy: a diffusion magnetic resonance study. 2006 , 21, 847-52	55
1400	Association of the Tau haplotype with Parkinson's disease in the Greek population. 2006 , 21, 1036-9	22
1399	Sleep complaints and their relation with drug treatment in patients suffering from Parkinson's disease. 2006 , 21, 983-8	34
1398	Protein intake in Parkinsonian patients using the EPIC food frequency questionnaire. 2006 , 21, 1229-31	29
1397	Cardiac 123I-MIBG scintigraphy in patients with essential tremor. 2006 , 21, 1235-8	27
1396	Head tremor in Parkinson's disease. 2006 , 21, 1245-8	49

1395	Minor depression and brain perfusion images in Parkinson's disease. 2006 , 21, 1169-74	28
1394	Effect of rivastigmine on tremor in patients with Parkinson's disease and dementia. 2006 , 21, 1663-6	28
1393	What is the evidence for a premorbid parkinsonian personality: a systematic review. 2006 , 21, 1066-72	125
1392	Clinical phenotype of subjects with Parkinson's disease and orthostatic hypotension: autonomic symptom and demographic comparison. 2006 , 21, 1851-5	50
1391	Special low-protein foods ameliorate postprandial off in patients with advanced Parkinson's disease. 2006 , 21, 1682-7	37
1390	Efficacy and safety of herbal medicines for idiopathic Parkinson's disease: a systematic review. 2006 , 21, 1709-15	49
1389	Noninvasive cortical stimulation with transcranial direct current stimulation in Parkinson's disease. 2006 , 21, 1693-702	298
1388	NR4A2 genetic variation in sporadic Parkinson's disease: a genome-wide approach. 2006 , 21, 1960-3	14
1387	Direct costs of managing Parkinson's disease in India: concerns in a developing country. 2006 , 21, 1755-8	19
1386	Predictive value of transcranial sonography in the diagnosis of Parkinson's disease. 2006 , 21, 1763-5	51
1385	Correlation between cardiac 123I-MIBG and odor identification in patients with Parkinson's disease and multiple system atrophy. 2006 , 21, 1975-7	68
1384	Neurofilament heavy-chain NfH(SMI35) in cerebrospinal fluid supports the differential diagnosis of Parkinsonian syndromes. 2006 , 21, 2224-7	65
1383	Hypoperfusion of the visual pathway in parkinsonian patients with visual hallucinations. 2006 , 21, 2140-4	63
1382	Hypoperfusion of the auditory and prefrontal cortices in Parkinsonian patients with verbal hallucinations. 2006 , 21, 2165-9	19
1381	Exploring an interaction of adenosine A2A receptor variability with coffee and tea intake in Parkinson's disease. 2006 , 141B, 634-6	13
1380	Clinical heterogeneity of alpha-synuclein gene duplication in Parkinson's disease. 2006 , 59, 298-309	281
1379	UCHL-1 is not a Parkinson's disease susceptibility gene. 2006 , 59, 627-33	107
1378	Interface between tauopathies and synucleinopathies: a tale of two proteins. 2006 , 59, 449-58	204

1377	Genetics of Parkinson's disease and parkinsonism. 2006 , 60, 389-98		252
1376	Transcranial sonography and [123I]FP-CIT SPECT disclose complementary aspects of Parkinson's disease. 2006 , 129, 1188-93		107
1375	Visual recognition memory differentiates dementia with Lewy bodies and Parkinson's disease dementia. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2007 , 78, 738-41	5.5	40
1374	Pesticides and Parkinson's disease--is there a link?. 2006 , 114, 156-64		281
1373	The DONPAD-study--treatment of dementia in patients with Parkinson's disease with donepezil. 2006 , 27-30		14
1372	Growth hormone stimulation tests in the differential diagnosis of Parkinson's disease. 2006 , 4, 322-5		11
1371	Differential diagnosis of Parkinson's disease: a new blood test?. 2006 , 4, 246-7		0
1370	Causes of death in multiple system atrophy. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2007 , 78, 327-9	5.5	46
1369	Non-motor symptoms in Parkinson's disease: an underdiagnosed problem. 2006 , 2, 967-982		14
1368	Impaired visual acuity as a risk factor for visual hallucinations in Parkinson's disease. 2006 , 19, 36-40		61
1367	A multicentre longitudinal observational study of changes in self reported health status in people with Parkinson's disease left untreated at diagnosis. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2007 , 78, 465-9	5.5	100
1366	Artificial neural network classifier for the diagnosis of Parkinson's disease using [99mTc]TRODAT-1 and SPECT. 2006 , 51, 3057-66		28
1365	Voxel-wise analysis of diffusion weighted imaging reveals disruption of the olfactory tract in Parkinson's disease. 2006 , 129, 538-42		108
1364	Frontal assessment battery and brain perfusion image in Parkinson's disease. 2006 , 19, 41-5		32
1363	Association of tau haplotype-tagging polymorphisms with Parkinson's disease in diverse ethnic Parkinson's disease cohorts. 2006 , 3, 327-33		32
1362	Measuring therapy adherence in Parkinson's disease: a comparison of methods. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2006 , 77, 249-51	5.5	46
1361	Practice Parameter: diagnosis and prognosis of new onset Parkinson disease (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology. 2006 , 66, 968-75		216
1360	Life goals of patients with Parkinson's disease: A pilot study on correlations with mood and cognitive functions. 2006 , 20, 818-26		26

1359	Immediate placebo effect in Parkinson's disease--is the subjective relief accompanied by objective improvement?. 2006 , 56, 222-9	39
1358	Levodopa, motor fluctuations and dyskinesia in Parkinson's disease. 2006 , 7, 1715-30	58
1357	Multiregional gene expression profiling identifies MRPS6 as a possible candidate gene for Parkinson's disease. 2006 , 13, 205-15	58
1356	Can mid-sagittal MRI be used to diagnose progressive supranuclear palsy?. 2006 , 2, 12-3	1
1355	C-terminal truncation and Parkinson's disease-associated mutations down-regulate the protein serine/threonine kinase activity of PTEN-induced kinase-1. 2006 , 15, 3251-62	123
1354	Molecular markers of early Parkinson's disease based on gene expression in blood. 2007 , 104, 955-60	381
1353	Parkinson's Disease: Genetics and Pathogenesis. 2007 ,	
1352	Environmental risk factors for Parkinson's disease and parkinsonism: the Geoparkinson study. 2007 , 64, 666-72	172
1351	NICE guideline for Parkinson's disease. 2007 , 36, 240-2	28
1350	Parkinsonism. 2007 , 79-103	
1349	G2019S LRRK2 mutation causing Parkinson's disease without Lewy bodies. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2007 , 78, 626-8	5.5 76
1348	Diet with LPP for renal patients increases daily energy expenditure and improves motor function in parkinsonian patients with motor fluctuations. 2007 , 10, 129-35	12
1347	A prospective study of familial versus sporadic Parkinson's disease. 2007 , 4, 424-7	29
1346	Serum heart-type fatty acid-binding protein and cerebrospinal fluid tau: marker candidates for dementia with Lewy bodies. 2007 , 4, 366-75	55
1345	Comprehensive screening of a North American Parkinson's disease cohort for LRRK2 mutation. 2007 , 4, 386-91	23
1344	Detection of the subthalamic nucleus in microelectrographic recordings in Parkinson disease using the high-frequency (> 500 hz) neuronal background. Technical note. 2007 , 106, 175-9	44
1343	Mutations in the glucocerebrosidase gene are associated with early-onset Parkinson disease. 2007 , 69, 1270-7	194
1342	Cognitive slowing in Parkinson disease is accompanied by hypofunctioning of the striatum. 2007 , 68, 1062-8	64

1341	Consumption of dairy products and risk of Parkinson's disease. 2007 , 165, 998-1006		116
1340	New onset heightened interest or drive for gambling, shopping, eating or sexual activity in patients with Parkinson's disease: the role of dopamine agonist treatment and age at motor symptoms onset. 2007 , 21, 501-6		136
1339	Motor and nonmotor symptom follow-up in parkinsonian patients after deep brain stimulation of the subthalamic nucleus. 2007 , 58, 218-23		89
1338	Ablation of D1 dopamine receptor-expressing cells generates mice with seizures, dystonia, hyperactivity, and impaired oral behavior. 2007 , 104, 4182-7		53
1337	Prevalence and pattern of perceived intelligibility changes in Parkinson's disease. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2007 , 78, 1188-90	5.5	103
1336	Delayed blink reflex in dementia with Lewy bodies. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2007 , 78, 1137-9	5.5	23
1335	Odour identification test and its relation to cardiac 123I-metaiodobenzylguanidine in patients with drug induced parkinsonism. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2007 , 78, 1250-2	5.5	48
1334	Effects of tango on functional mobility in Parkinson's disease: a preliminary study. 2007 , 31, 173-9		190
1333	Profile of cognitive impairment in dementia associated with Parkinson's disease compared with Alzheimer's disease. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2007 , 78, 1064-8	5.5	68
1332	The Role of Levodopa in the Chronic Neurodegenerative Disorder â Parkinson's Disease. 2007 , 237-246		
1331	Circadian variation of core body temperature in Parkinson disease patients with depression: a potential biological marker for depression in Parkinson disease. 2007 , 56, 172-9		28
1330	Glucocerebrosidase gene mutation is a risk factor for early onset of Parkinson disease among Taiwanese. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2007 , 78, 977-9	5.5	65
1329	Analysis of ferritin genes in Parkinson disease. 2007 , 45, 1450-6		22
1328	Presynaptic alpha-synuclein aggregates, not Lewy bodies, cause neurodegeneration in dementia with Lewy bodies. 2007 , 27, 1405-10		415
1327	Influence of motor symptoms upon the quality of life of patients with Parkinson's disease. 2007 , 57, 161-5		89
1326	Functional ability correlates with cognitive impairment in Parkinson's disease and Alzheimer's disease. 2007 , 24, 327-34		32
1325	Transcranial sonography in the evaluation of Parkinson disease. 2007 , 26, 509-12		18
1324	Chapter 6 Progressive Supranuclear Palsy and Corticobasal Degeneration. 2007 , 30, 141-164		

1323	Thalamic hyperperfusion in verbal hallucination of Parkinsonian patients. 2007 , 46, 1765-9	9
1322	"Idiopathic" rapid-eye-movement (REM) sleep behavior disorder is associated with future development of neurodegenerative diseases. 2007 , 13, 98-101	26
1321	Educational level as a modulator of cognitive performance and neuropsychiatric features in Parkinson disease. 2007 , 20, 68-72	25
1320	Hormonal replacement therapy in women with Parkinson disease and levodopa-induced dyskinesia: a crossover trial. 2007 , 30, 276-80	30
1319	Leucine-rich repeat kinase 2 G2385R variant is a risk factor for Parkinson disease in Asian population. 2007 , 18, 273-5	111
1318	[123I]FP-CIT striatal binding in early Parkinson's disease patients with tremor vs. akinetic-rigid onset. 2007 , 18, 1499-502	48
1317	Progressive supranuclear palsy (Steele-Richardson-Olszewski syndrome): a short historical review. 2007 , 13, 302-4	3
1316	Association between caffeine intake and risk of Parkinson's disease among fast and slow metabolizers. 2007 , 17, 1001-5	35
1315	Relation between subtype of Parkinson's disease and REM sleep behavior disorder. 2007 , 8, 779-83	105
1314	Glucocerebrosidase mutations in Chinese subjects from Taiwan with sporadic Parkinson disease. 2007 , 91, 195-200	93
1313	LRRK2 mutations and Parkinson's disease in Sardinia--A Mediterranean genetic isolate. 2007 , 13, 17-21	12
1312	Effectiveness of physiotherapy in Parkinson's disease: the feasibility of a randomised controlled trial. 2007 , 13, 115-21	33
1311	Recognition memory for unfamiliar faces in Parkinson's disease: behavioral and electrophysiologic measures. 2007 , 13, 157-64	17
1310	Heterogeneous factors in dementia with Parkinson's disease: IMP-SPECT study. 2007 , 13, 174-81	10
1309	The effect of cigarette smoking, tea, and coffee consumption on the progression of Parkinson's disease. 2007 , 13, 243-5	28
1308	Association of alpha-synuclein gene haplotypes with Parkinson's disease. 2007 , 13, 343-7	14
1307	Differentiation of Parkinson's disease and progressive supranuclear palsy with magnetic resonance imaging: the first Brazilian experience. 2007 , 13, 389-93	17
1306	Auditory event-related potentials in Parkinson's disease: prominent correlation with attention. 2007 , 13, 394-8	18

1305	Botulinum toxin A for drooling in Parkinson's disease: a pilot study to compare submandibular to parotid gland injections. 2007 , 13, 532-4	28
1304	CSF neurofilament light chain and tau differentiate multiple system atrophy from Parkinson's disease. 2007 , 28, 742-7	110
1303	La Maladie de Parkinson. 2007 , 11-88	1
1302	Introduction to Parkinson's disease. 2007 , 53, 195-9	11
1301	Entacapone improves complex movement performance in patients with Parkinson's disease. 2007 , 14, 424-8	10
1300	Prevalence of Parkinson's disease in Korea. 2007 , 14, 1155-7	45
1299	La maladie de Parkinson et les syndromes parkinsoniens apparentés. 2007 , 31, 304-313	6
1298	Phenotypic associations of tau and ApoE in Parkinson's disease. 2007 , 414, 141-4	41
1297	BDNF tagging polymorphisms and haplotype analysis in sporadic Parkinson's disease in diverse ethnic groups. 2007 , 415, 59-63	20
1296	Grooved pegboard test as a biomarker of nigrostriatal denervation in Parkinson's disease. 2007 , 424, 185-9	46
1295	Substantia nigra echomorphology in the healthy very old: Correlation with motor slowing. 2007 , 34, 1054-9	60
1294	3,4-dihydroxy-6-[18F]-fluoro-L-phenylalanine positron emission tomography in patients with central motor disorders and in evaluation of brain and other tumors. 2007 , 37, 440-50	27
1293	[Hedonistic homeostasis in Parkinson disease]. 2007 , 33, 876-8	1
1292	The effects of incremental speed-dependent treadmill training on postural instability and fear of falling in Parkinson's disease. 2007 , 21, 698-705	157
1291	Paralisi sopranucleare progressiva (malattia di Steele-Richardson-Olszewski). 2007 , 7, 1-12	
1290	Morphological substrates of parkinsonism with and without dementia: a retrospective clinico-pathological study. 2007 , 91-104	54
1289	Pharmacotherapy and Treatment of Parkinson's Disease. 2007 ,	
1288	Early detection of Parkinson's disease. 2007 , 83, 457-77	1

1287	Autosomal dominant Parkinson's disease and the route to new therapies. 2007 , 7, 649-56	2
1286	Cueing training in the home improves gait-related mobility in Parkinson's disease: the RESCUE trial. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2007 , 78, 134-40	55 563
1285	Changes in network activity with the progression of Parkinson's disease. 2007 , 130, 1834-46	318
1284	Motor symptoms in Parkinson's disease. 2007 , 83, 329-42	18
1283	[Multi-infarct disorder presenting as corticobasal degeneration (DCB): vascular pseudo-corticobasal degeneration?]. 2007 , 163, 1191-9	12
1282	New approaches to understanding hallucinations in Parkinson's disease: phenomenology and possible origins. 2007 , 7, 1731-50	25
1281	[Subthalamic nucleus stimulation using a Fisher ZD stereotactic frame, MR-CT fusion guidance and peroperative orthogonal radiographs, in Parkinson disease]. 2007 , 53, 463-9	2
1280	Is cerebral autoregulation impaired in Parkinson's disease? A transcranial Doppler study. 2007 , 254, 49-53	39
1279	MRI confirms mild cognitive impairments prodromal for Alzheimer's, vascular and Parkinson-Lewy body dementias. 2007 , 257, 97-104	59
1278	Utilidad diagn�stica de la SPECT con FP-CIT en el estudio de pacientes con parkinsonismo. 2007 , 26, 277-285	8
1277	Diagnostic accuracy of FP-CIT SPECT in patients with Parkinsonism. 2007 , 26, 277-285	6
1276	Parkinson's disease. 2007 , 335, 441-5	61
1275	Lewy Body Disorders. 2007 , 267-343	3
1274	Cognitive function assessment in idiopathic Parkinson's disease. 2007 , 65, 942-6	15
1273	Use of the Putamen/Caudate Volume Ratio for Early Differentiation between Parkinsonian Variant of Multiple System Atrophy and Parkinson Disease. 2007 , 3, 79-81	12
1272	Analysis of brief language tests in the detection of cognitive decline and dementia. 2007 , 1, 37-45	17
1271	Quality of life scale in Parkinson's disease PDQ-39 - (Brazilian Portuguese version) to assess patients with and without levodopa motor fluctuation. 2007 , 65, 787-91	41
1270	[Olfactory dysfunction in Parkinson's disease]. 2007 , 65, 647-52	13

1269	Heterozygous parkin point mutations are as common in control subjects as in Parkinson's patients. 2007 , 61, 47-54	96
1268	Effect of quetiapine in psychotic Parkinson's disease patients: a double-blind labeled study of 3 months' duration. 2007 , 22, 313-8	195
1267	Validation of a new scale for the evaluation of sialorrhea in patients with Parkinson's disease. 2007 , 22, 107-11	59
1266	Subthalamic nucleus stimulation is efficacious in patients with Parkinsonism and LRRK2 mutations. 2007 , 22, 119-22	33
1265	Transcranial brain sonography findings in clinical subgroups of idiopathic Parkinson's disease. 2007 , 22, 48-54	73
1264	Acute effects of immediate and controlled-release levodopa on mood in Parkinson's disease: A double-blind study. 2007 , 22, 62-7	59
1263	Independent validation of SCOPA-psychosocial and metric properties of the PDQ-39 Brazilian version. 2007 , 22, 91-8	49
1262	Unilateral versus bilateral tasks in early asymmetric Parkinson's disease: differential effects on bradykinesia. 2007 , 22, 328-33	28
1261	Characteristics of sleep disturbances in Japanese patients with Parkinson's disease. A study using Parkinson's disease sleep scale. 2007 , 22, 1245-51	34
1260	Testosterone not associated with violent dreams or REM sleep behavior disorder in men with Parkinson's. 2007 , 22, 411-4	22
1259	Midbrain sonography in patients with essential tremor. 2007 , 22, 414-7	104
1258	Caregiver burden in Parkinson's disease. 2007 , 22, 924-31; quiz 1060	159
1257	Simple clinical tests may predict severe oropharyngeal dysphagia in Parkinson's disease. 2007 , 22, 640-4	51
1256	Determinants of quality of life in Brazilian patients with Parkinson's disease. 2007 , 22, 1408-1415	68
1255	Nonpharmacological treatment, fludrocortisone, and domperidone for orthostatic hypotension in Parkinson's disease. 2007 , 22, 1543-9	102
1254	Mild Parkinsonian signs: An overview of an emerging concept. 2007 , 22, 1681-8	114
1253	Controlled study of decision-making and cognitive impairment in Parkinson's disease. 2007 , 22, 1430-1435	102
1252	[123I] FP-CIT spect study in vascular parkinsonism and Parkinson's disease. 2007 , 22, 1278-85	87

1251	Myocardial sympathetic degeneration correlates with clinical phenotype of Parkinson's disease. 2007, 22, 1004-8	77
1250	Deep brain stimulation and medication for parkinsonian tremor during secondary tasks. 2007, 22, 1157-63	11
1249	The Unified Parkinson's Disease Rating Scale: validation study of the mentation, behavior, and mood section. 2007, 22, 2156-61	42
1248	High prevalence of LRRK2 mutations in familial and sporadic Parkinson's disease in Portugal. 2007, 22, 1194-201	66
1247	Prognostic factors for the progression of Parkinson's disease: a systematic review. 2007, 22, 1839-51; quiz 1988	162
1246	A nationwide survey of excessive daytime sleepiness in Parkinson's disease in France. 2007, 22, 1567-72	93
1245	Functional abnormalities in the primary orofacial sensorimotor cortex during speech in Parkinson's disease. 2007, 22, 2043-51	64
1244	Video analysis of motor events in REM sleep behavior disorder. 2007, 22, 1464-1470	99
1243	A novel LRRK2 mutation in an Austrian cohort of patients with Parkinson's disease. 2007, 22, 1640-3	16
1242	Prevalence of nonmotor symptoms in Parkinson's disease in an international setting; study using nonmotor symptoms questionnaire in 545 patients. 2007, 22, 1623-9	375
1241	The metric properties of a novel non-motor symptoms scale for Parkinson's disease: Results from an international pilot study. 2007, 22, 1901-11	638
1240	Restless legs syndrome in Parkinson's disease. 2007, 22, 1912-6	96
1239	Midbrain transcranial sonography in Korean patients with Parkinson's disease. 2007, 22, 1922-6	56
1238	Deep brain stimulation for the treatment of atypical parkinsonism. 2007, 22, 2149-55	71
1237	Myoclonus or tremor in orthostatism: an under-recognized cause of unsteadiness in Parkinson's disease. 2007, 22, 2063-9	102
1236	Analysis of LRRK2 Gly2385Arg genetic variant in non-Chinese Asians. 2007, 22, 1816-8	25
1235	Comparison of brain MRI and 18F-FDG PET in the differential diagnosis of multiple system atrophy from Parkinson's disease. 2007, 22, 2352-8	33
1234	Ipratropium bromide spray as treatment for sialorrhea in Parkinson's disease. 2007, 22, 2268-73	54

1233	Rotigotine transdermal patch in early Parkinson's disease: a randomized, double-blind, controlled study versus placebo and ropinirole. 2007 , 22, 2398-404	174
1232	The prevalence of LRRK2 Gly2385Arg variant in Chinese Han population with Parkinson's disease. 2007 , 22, 2439-43	42
1231	Effective quantitative real-time polymerase chain reaction analysis of the parkin gene (PARK2) exon 1-12 dosage. 2007 , 8, 6	22
1230	Association of A313 G polymorphism (GSTP1*B) in the glutathione-S-transferase P1 gene with sporadic Parkinson's disease. 2007 , 14, 156-61	31
1229	Striatal dopamine transporter binding in patients with Parkinson's disease and severe occupational hydrocarbon exposure. 2007 , 14, 297-9	8
1228	Immune reactivity towards insulin, its amyloid and protein S100B in blood sera of Parkinson's disease patients. 2007 , 14, 327-34	48
1227	A common leucine-rich repeat kinase 2 gene mutation in familial and sporadic Parkinson's disease in Russia. 2007 , 14, 413-7	21
1226	Molecular imaging in hereditary forms of parkinsonism. 2007 , 14, 359-68	6
1225	The G2019S LRRK2 mutation is uncommon amongst Greek patients with sporadic Parkinson's disease. 2007 , 14, 1088-90	12
1224	A comparison of cerebral glucose metabolism in Parkinson's disease, Parkinson's disease dementia and dementia with Lewy bodies. 2007 , 14, 1357-62	98
1223	Hyperechogenicity of the substantia nigra in Parkinson's disease. 2007 , 17, 164-7	43
1222	Wisconsin Card Sorting Test in Parkinson's disease: diffusion tensor imaging. 2007 , 116, 108-12	39
1221	Dementia in Parkinson's disease: diffusion tensor imaging. 2007 , 116, 177-81	75
1220	Clinical evaluation of Parkinson's disease dementia: association with aging and visual hallucination. 2007 , 116, 190-5	14
1219	Bone mass in elderly patients with Parkinson's disease. 2007 , 116, 248-54	36
1218	Assessment of hallucinations in Parkinson's disease using a novel scale. 2008 , 117, 35-40	8
1217	Meta-analysis of the literature on diagnostic accuracy of SPECT in parkinsonian syndromes. 2007 , 7, 27	85
1216	Protocol of a prospective study on the diagnostic value of transcranial duplex scanning of the substantia nigra in patients with parkinsonian symptoms. 2007 , 7, 28	6

1215	The striatum and probabilistic implicit sequence learning. 2007 , 1137, 117-30	55
1214	Feedback-based versus observational classification learning in healthy aging and Parkinson's disease. 2007 , 1142, 178-88	32
1213	The application of network mapping in differential diagnosis of parkinsonian disorders. 2007 , 6, 359-366	11
1212	Osteopontin is elevated in Parkinson's disease and its absence leads to reduced neurodegeneration in the MPTP model. 2007 , 25, 473-82	91
1211	Impaired recognition of facial expressions of anger in Parkinson's disease patients acutely withdrawn from dopamine replacement therapy. 2007 , 45, 65-74	130
1210	Dopamine asymmetry interacts with medication to affect cognition in Parkinson's disease. 2007 , 45, 357-67	39
1209	Higher frequency of regulatory T cells in the elderly and increased suppressive activity in neurodegeneration. 2007 , 188, 117-27	170
1208	Effects of STN DBS on memory guided force control in Parkinson's disease (June 2007). 2007 , 15, 155-65	4
1207	Effects of STN DBS on rigidity in Parkinson's disease. 2007 , 15, 173-81	51
1206	Deep brain stimulation of the subthalamic nucleus improves set shifting but does not affect dual task performance in Parkinson's disease. 2007 , 15, 198-206	17
1205	Gender differences in Parkinson's disease. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2007 , 78, 819-24	5.5 409
1204	Diagnostic value of asymmetric striatal D2 receptor upregulation in Parkinson's disease: an [123I]IBZM and [123I]FP-CIT SPECT study. 2007 , 34, 502-7	35
1203	Quantification of Parkinson's disease-related network expression with ECD SPECT. 2007 , 34, 496-501	65
1202	Imaging non-dopaminergic function in Parkinson's disease. 2007 , 9, 217-22	32
1201	Autonomic and cognitive dysfunction in Parkinson's disease. 2007 , 17, 93-8	49
1200	A Study on the Effects of Argentine Tango as a Form of Partnered Dance for those with Parkinson Disease and the Healthy Elderly. 2007 , 29, 109-127	85
1199	Striatal FP-CIT uptake differs in the subtypes of early Parkinson's disease. 2007 , 114, 331-5	132
1198	Motor fluctuations and dyskinesias in advanced/end stage Parkinson's disease: a study from a population of brain donors. 2007 , 114, 341-5	13

1197	Growth hormone response in low-dose apomorphine test correlates with nigrostriatal dopamine transporter binding in patients with Parkinson's disease. 2007 , 114, 589-94	3
1196	Orthostatic hypotension and attention in Parkinson's disease with and without dementia. 2007 , 114, 585-8	61
1195	Dopamine transporter immunoreactivity in peripheral blood lymphocytes discriminates Parkinson's disease from essential tremor. 2007 , 114, 935-8	29
1194	Tauopathies and synucleinopathies: do cerebrospinal fluid beta-amyloid peptides reflect disease-specific pathogenesis?. 2007 , 114, 919-27	32
1193	The attentional cost of external rhythmical cues and their impact on gait in Parkinson's disease: effect of cue modality and task complexity. 2007 , 114, 1243-8	99
1192	Subacute hemispherical parkinsonism in 5 patients with infarcts of the basal ganglia. 2007 , 114, 1463-7	10
1191	Detecting asymmetries in balance control with system identification: first experimental results from Parkinson patients. 2007 , 114, 1333-7	29
1190	The LRRK2 Gly2385Arg variant is associated with Parkinson's disease: genetic and functional evidence. 2007 , 120, 857-63	131
1189	The effect of age of onset of PD on risk of dementia. 2007 , 254, 38-45	118
1188	Depression in Parkinson's disease. Diffusion tensor imaging study. 2007 , 254, 1170-3	71
1187	Selective hyposmia and nigrostriatal dopaminergic denervation in Parkinson's disease. 2007 , 254, 84-90	103
1186	¹⁸ F-FP-CIT PET imaging and SPM analysis of dopamine transporters in Parkinson's disease in various Hoehn & Yahr stages. 2007 , 254, 185-90	73
1185	Progression of brain atrophy in multiple system atrophy. A longitudinal VBM study. 2007 , 254, 191-6	100
1184	Relationship between age and subtypes of psychotic symptoms in Parkinson's disease. 2007 , 254, 448-52	40
1183	Transcranial color-coded sonography helps differentiation between idiopathic Parkinson's disease and vascular parkinsonism. 2007 , 254, 501-7	59
1182	Association of daytime sleepiness with nigrostriatal dopaminergic degeneration in early Parkinson's disease. 2007 , 254, 1037-43	63
1181	T2*-weighted MRI in diagnosis of multiple system atrophy. A practical approach for clinicians. 2007 , 254, 1184-8	54
1180	Olfactory dysfunction in Parkinson's disease. 2007 , 254, IV2-IV7	5

1179	Morbus Parkinson: Klinik, Differenzialdiagnostik und Therapie. Von Priv.-Doz. Dr. med. Carsten Buhmann, Universitätsklinikum Eppendorf, Hamburg. 2007 , 1, 33-39	
1178	Ambulatory monitoring of freezing of gait in Parkinson's disease. 2008 , 167, 340-8	326
1177	Twenty-first century brain banking: practical prerequisites and lessons from the past: the experience of New York Brain Bank, Taub Institute, Columbia University. 2008 , 9, 247-58	39
1176	Rasch analysis of the short form 8-item Parkinson's Disease Questionnaire (PDQ-8). 2008 , 17, 541-8	26
1175	Neuropsychological characteristics of dementia with Lewy bodies and Parkinson's disease with dementia: differentiation, early detection, and implications for "mild cognitive impairment" and biomarkers. 2008 , 18, 103-19	142
1174	Metabolomic analysis of urine and serum in Parkinson's disease. 2008 , 4, 191-201	79
1173	Sudden turn during walking is impaired in people with Parkinson's disease. 2008 , 190, 43-51	49
1172	The cost effectiveness of 123I-FP-CIT SPECT imaging in patients with an uncertain clinical diagnosis of parkinsonism. 2008 , 35, 1367-76	38
1171	[Atypical Parkinson syndromes]. 2008 , 79, 1203-20; quiz 1221-2	1
1170	Nocturnal restlessness and distressing dreams in patients with early Parkinson's disease: Role of the Parkinson's disease sleep scale (PDSS). 2008 , 12, 50-55	1
1169	Nonsynonymous polymorphisms of histamine-metabolising enzymes in patients with Parkinson's disease. 2008 , 10, 10-6	27
1168	The LRRK2 Arg1628Pro variant is a risk factor for Parkinson's disease in the Chinese population. 2008 , 9, 271-6	50
1167	The PRIAMO study: background, methods and recruitment. 2008 , 29, 61-5	24
1166	Dopaminergic modulation of emotional memory in Parkinson's disease. 2008 , 115, 1159-63	5
1165	Clinical characteristics of Parkinson's disease among Jewish Ethnic groups in Israel. 2008 , 115, 1279-84	14
1164	Evidence that incidental Lewy body disease is pre-symptomatic Parkinson's disease. 2008 , 115, 437-44	283
1163	MR imaging of brainstem atrophy in progressive supranuclear palsy. 2008 , 255, 37-44	39
1162	Polymorphisms in the proteasomal subunit alpha4 are not associated with Parkinson's disease. 2008 , 255, 441-2	

1161	Is REM sleep behaviour disorder (RBD) a risk factor of dementia in idiopathic Parkinson's disease?. 2008, 255, 192-6	102
1160	Subthalamic nucleus stimulation and levodopa-resistant postural instability in Parkinson's disease. 2008, 255, 205-10	49
1159	The impact of subthalamic deep brain stimulation on bradykinesia of proximal and distal upper limb muscles in Parkinson's disease. 2008, 255, 429-37	17
1158	Cognitive impairment in 873 patients with idiopathic Parkinson's disease. Results from the German Study on Epidemiology of Parkinson's Disease with Dementia (GEPAD). 2008, 255, 255-64	199
1157	Movement disorders at a university hospital emergency room. An analysis of clinical pattern and etiology. 2008, 255, 745-9	9
1156	Parkinsonian patients show impaired predictive smooth pursuit. 2008, 255, 1071-8	10
1155	Lower serum ceruloplasmin levels correlate with younger age of onset in Parkinson's disease. 2008, 255, 1957-62	47
1154	Genetic variability of histamine receptors in patients with Parkinson's disease. 2008, 9, 15	22
1153	Test-retest repeatability of assessing environmental and lifestyle factors in Parkinson's disease. 2008, 23, 1032-1036	3
1152	The arginine growth hormone stimulation test in bradykinetic-rigid parkinsonisms. 2008, 23, 190-4	6
1151	Anger in Parkinson's disease: a case-control study. 2008, 23, 195-9	12
1150	Psychometric attributes of the SCOPA-COG Brazilian version. 2008, 23, 81-7	24
1149	Tremor dominant parkinsonism: Clinical description and LRRK2 mutation screening. 2008, 23, 518-23	41
1148	Transcranial sonography findings in welding-related Parkinsonism in comparison to Parkinson's disease. 2008, 23, 141-5	22
1147	Mirror movements in patients with Parkinson's disease. 2008, 23, 253-8	33
1146	Benign tremulous parkinsonism: a clinicopathological study. 2008, 23, 311-2	9
1145	Pathogenicity of LRRK2 P755L variant in Parkinson's disease. 2008, 23, 734-6	7
1144	A prospective study of delusional misidentification syndromes in Parkinson's disease with dementia. 2008, 23, 443-8	34

1143	A validation study of depressive syndromes in Parkinson's disease. 2008 , 23, 538-46	69
1142	Validity of spiral analysis in early Parkinson's disease. 2008 , 23, 531-7	89
1141	For better or worse: The effect of levodopa on speech in Parkinson's disease. 2008 , 23, 574-80	102
1140	Footstep adjustments used to turn during walking in Parkinson's disease. 2008 , 23, 817-23	55
1139	Abnormal metabolic networks in atypical parkinsonism. 2008 , 23, 727-33	140
1138	Head and trunk rotation during walking turns in Parkinson's disease. 2008 , 23, 1391-7	59
1137	Ultrasound-guided injection of the iliopsoas muscle with botulinum toxin in camptocormia. 2008 , 23, 889-92	55
1136	Effect of short and long term STN stimulation periods on parkinsonian signs. 2008 , 23, 866-74	8
1135	Parkinson's disease-cognitive rating scale: a new cognitive scale specific for Parkinson's disease. 2008 , 23, 998-1005	215
1134	The Montreal cognitive assessment as a screening tool for cognitive impairment in Parkinson's disease. 2008 , 23, 1043-1046	240
1133	On the structure of motor symptoms of Parkinson's disease. 2008 , 23, 1307-12	33
1132	The frequency of cardiac valvular regurgitation in Parkinson's disease. 2008 , 23, 935-941	26
1131	Circadian rest-activity rhythm is altered in Parkinson's disease patients with hallucinations. 2008 , 23, 1137-45	77
1130	Cognitive dysfunction in Nigerians with Parkinson's disease. 2008 , 23, 1378-83	22
1129	Manifestations of Parkinson disease differ in association with REM sleep behavior disorder. 2008 , 23, 1665-72	139
1128	REM behavior disorder, hallucinations and cognitive impairment in Parkinson's disease: a two-year follow up. 2008 , 23, 1441-5	66
1127	Striatal dopamine transporter imaging correlates with depressive symptoms and tower of London task performance in Parkinson's disease. 2008 , 23, 1580-7	66
1126	High-frequency rTMS over the supplementary motor area for treatment of Parkinson's disease. 2008 , 23, 1524-31	106

1125	Cut-off score of the Mattis Dementia Rating Scale for screening dementia in Parkinson's disease. 2008 , 23, 1546-50	106
1124	Comparison of a timed motor test battery to the Unified Parkinson's Disease Rating Scale-III in Parkinson's disease. 2008 , 23, 1707-17	53
1123	Longitudinal psychometric attributes, responsiveness, and importance of change: An approach using the SCOPA-Psychosocial questionnaire. 2008 , 23, 1516-23	15
1122	Walking speed during single and dual tasks in Parkinson's disease: which characteristics are important?. 2008 , 23, 2312-8	67
1121	Frequency of social phobia and psychometric properties of the Liebowitz social anxiety scale in Parkinson's disease. 2008 , 23, 1739-43	44
1120	Balance self-efficacy determines walking capacity in people with Parkinson's disease. 2008 , 23, 1936-9	23
1119	Prevalence of movement disorders in an elderly nursing home population. 2008 , 46, 359-66	17
1118	The prevalence of Parkinson's disease among Vilnius inhabitants. 2008 , 3, 195-198	1
1117	Advances in the genetics of Parkinson's disease. 2008 , 29, 21-34	20
1116	Executive dysfunction in non-demented Parkinson's disease patients with hallucinations. 2008 , 117, 255-9	49
1115	Depressive illness in Parkinson's disease--indication of a more advanced and widespread neurodegenerative process?. 2008 , 117, 295-304	36
1114	Diagnosis and management of Parkinson's disease dementia. 2008 , 62, 1581-7	61
1113	Cerebral mitochondrial metabolism in early Parkinson's disease. 2008 , 28, 1754-60	29
1112	Conformationally altered p53: a novel Alzheimer's disease marker?. 2008 , 13, 641-7	61
1111	Is quality of life in non-demented Parkinson's disease patients related to cognitive performance? A clinic-based cross-sectional study. 2008 , 15, 128-33	99
1110	LRRK2 Gly2385Arg variant is a risk factor of Parkinson's disease among Han-Chinese from mainland China. 2008 , 15, 301-5	55
1109	Impact of fatigue on quality of life in patients with Parkinson's disease. 2008 , 15, 475-80	66
1108	Diagnostic performance of clinical motor and non-motor tests of Parkinson disease: a matched case-control study. 2008 , 15, 685-91	42

1107	Levodopa/DDCI and entacapone is the preferred treatment for Parkinson's disease patients with motor fluctuations in routine practice: a retrospective, observational analysis of a large French cohort. 2008 , 15, 643-8	3
1106	No association of the Val158Met COMT polymorphism with Parkinson's disease in the Greek population. 2008 , 15, e83	8
1105	Diagnostic value of brain MRI and 18F-FDG PET in the differentiation of Parkinsonian-type multiple system atrophy from Parkinson's disease. 2008 , 15, 1043-9	21
1104	Assessment of sexual dysfunction in patients with Parkinson's disease: a case-control study. 2008 , 15, 1168-72	37
1103	Analysis of Parkinson disease patients from Portugal for mutations in SNCA, PRKN, PINK1 and LRRK2. 2008 , 8, 1	32
1102	A questionnaire-based (UM-PDHQ) study of hallucinations in Parkinson's disease. 2008 , 8, 21	56
1101	The predictive value of transcranial duplex sonography for the clinical diagnosis in undiagnosed parkinsonian syndromes: comparison with SPECT scans. 2008 , 8, 42	27
1100	Trace elements in serum from patients with Parkinson's disease--a prospective case-control study: the Nord-Trøndelag Health Study (HUNT). 2008 , 1219, 111-5	27
1099	The specificity and sensitivity of transcranial ultrasound in the differential diagnosis of Parkinson's disease: a prospective blinded study. 2008 , 7, 417-24	195
1098	Neuropsychological and psychiatric changes after deep brain stimulation for Parkinson's disease: a randomised, multicentre study. 2008 , 7, 605-14	494
1097	Transcranial sonography in movement disorders. 2008 , 7, 1044-55	290
1096	Patients with Parkinson's disease learn to control complex systems via procedural as well as non-procedural learning. 2008 , 46, 2355-63	12
1095	The effect of feedback on non-motor probabilistic classification learning in Parkinson's disease. 2008 , 46, 2683-95	31
1094	Neuropsychology of aging and dementia. 2008 , 88, 113-35	5
1093	Association of visual hallucinations with reduction of MIBG cardiac uptake in Parkinson's disease. 2008 , 264, 22-6	24
1092	Serum heart-fatty acid binding protein levels in patients with Lewy body disease. 2008 , 266, 20-4	29
1091	Evaluation of ActiTrac (ambulatory activity monitor) in Parkinson's Disease. 2008 , 270, 67-9	10
1090	Screening for the LRRK2 G2019S and codon-1441 mutations in a pathological series of parkinsonian syndromes and frontotemporal lobar degeneration. 2008 , 270, 94-8	31

1089	Excessive daytime sleepiness and sleep episodes in Japanese patients with Parkinson's disease. 2008 , 271, 47-52	41
1088	Decreased activities of lysosomal acid alpha-D-galactosidase A in the leukocytes of sporadic Parkinson's disease. 2008 , 271, 168-73	29
1087	Depression in patients with Parkinson's disease: impact on functioning. 2008 , 272, 158-63	16
1086	Levodopa/carbidopa/entacapone-induced acute Pisa syndrome in a Parkinson's disease patient. 2008 , 275, 154-6	28
1085	Mutations in the GIGYF2 (TNRC15) gene at the PARK11 locus in familial Parkinson disease. 2008 , 82, 822-33	135
1084	Differentiating phase shift and delay in narrow band coherent signals. 2008 , 119, 1062-70	14
1083	RNA biomarkers of Parkinson's disease: developing tools for novel therapies. 2008 , 2, 41-53	16
1082	Genetic variability in the SNCA gene influences alpha-synuclein levels in the blood and brain. 2008 , 22, 1327-34	209
1081	Vascular parkinsonism. 2008 , 5, 237-255	25
1080	Cognitive deficits and striato-frontal dopamine release in Parkinson's disease. 2008 , 131, 1294-302	204
1079	Is the G2019S LRRK2 mutation common in all southern European populations?. 2008 , 15, 1027-30	16
1078	Association between AKT1 gene and Parkinson's disease: a protective haplotype. 2008 , 436, 232-4	51
1077	Lack of evidence for association of a UCH-L1 S18Y polymorphism with Parkinson's disease in a Han-Chinese population. 2008 , 442, 200-2	22
1076	Selective hyposmia in Parkinson disease: association with hippocampal dopamine activity. 2008 , 447, 12-6	75
1075	Lack of association of APOE and tau polymorphisms with dementia in Parkinson's disease. 2008 , 448, 20-3	49
1074	An ambulatory persistence power curve: motor planning affects ambulatory persistence in Parkinson's disease. 2008 , 448, 105-9	7
1073	Measuring free-living physical activity in adults with and without neurologic dysfunction with a triaxial accelerometer. 2008 , 89, 1765-71	92
1072	Effect of subthalamic nucleus deep brain stimulation on axial motor control and protective arm responses in Parkinson's disease. 2008 , 157, 798-812	22

1071	Social support plays a role in depression in Parkinson's disease: a cross-section study in a Chinese cohort. 2008 , 14, 43-5	47
1070	Screening for cognitive deficits in Parkinson's disease with the Parkinson neuropsychometric dementia assessment (PANDA) instrument. 2008 , 14, 93-101	142
1069	Plasma lipid peroxidation and antioxidant status of Parkinson's disease patients in the Indian population. 2008 , 14, 52-7	37
1068	Association between Parkinson's disease and glucocerebrosidase mutations in Brazil. 2008 , 14, 58-62	48
1067	Anxiety and depression: main determinants of health-related quality of life in Brazilian patients with Parkinson's disease. 2008 , 14, 102-8	83
1066	Long-term outcome of 50 consecutive Parkinson's disease patients treated with subthalamic deep brain stimulation. 2008 , 14, 114-9	101
1065	Young onset Parkinson's disease. Practical management of medical issues. 2008 , 14, 133-42	21
1064	Clinical and psychosocial factors associated with fatigue in patients with Parkinson's disease. 2008 , 14, 187-92	38
1063	Parkin analysis in early onset Parkinson's disease. 2008 , 14, 326-33	37
1062	HFE gene mutations in a population of Italian Parkinson's disease patients. 2008 , 14, 426-30	23
1061	Autosomal dominant dopa-responsive parkinsonism in a multigenerational Swiss family. 2008 , 14, 465-70	44
1060	Validation of the sleep related items of the Non-motor Symptoms Questionnaire for Parkinson's disease (NMSQuest). 2008 , 14, 641-5	12
1059	Early neuropsychological detection and the characteristics of Parkinson's disease associated with mild dementia. 2008 , 14, 558-62	20
1058	Handedness as a predictor of side of onset of Parkinson's disease. 2008 , 14, 633-5	51
1057	Progress in Parkinson's disease-where do we stand?. 2008 , 85, 376-92	140
1056	Long-term Parkinson's disease--time for optimism. 2008 , 62, 233-5	8
1055	Unilateral subthalamic nucleus stimulation has a measurable ipsilateral effect on rigidity and bradykinesia in Parkinson disease. 2008 , 211, 234-42	61
1054	Evidence of dopamine dysfunction in the hypothalamus of patients with Parkinson's disease: an in vivo 11C-raclopride PET study. 2008 , 214, 112-6	84

1053	Basal ganglia, dopamine and temporal processing: performance on three timing tasks on and off medication in Parkinson's disease. 2008 , 68, 30-41	86
1052	Tai Chi improves balance and mobility in people with Parkinson disease. 2008 , 28, 456-60	200
1051	The recognition of facial emotion expressions in Parkinson's disease. 2008 , 18, 835-48	84
1050	Single-photon emission computed tomography and positron emission tomography evaluations of patients with central motor disorders. 2008 , 38, 274-86	16
1049	Fatigue in Parkinson's disease is not related to excessive sleepiness or quality of sleep. 2008 , 270, 107-13	42
1048	Utilidad de la sonografía del parhquima cerebral en la enfermedad de Parkinson: Estudio comparativo con 123I-FP-CIT SPECT. 2008 , 131, 285-289	3
1047	Diagnostic value of 123I-ioflupane and 123I-iodobenzamide SPECT scans in 248 patients with parkinsonian syndromes. 2008 , 59, 258-66	97
1046	Sensory deficit in Parkinson's disease: evidence of a cutaneous denervation. 2008 , 131, 1903-11	275
1045	The relationship between nosology, etiology and pathogenesis in neurodegenerative diseases. 2008 , 89, 189-92	1
1044	Subthalamic nucleus stimulation affects orbitofrontal cortex in facial emotion recognition: a PET study. 2008 , 131, 1599-608	96
1043	Diffusion-weighted brain imaging study of patients with clinical diagnosis of corticobasal degeneration, progressive supranuclear palsy and Parkinson's disease. 2008 , 131, 2690-700	114
1042	Identification of responders to rivastigmine: a prospective cohort study. 2008 , 25, 60-6	3
1041	Cognitive dysfunctions in mild Parkinson's disease dementia: comparison with patients having mild Alzheimer's disease and normal controls. 2008 , 59, 49-54	15
1040	Cerebral metabolic dysfunction in patients with dementia with Lewy bodies and visual hallucinations. 2008 , 25, 531-8	75
1039	Validity, sensitivity and specificity of the mentation, behavior and mood subscale of the UPDRS. 2008 , 30, 493-6	9
1038	Comparison of cerebral glucose metabolism between multiple system atrophy Parkinsonian type and Parkinson's disease. 2008 , 30, 377-82	12
1037	Dissociation of metabolic and neurovascular responses to levodopa in the treatment of Parkinson's disease. 2008 , 28, 4201-9	117
1036	Changes in cerebral glucose metabolism in patients with Parkinson disease with dementia after cholinesterase inhibitor therapy. 2008 , 49, 2006-11	18

1035	Neuropathology of dementia with Lewy bodies. 2008 , 89, 321-30	12
1034	Animal Models of Parkinson's Disease to Aid Drug Discovery and Development. 2008 , 159-205	1
1033	How do I sound to me? Perceived changes in communication in Parkinson's disease. 2008 , 22, 14-22	82
1032	Parkinson's disease: emerging pharmacotherapy. 2008 , 13, 573-91	17
1031	Evidence that common variation in NEDD9 is associated with susceptibility to late-onset Alzheimer's and Parkinson's disease. 2008 , 17, 759-67	35
1030	Technology insight: imaging neurodegeneration in Parkinson's disease. 2008 , 4, 267-77	28
1029	Subthalamic nucleus stimulation-induced regional blood flow responses correlate with improvement of motor signs in Parkinson disease. 2008 , 131, 2710-9	81
1028	Single photon-emission computed tomography imaging in early Parkinson's disease. 2008 , 8, 1853-64	4
1027	Subthalamic deep brain stimulation after anesthetic inhalation in Parkinson disease: a preliminary study. 2008 , 109, 238-44	65
1026	Comparative genome hybridization array analysis for sporadic Parkinson's disease. 2008 , 118, 1331-45	4
1025	Efficacy and safety of acupuncture for idiopathic Parkinson's disease: a systematic review. 2008 , 14, 663-71	54
1024	Progress in the pathogenesis and genetics of Parkinson's disease. 2008 , 363, 2215-27	59
1023	Levodopa improves time-based prospective memory in Parkinson's disease. 2008 , 14, 601-10	33
1022	Spinocerebellar ataxia type 12 was not found in Korean Parkinsonian patients. 2008 , 35, 488-90	7
1021	Atrophie multisystématique. 2008 , 5, 1-12	
1020	Levodopa and executive performance in Parkinson's disease: a randomized study. 2008 , 14, 832-41	34
1019	[Clinical and pathological study on early diagnosis of Parkinson's disease and dementia with Lewy bodies]. 2008 , 48, 11-24	12
1018	Effects of ropinirole on nonmotor symptoms of Parkinson disease: a prospective multicenter study. 2008 , 31, 261-6	55

1017	Quantification of electromyographic activity during REM sleep in multiple muscles in REM sleep behavior disorder. 2008 , 31, 724-31	133
1016	Local field potential recordings from the pedunculopontine nucleus in a Parkinsonian patient. 2008 , 19, 59-62	27
1015	Outcome of bilateral deep brain subthalamic stimulation in patients carrying the R1441G mutation in the LRRK2 dardarin gene. 2008 , 62, 857-62; discussion 862-3	14
1014	Nondemented Parkinson disease patients: is cognitive performance associated with depressive difficulties?. 2008 , 21, 87-91	13
1013	Catechol-O-methyltransferase inhibition improves levodopa-associated strength increase in patients with Parkinson disease. 2008 , 31, 134-40	11
1012	Central Nervous System (CNS). 2008 , 1	
1011	Dementia and functional decline in patients with Parkinson's disease. 2008 , 2, 96-101	4
1010	Working memory in Parkinson's disease patients: clinical features and response to levodopa. 2008 , 66, 147-51	38
1009	123I-MIBG cardiac scintigraphy provides clues to the underlying neurodegenerative disorder in idiopathic REM sleep behavior disorder. 2008 , 31, 717-23	103
1008	Dorsolateral prefrontal cortex: a possible target for modulating dyskinesias in Parkinson's disease by repetitive transcranial magnetic stimulation. 2008 , 2008, 372125	21
1007	Features associated with the development of non-motor manifestations in Parkinson's disease. 2008 , 66, 22-5	9
1006	Pain in Parkinson's disease: analysis of 50 cases in a clinic of movement disorders. 2008 , 66, 26-9	25
1005	Association between parkinsonism and participation in agriculture in Korea. 2008 , 4, 23-8	13
1004	Therapy of idiopathic normal pressure hydrocephalus. 482-490	
1003	Clinical and molecular neuroimaging characteristics of Brazilian patients with Parkinson's disease and mutations in PARK2 or PARK8 genes. 2009 , 67, 7-11	8
1002	Fatigue in a cohort of geriatric patients with and without Parkinson's disease. 2009 , 42, 771-5	21
1001	Depression in Parkinson's disease: clinical-epidemiological correlates and comparison with a controlled group of non-parkinsonian geriatric patients. 2009 , 31, 39-42	18
1000	Neuroimaging in Parkinsonism: a study with magnetic resonance and spectroscopy as tools in the differential diagnosis. 2009 , 67, 1-6	7

999	Evaluation of body image and self-concept and their correlation with depressive symptoms in Parkinson's disease. 2009 , 67, 585-90		10
998	Pain in Parkinson's disease. 2009 , 67, 591-4		14
997	A cross-study transcriptional analysis of Parkinson's disease. 2009 , 4, e4955		70
996	Regional brain stem atrophy in idiopathic Parkinson's disease detected by anatomical MRI. 2009 , 4, e8247		49
995	Physiological MR in neurodegenerative diseases. 630-641		
994	The short-term effects of different cueing modalities on turn speed in people with Parkinson's disease. 2009 , 23, 831-6		73
993	Deep brain stimulation activation volumes and their association with neurophysiological mapping and therapeutic outcomes. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2009 , 80, 659-66	5.5	162
992	Phosphorus and proton magnetic resonance spectroscopy demonstrates mitochondrial dysfunction in early and advanced Parkinson's disease. 2009 , 132, 3285-97		148
991	The effect of a vibratory lumbar orthosis on walking velocity in patients with Parkinson's disease. 2009 , 33, 82-8		7
990	[A novel posturographic method to differentiate sway patterns of patients with Parkinson's disease from patients with cerebellar ataxia]. 2009 , 54, 347-56		12
989	Simple ratio analysis of 18F-fluorodopa uptake in striatal subregions separates patients with early Parkinson disease from healthy controls. 2009 , 50, 893-9		55
988	A population-based study of parkinsonism in an Amish community. 2009 , 33, 225-30		15
987	Central and peripheral dopamine transporter reduction in Parkinson's disease. 2009 , 31, 687-91		14
986	Variation in GIGYF2 is not associated with Parkinson disease. 2009 , 72, 1886-92		37
985	Glucocerebrosidase mutations in clinical and pathologically proven Parkinson's disease. 2009 , 132, 1783-94		488
984	Does clinical intolerance to a diagnostic acute levodopa challenge differentiate multiple system atrophy from PD?. 2009 , 119, 2257-61		4
983	Eye tracking during a visual paired comparison task as a predictor of early dementia. 2009 , 24, 258-66		86
982	Association between the ubiquitin carboxyl-terminal esterase L1 gene (UCHL1) S18Y variant and Parkinson's Disease: a HuGE review and meta-analysis. 2009 , 170, 1344-57		61

981	Cerebrospinal hypocretin, daytime sleepiness and sleep architecture in Parkinson's disease dementia. 2009 , 132, 3308-17	111
980	History of falls in Parkinson disease is associated with reduced cholinergic activity. 2009 , 73, 1670-6	306
979	Markers of neurodegeneration in idiopathic rapid eye movement sleep behaviour disorder and Parkinson's disease. 2009 , 132, 3298-307	206
978	Levodopa-related wearing-off in Parkinson's disease: identification and management. 2009 , 25, 841-9	61
977	Network biomarkers for the diagnosis and treatment of movement disorders. 2009 , 35, 141-7	30
976	Are dopaminergic pathways involved in theory of mind? A study in Parkinson's disease. 2009 , 47, 406-14	110
975	Decision making under risk and under ambiguity in Parkinson's disease. 2009 , 47, 1901-8	58
974	Startle reflex hyporeactivity in Parkinson's disease: an emotion-specific or arousal-modulated deficit?. 2009 , 47, 1917-27	36
973	The role of the basal ganglia and its cortical connections in sequence learning: evidence from implicit and explicit sequence learning in Parkinson's disease. 2009 , 47, 2564-73	60
972	Dissociation of decision-making under ambiguity and decision-making under risk in patients with Parkinson's disease: a neuropsychological and psychophysiological study. 2009 , 47, 2882-90	131
971	Detecting new neurodegenerative disease genes: does phenotype accuracy limit the horizon?. 2009 , 25, 486-8	12
970	Clinical diagnosis of Parkinson's disease. Proposal of diagnostic subgroups classified at different levels of confidence. 1994 , 89, 242-51	98
969	Prevalence of Parkinson's disease in the elderly: a population study in Gironde, France. 1994 , 90, 111-5	62
968	Proton magnetic resonance spectroscopy in suspected vascular ischemic parkinsonism. 1994 , 90, 405-11	11
967	Loss of libido in Parkinson's disease. 2009 , 6, 1024-1031	36
966	LRRK2 R1628P contributes to Parkinson's disease susceptibility in Chinese Han populations from mainland China. 2009 , 1296, 113-6	21
965	In vivo imaging markers of neurodegeneration of the substantia nigra. 2009 , 44, 4-9	9
964	Occupational factors and risk of Parkinson's disease: A population-based case-control study. 2010 , 53, 217-23	61

963	Premotor Parkinson's disease: clinical features, detection, and prospects for treatment. 2008 , 64 Suppl 2, S139-47	43
962	Cognition and mood in Parkinson's disease in subthalamic nucleus versus globus pallidus interna deep brain stimulation: the COMPARE trial. 2009 , 65, 586-95	415
961	A novel haplotype-sharing approach for genome-wide case-control association studies implicates the calpastatin gene in Parkinson's disease. 2009 , 33, 657-67	24
960	Psychopathological features in patients with Parkinson's disease and related caregivers' burden. 2009 , 24, 1158-65	35
959	Parkinson's disease is overdiagnosed clinically at baseline in diagnostically uncertain cases: a 3-year European multicenter study with repeat [123I]FP-CIT SPECT. 2009 , 24, 500-8	157
958	Adherence to antiparkinson medication in a multicenter European study. 2009 , 24, 826-32	131
957	Parkin-related disease clinically diagnosed as a pallido-pyramidal syndrome. 2009 , 24, 138-40	9
956	Expression of Lewy body protein septin 4 in postmortem brain of Parkinson's disease and control subjects. 2009 , 24, 204-10	30
955	Atomoxetine for the treatment of executive dysfunction in Parkinson's disease: a pilot open-label study. 2009 , 24, 277-82	98
954	No association between common POLG1 variants and sporadic idiopathic Parkinson's disease. 2009 , 24, 1092-4	19
953	Backward walking in Parkinson's disease. 2009 , 24, 218-23	68
952	Functional brain imaging in pure akinesia with gait freezing: [18F] FDG PET and [18F] FP-CIT PET analyses. 2009 , 24, 237-45	52
951	Odor identification test as an indicator of idiopathic REM sleep behavior disorder. 2009 , 24, 268-73	53
950	LRRK2 R1628P variant is a risk factor of Parkinson's disease among Han-Chinese from mainland China. 2009 , 24, 1902-5	30
949	Replacement of dopaminergic medication with subthalamic nucleus stimulation in Parkinson's disease: long-term observation. 2009 , 24, 557-63	60
948	Premotor Parkinson's disease: clinical features and detection strategies. 2009 , 24 Suppl 2, S665-70	28
947	Mortality in Parkinson's disease: a 20-year follow-up study. 2009 , 24, 819-25	91
946	Validity of the Cornell scale for depression in dementia in Parkinson's disease with and without cognitive impairment. 2009 , 24, 433-7	14

945	Effects of inhibitory rTMS on bladder function in Parkinson's disease patients. 2009 , 24, 445-8	32
944	How cautious should we be when assessing apathy with the Unified Parkinson's Disease Rating Scale?. 2009 , 24, 684-8	29
943	Examination of the Lille Apathy Rating Scale in Parkinson disease. 2009 , 24, 677-83	48
942	Motor-related circuit dysfunction in MSA-P: Usefulness of combined whole-brain imaging analysis. 2009 , 24, 863-70	32
941	Weight loss, body fat mass, and leptin in Parkinson's disease. 2009 , 24, 885-90	78
940	Gene expression changes in blood as a putative biomarker for Huntington's disease. 2009 , 24, 2277-81	23
939	Midbrain hyperechogenicity in idiopathic REM sleep behavior disorder. 2009 , 24, 1906-9	80
938	Homocysteine and cognitive impairment in Parkinson's disease: a biochemical, neuroimaging, and genetic study. 2009 , 24, 1437-44	66
937	Trunk muscle strength, but not trunk rigidity, is independently associated with bone mineral density of the lumbar spine in patients with Parkinson's disease. 2009 , 24, 1176-82	16
936	Are current recommendations to diagnose orthostatic hypotension in Parkinson's disease satisfactory?. 2009 , 24, 1747-51	47
935	Transcranial ultrasound as a risk marker for Parkinson's disease. 2009 , 24 Suppl 2, S677-83	29
934	Perverved head-shaking and positional downbeat nystagmus in patients with multiple system atrophy. 2009 , 24, 1290-5	29
933	The syndromal validity and nosological position of apathy in Parkinson's disease. 2009 , 24, 1211-6	105
932	Cerebrospinal tau, phospho-tau, and beta-amyloid and neuropsychological functions in Parkinson's disease. 2009 , 24, 2203-10	127
931	Homocysteine levels after acute levodopa intake in patients with Parkinson's disease. 2009 , 24, 1339-43	28
930	Prevalence of anxiety disorders and anxiety subtypes in patients with Parkinson's disease. 2009 , 24, 1333-8	203
929	The relationship between quality of life and swallowing in Parkinson's disease. 2009 , 24, 1352-8	135
928	Micro lesion effect of the globus pallidus internus and outcome with deep brain stimulation in patients with Parkinson disease and dystonia. 2009 , 24, 1488-93	39

927	Potential of advanced MR imaging techniques in the differential diagnosis of parkinsonism. 2009 , 24 Suppl 2, S711-20	39
926	Handedness does not predict side of onset of motor symptoms in Parkinson's disease. 2009 , 24, 1836-9	18
925	Is impact of fatigue an independent factor associated with physical activity in patients with idiopathic Parkinson's disease?. 2009 , 24, 1512-8	58
924	Expanding the clinical phenotype of SNCA duplication carriers. 2009 , 24, 1811-9	103
923	Restless legs syndrome in Parkinson's disease. 2009 , 24, 2076-80	100
922	Fatigue in Japanese patients with Parkinson's disease: a study using Parkinson fatigue scale. 2009 , 24, 1977-83	29
921	Idiopathic REM sleep behavior disorder in the transition to degenerative disease. 2009 , 24, 2225-32	86
920	Levodopa response in early Parkinson's disease. 2009 , 24, 2328-36	36
919	Levosulpiride-induced movement disorders. 2009 , 24, 2249-53	50
918	Accuracy of Parkinson's disease diagnosis in 610 general practice patients in the West of Scotland. 2009 , 24, 2379-85	36
917	The core body temperature rhythm is altered in progressive supranuclear palsy. 2009 , 19, 65-8	6
916	Use of a single [123I]-FP-CIT SPECT to predict the severity of clinical symptoms of Parkinson disease. 2009 , 30, 301-5	14
915	Effects of treadmill training on walking economy in Parkinson's disease: a pilot study. 2009 , 30, 499-504	28
914	Dopamine transporter immunoreactivity in peripheral blood lymphocytes in multiple system atrophy. 2009 , 116, 161-5	13
913	A single-nucleotide polymorphism of the osteopontin gene may contribute to a susceptibility to Lewy body disease. 2009 , 116, 599-605	13
912	Olfactory bulb alpha-synucleinopathy has high specificity and sensitivity for Lewy body disorders. 2009 , 117, 169-74	151
911	A decision tool to support appropriate referral for deep brain stimulation in Parkinson's disease. 2009 , 256, 83-8	37
910	The leucine rich repeat kinase 2 (LRRK2) G2019S substitution mutation. Association with Parkinson disease, malignant melanoma and prevalence in ethnic groups in Israel. 2009 , 256, 483-7	41

909	Chocolate consumption is increased in Parkinson's disease. Results from a self-questionnaire study. 2009 , 256, 488-92	27
908	Transcranial duplex in the differential diagnosis of parkinsonian syndromes: a systematic review. 2009 , 256, 530-8	45
907	Balance confidence and functional mobility are independently associated with falls in people with Parkinson's disease. 2009 , 256, 742-9	103
906	Greater improvement in quality of life following unilateral deep brain stimulation surgery in the globus pallidus as compared to the subthalamic nucleus. 2009 , 256, 1321-9	108
905	Parkinson's disease sleep scale, sleep logs, and actigraphy in the evaluation of sleep in parkinsonian patients. 2009 , 256, 1480-4	30
904	HMPAO SPECT in Parkinson's disease (PD) with major depression (MD) before and after antidepressant treatment. 2009 , 256, 1510-8	21
903	Fear of falling is independently associated with recurrent falls in patients with Parkinson's disease: a 1-year prospective study. 2009 , 256, 1689-95	132
902	Is there a difference in gastric emptying between Parkinson's disease patients under long-term L-dopa therapy with and without motor fluctuations? An analysis using the 13C-acetate breath test. 2009 , 256, 1972-6	29
901	Interleukin-6 serum levels in patients with Parkinson's disease. 2009 , 34, 1401-4	55
900	Neuroticism and extraversion in association with quality of life in patients with Parkinson's disease. 2009 , 18, 33-42	29
899	Quality of life in Serbian patients with Parkinson's disease. 2009 , 18, 833-9	16
898	Adaptive windowing for gait phase discrimination in Parkinsonian gait using 3-axis acceleration signals. 2009 , 47, 1155-64	18
897	[Direct costs for Parkinson's treatment in private neurology practices in Berlin]. 2009 , 80, 452-8	15
896	[Deep brain stimulation for Parkinson's disease. Consensus recommendations of the German Deep Brain Stimulation Association]. 2009 , 80, 646-55	33
895	Monoamine transporter availability in Parkinson's disease patients with or without depression. 2009 , 36, 428-35	66
894	alpha-Synuclein and neuronal cell death. 2009 , 4, 9	257
893	Decrease of nicotinic receptors in the nigrostriatal system in Parkinson's disease. 2009 , 29, 1601-8	45
892	Genome-wide association study reveals genetic risk underlying Parkinson's disease. 2009 , 41, 1308-12	1469

891	Autonomic dysfunction in Parkinson's disease and vascular parkinsonism. 1997 , 96, 359-65	14
890	Review article Progressive supranuclear palsy revisited. 2009 , 98, 73-84	9
889	Delayed motor response correlates with striatal degeneration in Parkinson's disease. 1999 , 100, 227-30	6
888	Distinguishing Parkinson's disease and essential tremor with transcranial sonography. 2009 , 119, 17-21	48
887	The relationship of pain and health-related quality of life in Korean patients with Parkinson's disease. 2009 , 119, 397-403	34
886	Cerebrospinal fluid metabolite and nigrostriatal dopaminergic function in Parkinson's disease. 2010 , 122, 46-51	11
885	Dermal sheet preparations in the evaluation of dermal innervation in Parkinson's disease and multiple system atrophy. 2009 , 36, 296-301	7
884	Biomarkers in Huntington's and Parkinson's Disease. 2009 , 1180, 97-110	21
883	Cross-cultural validation of the Scales for Outcomes in Parkinson's Disease-Psychosocial questionnaire (SCOPA-PS) in four Latin American countries. 2009 , 12, 385-91	10
882	Absence of nigral degeneration in aged parkin/DJ-1/PINK1 triple knockout mice. 2009 , 111, 696-702	183
881	Addenbrooke's Cognitive Examination validation in Parkinson's disease. 2009 , 16, 142-7	63
880	Subthalamic deep brain stimulation and impulse control in Parkinson's disease. 2009 , 16, 493-7	156
879	Dopaminergic treatment is associated with decreased body weight in patients with Parkinson's disease and dyskinesias. 2009 , 16, 895-901	56
878	Trends in Parkinson's disease related mortality in England and Wales, 1993-2006. 2009 , 16, 1010-6	18
877	The severity of leukoaraiosis correlates with the clinical phenotype of Parkinson's disease. 2009 , 49, 255-259	51
876	Relationship between clinical phenotypes and cognitive impairment in Parkinson's disease (PD). 2009 , 49, 351-4	29
875	Dementias. 2009 , 215-257	
874	Movement Disorders. 2009 , 341-394	

873	Parkinson's disease: the most common diagnostic mistakes in Lithuania. 2009 , 4, 304-309	1
872	Systemic neurophysiological analysis of Parkinson's disease. 2009 , 35, 43-50	1
871	Awareness of expressivity deficits in non-demented Parkinson disease. 2009 , 23, 805-17	13
870	The association of type D personality with quality of life in patients with Parkinson's disease. 2009 , 13, 905-12	19
869	Short duration, intensive tango dancing for Parkinson disease: an uncontrolled pilot study. 2009 , 17, 203-7	86
868	Reduced performance in balance, walking and turning tasks is associated with increased neck tone in Parkinson's disease. 2009 , 219, 430-8	76
867	Cerebrospinal fluid-orexin levels and sleep attacks in four patients with Parkinson's disease. 2009 , 111, 341-4	44
866	Application of depression criteria (DSM-IV) in patients with Parkinson's disease. 2009 , 111, 665-9	15
865	Serum uric acid levels in patients with Parkinson's disease: their relationship to treatment and disease duration. 2009 , 111, 724-8	90
864	Female gender but not cigarette smoking delays the onset of Parkinson's disease. 2009 , 111, 738-41	10
863	A multicentre retrospective study of the clinical use of ropinirole in the treatment of Parkinson's disease: the ROPI-PARK study. 2009 , 111, 742-7	5
862	Peripheral cytokines profile in Parkinson's disease. 2009 , 23, 55-63	350
861	Reliability of the new freezing of gait questionnaire: agreement between patients with Parkinson's disease and their carers. 2009 , 30, 459-63	347
860	Right prefrontal hypometabolism predicts delusions in dementia with Lewy bodies. 2009 , 30, 1420-9	19
859	Further delineation of the association signal on chromosome 5 from the first whole genome association study in Parkinson's disease. 2009 , 30, 1706-9	1
858	Correlation between depressive symptoms and nocturnal disturbances in Japanese patients with Parkinson's disease. 2009 , 15, 15-9	35
857	Vascular pathology in patients with idiopathic Parkinson's disease. 2009 , 15, 24-9	44
856	Smoking and tea consumption delay onset of Parkinson's disease. 2009 , 15, 41-6	63

855	Frequency of psychiatric disorders in young-onset Parkinson's disease does not differ from typical-onset Parkinson's disease. 2009 , 15, 153-5	18
854	Neuro-psychiatric therapy during chronic subthalamic stimulation in Parkinson's disease. 2009 , 15, 128-33	7
853	Cardiac denervation occurs independent of orthostatic hypotension and impaired heart rate variability in Parkinson's disease. 2009 , 15, 134-7	76
852	Brain magnetic resonance imaging (MRI) in parkinsonian disorders. 2009 , 15, 165-74	41
851	The neuropathological basis for depression in Parkinson's disease. 2009 , 15, 144-8	101
850	LRRK2 gene G2019S mutation and SNPs [haplotypes] in subtypes of Parkinson's disease. 2009 , 15, 175-80	9
849	Genetic screening for LRRK2 gene G2019S mutation in Parkinson's disease patients from Southern Italy. 2009 , 15, 242-4	10
848	Transcranial sonography of the substantia nigra and MIBG myocardial scintigraphy: complementary role in the diagnosis of Parkinson's disease. 2009 , 15, 270-2	13
847	Does laterality of motor impairment tell us something about cognition in Parkinson disease?. 2009 , 15, 315-7	28
846	Acute stepwise challenge test with levodopa in treated patients with parkinsonism. 2009 , 15, 354-8	7
845	Anxiety, depression and swallowing disorders in patients with Parkinson's disease. 2009 , 15, 453-6	40
844	Psychometric properties of the Parkinson's Disease Sleep Scale--Brazilian version. 2009 , 15, 495-9	21
843	PARK11 gene (GIGYF2) variants Asn56Ser and Asn457Thr are not pathogenic for Parkinson's disease. 2009 , 15, 532-4	26
842	128-channel somatosensory evoked potentials in the differential diagnosis of parkinsonian disorders. 2009 , 15, 564-71	3
841	Levodopa-induced striatal activation in Parkinson's disease: a functional MRI study. 2009 , 15, 558-63	38
840	Performance on an Alzheimer-selective odor identification test in patients with Parkinson's disease and its relationship with cerebral dopamine transporter activity. 2009 , 15, 640-3	18
839	Plantar cutaneous sensory stimulation improves single-limb support time, and EMG activation patterns among individuals with Parkinson's disease. 2009 , 15, 697-702	55
838	Enhanced cued recall and clock drawing test performances differ in Parkinson's and Alzheimer's disease-related cognitive dysfunction. 2009 , 15, 688-91	27

837	Histopathological analysis of skeletal muscle in patients with Parkinson's disease and 'dropped head'/'bent spine' syndrome. 2009 , 15, 633-9	52
836	Overnight switching from ergot-derived dopamine agonists to pramipexole in patients with Parkinson's disease: an open preliminary trial in Japan. 2009 , 16, 790-2	1
835	Risk factors in development of motor complications in Chinese patients with idiopathic Parkinson's disease. 2009 , 16, 1034-7	12
834	Electromyographic activity of sternocleidomastoid muscle in patients with Parkinson's disease. 2009 , 19, 591-7	7
833	EMG and MMG activities of agonist and antagonist muscles in Parkinson's disease patients during absolute submaximal load holding. 2009 , 19, 903-14	32
832	Cerebrospinal fluid alpha-synuclein in neurodegenerative disorders-a marker of synapse loss?. 2009 , 450, 332-5	175
831	Complete screening for glucocerebrosidase mutations in Parkinson disease patients from Greece. 2009 , 452, 87-9	75
830	Quantitative plasma DNA analysis in Parkinson's disease. 2009 , 452, 5-7	6
829	Impulse control disorders in Parkinson's disease in a Chinese population. 2009 , 465, 6-9	67
828	Effect of deep brain stimulation of the subthalamic nucleus upon the contralateral subthalamic nucleus in Parkinson disease. 2009 , 463, 12-6	26
827	GIGYF2 Asn56Ser mutation is rare in Chinese Parkinson's disease patients. 2009 , 463, 172-5	6
826	Pharmacological management of psychosis in elderly patients with parkinsonism. 2009 , 122, 614-22	15
825	High-resolution diffusion tensor imaging in the substantia nigra of de novo Parkinson disease. 2009 , 72, 1378-84	348
824	Variability of EMG patterns: a potential neurophysiological marker of Parkinson's disease?. 2009 , 120, 390-7	46
823	High resolution positron emission tomography demonstrates basal ganglia dysfunction in early Parkinson's disease. 2009 , 276, 27-30	34
822	Cardiac parasympathetic dysfunction concurrent with cardiac sympathetic denervation in Parkinson's disease. 2009 , 276, 79-83	61
821	Diabetes mellitus and drug-induced Parkinsonism: a case-control study. 2009 , 284, 140-3	13
820	High-frequency rTMS over the supplementary motor area improves bradykinesia in Parkinson's disease: subanalysis of double-blind sham-controlled study. 2009 , 287, 143-6	49

819	Methylenetetrahydrofolate reductase polymorphisms and plasma homocysteine in levodopa-treated and non-treated Parkinson's disease patients. 2009 , 287, 64-8	27
818	[Parkinson disease and amyotrophic lateral sclerosis. Tauopathies, TDP-43 and SOD mutations]. 2009 , 165, 15-30	3
817	Biological fluid biomarkers in neurodegenerative parkinsonism. 2009 , 5, 561-70	54
816	Is the n-back task a valid neuropsychological measure for assessing working memory?. 2009 , 24, 711-7	112
815	Impaired verbal memory in Parkinson disease: relationship to prefrontal dysfunction and somatosensory discrimination. 2009 , 5, 49	5
814	Cognitive declines one year after unilateral deep brain stimulation surgery in Parkinson's disease: a controlled study using reliable change. 2009 , 23, 385-405	52
813	Transcranial brain sonography findings in Parkinson's disease: implications for pathogenesis, early diagnosis and therapy. 2009 , 9, 835-46	11
812	Inappropriate crying and laughing in Parkinson disease and movement disorders. 2009 , 10, 234-40	33
811	Recognition and management of Parkinson's disease during the premotor (prodromal) phase. 2009 , 9, 847-57	11
810	MRI characteristics of the substantia nigra in Parkinson's disease: a combined quantitative T1 and DTI study. 2009 , 47, 435-41	142
809	Management of antiparkinsonian therapy during chronic subthalamic stimulation in Parkinson's disease. 2009 , 15 Suppl 4, S76-80	6
808	Parkinson disease and comorbid cerebrovascular disease. 2009 , 5, 533-41	40
807	[Comparison of quality of life in multiple system atrophy and Parkinson's disease]. 2009 , 165, 911-5	5
806	Fluoro-deoxy-glucose positron emission tomography correlates of impaired activities of daily living in dementia with Lewy bodies: implications for cognitive reserve. 2009 , 17, 188-95	21
805	The pattern of cognitive-functional decline in elderly essential tremor patients: an exploratory-comparative study with Parkinson's and Alzheimer's disease patients. 2009 , 10, 238-42	21
804	Positron emission tomography for neurologists. 2009 , 27, 61-88, viii	10
803	Botulinum toxin A for overactive bladder and detrusor muscle overactivity in patients with Parkinson's disease and multiple system atrophy. 2009 , 182, 1453-7	92
802	Atrofia multisistemica. 2009 , 9, 1-12	

801	Depression impairs executive functioning in Parkinson disease patients with low educational level. 2009 , 22, 167-72	24
800	The G2019S LRRK2 Mutation is Rare in Korean Patients with Parkinson's Disease and Multiple System Atrophy. 2009 , 5, 29-32	17
799	Molecular imaging studies in Parkinson disease: reducing diagnostic uncertainty. 2009 , 15, 6-16	41
798	Peripheral chemo-cytokine profiles in Alzheimer's and Parkinson's diseases. 2009 , 9, 1229-41	59
797	Interobserver reproducibility of the interpretation of I-123 FP-CIT single-photon emission computed tomography. 2010 , 31, 717-25	15
796	Maladie de Parkinson idiopathique: aspects cliniques, diagnostiques et thérapeutiques. 2010 , 7, 1-30	
795	Dietary intake of folate, vitamin B6, vitamin B12 and riboflavin and risk of Parkinson's disease: a case-control study in Japan. 2010 , 104, 757-64	64
794	Outcomes of patients with Parkinson disease and pathological gambling. 2010 , 37, 473-7	14
793	Corpus callosum and cingulum tractography in Parkinson's disease. 2010 , 37, 595-600	41
792	Cortical and subcortical patterns of I-123 iodobenzamide SPECT in striatal D(2) receptor parkinsonisms. 2010 , 35, 228-33	5
791	Overview of common movement disorders. 2010 , 16, 13-48	11
790	Downhill walking training in individuals with Parkinson's disease: a randomized controlled trial. 2010 , 89, 706-14	31
789	Whole body and cardiac metaiodobenzylguanidine kinetics in Parkinson disease and multiple system atrophy: implications for the diagnostic role of imaging. 2010 , 35, 311-6	7
788	Generalized anxiety disorder and the Hamilton Anxiety Rating Scale in Parkinson's disease. 2010 , 68, 495-501	40
787	Correlation between substantia nigra features detected by sonography and Parkinson disease symptoms. 2010 , 29, 37-42	20
786	Role of polymorphisms in dopamine synthesis and metabolism genes and association of DBH haplotypes with Parkinson's disease among North Indians. 2010 , 20, 435-41	17
785	Feeling-of-knowing in episodic memory in patients with Parkinson's disease with various motor symptoms. 2010 , 25, 1034-9	14
784	Predictive potential of pre-operative functional neuroimaging in patients treated with subthalamic stimulation. 2010 , 37, 12-22	1

783	Validation of cardiac (123)I-MIBG scintigraphy in patients with Parkinson's disease who were diagnosed with dopamine PET. 2010 , 37, 3-11	39
782	Brain metabolic correlates of dopaminergic degeneration in de novo idiopathic Parkinson's disease. 2010 , 37, 537-44	30
781	Subthalamic nucleus stimulation affects limbic and associative circuits: a PET study. 2010 , 37, 1512-20	52
780	[Differential diagnosis of parkinsonian syndromes using MRI]. 2010 , 81, 1168-79	10
779	Effects of five years of chronic STN stimulation on muscle strength and movement speed. 2010 , 205, 435-43	7
778	Hyperhomocysteinemia due to levodopa treatment as a risk factor for osteoporosis in patients with Parkinson's disease. 2010 , 86, 132-41	21
777	Usefulness of 3D-PRESTO imaging in evaluating putaminal abnormality in parkinsonian variant of multiple system atrophy. 2010 , 52, 809-14	20
776	Dynamical correlation of non-stationary signals in time domain—comparative study. 2010 , 5, 205-213	19
775	Glucocerebrosidase is present in α -synuclein inclusions in Lewy body disorders. 2010 , 120, 641-9	151
774	Modulation of metabolic brain function by bilateral subthalamic nucleus stimulation in the treatment of Parkinson's disease. 2010 , 257, 72-8	29
773	Cognitive status of patients with Parkinson's disease and pathological gambling. 2010 , 257, 247-52	42
772	Monoamines, BDNF, IL-6 and corticosterone in CSF in patients with Parkinson's disease and major depression. 2010 , 257, 524-32	55
771	Transient gender-related effects in Parkinson's disease patients with subthalamic stimulation. 2010 , 257, 603-8	19
770	Olfactory dysfunction and cardiovascular dysautonomia in Parkinson's disease. 2010 , 257, 969-76	44
769	Fluctuating cognition and different cognitive and behavioural profiles in Parkinson's disease with dementia: comparison of dementia with Lewy bodies and Alzheimer's disease. 2010 , 257, 1004-11	35
768	Frequency of dementia, depression, and other neuropsychiatric symptoms in 1,449 outpatients with Parkinson's disease. 2010 , 257, 1073-82	174
767	The comparison of clonidine, arginine and both combined: a growth hormone stimulation test to differentiate multiple system atrophy from idiopathic Parkinson's disease. 2010 , 257, 1486-91	7
766	Late-stage Parkinson's disease: the Barcelona and Lisbon cohort. 2010 , 257, 1524-32	89

765	Parkinsonian single fallers versus recurrent fallers: different fall characteristics and clinical features. 2010 , 257, 1543-51	85
764	The status of olfactory function and the striatal dopaminergic system in drug-induced parkinsonism. 2010 , 257, 1882-9	35
763	Putaminal abnormality on 3-T magnetic resonance imaging in early parkinsonism-predominant multiple system atrophy. 2010 , 257, 2065-70	25
762	Dopaminergic therapy and subthalamic stimulation in Parkinson's disease: a review of 5-year reports. 2010 , 257, S298-304	25
761	The effect of L-Dopa administration on pursuit ocular movements in suspected Parkinson's disease. 2010 , 31, 381-5	15
760	Myocardial MIBG scintigraphy: a useful clinical tool? : A retrospective study in 50 parkinsonian patients. 2010 , 31, 403-6	13
759	Protracted benefit from paradoxical kinesia in typical and atypical parkinsonisms. 2010 , 31, 751-6	20
758	Epigenetic clock acceleration is linked to age-at-onset of idiopathic and LRRK2 Parkinson's disease.	
757	Immediate-release/extended-release amantadine (OS320) to treat Parkinson's disease with levodopa-induced dyskinesia: Analysis of the randomized, controlled ALLAY-LID studies.. 2022 , 96, 65-73	2
756	Magnetoencephalography detects phase-amplitude coupling in Parkinson's disease.. 2022 , 12, 1835	0
755	Mechanisms of motor symptom improvement by long-term Tai Chi training in Parkinson's disease patients.. 2022 , 11, 6	1
754	The Role of NOTCH2NLC in Parkinson's Disease: A Clinical, Neuroimaging, and Pathological Study.. 2022 ,	0
753	Fluid markers of synapse degeneration in synucleinopathies.. 2022 , 129, 187	0
752	Self-Stigma in Parkinson's Disease: A 3-Year Prospective Cohort Study.. 2022 , 14, 790897	0
751	Retrograde Procedural Memory in Parkinson's Disease: A Cross-Sectional, Case-Control Study.. 2022 ,	
750	Deficiency in endocannabinoid synthase DAGLB contributes to Parkinson's disease and dopaminergic neuron dysfunction.	0
749	Computerised analysis of writing and drawing by essential tremor phenotype.. 2021 , 3, e000212	
748	Diagnostic value of cerebrospinal fluid alpha-synuclein seed quantification in synucleinopathies. 2021 ,	6

747	Do P1 and N1 evoked by the ERP task reflect primary visual processing in Parkinson's disease?. 2001 , 102, 83-93	8
746	Advances in the discovery of genetic risk factors for complex forms of neurodegenerative disorders: contemporary approaches, success, challenges and prospects. 2018 , 97, 625-648	1
745	Bibliographie. 2021 , 399-409	
744	Application of random forest in detection of Parkinson's disease. 2022 , 125-133	
743	Contribution and Clinical Significance of 3D and 2D Deep Learning and Radimoics Features Based on MR-T1W Images in Joint Diagnosis of Parkinson's Disease.	
742	OUP accepted manuscript.	4
741	Movement disorders and translational research. 2022 , 155-178	
740	Neurofeedback-guided kinesthetic motor imagery training in Parkinson's disease: Randomized trial.. 2022 , 34, 102980	0
739	Prologue: Why should we talk about sex and Parkinson's disease?. 2022 , 162, xi-xiv	
738	CSF and Serum Levels of Inflammatory Markers in PD: Sparse Correlation, Sex Differences and Association With Neurodegenerative Biomarkers.. 2022 , 13, 834580	2
737	Goal management training and psychoeducation / mindfulness for treatment of executive dysfunction in Parkinson's disease: A feasibility pilot trial.. 2022 , 17, e0263108	1
736	Presence of Skin Bsynuclein Deposits Discriminates Parkinson's Disease from Progressive Supranuclear Palsy and Corticobasal Syndrome. 2021 ,	1
735	Role of Specialized Pro-resolving Mediators in Reducing Neuroinflammation in Neurodegenerative Disorders.. 2022 , 14, 780811	2
734	Hand Pronation-Supination Movement as a Proxy for Remotely Monitoring Gait and Posture Stability in Parkinson's Disease.. 2022 , 22,	
733	The psychometric properties of the figure-of-eight walk test in people with Parkinson's disease.. 2022 , 1-9	0
732	Astrocytes expressing Vitamin D-activating enzyme identify Parkinson's disease.. 2022 ,	2
731	Cytokines, miRNAs, and Antioxidants as Combined Non-invasive Biomarkers for Parkinson's Disease.. 2022 , 1	1
730	Brain Morphometry Associated With Response to Levodopa and Deep Brain Stimulation in Parkinson Disease.. 2022 ,	0

729	Integration of Virtual Reality into Transcranial Magnetic Stimulation Improves Cognitive Function in Patients with Parkinson's Disease with Cognitive Impairment: A Proof-of-Concept Study.. 2021 ,	
728	Safety and tolerability of aripiprazole in patients with psychosis associated with Parkinson's disease-Results of a multicenter open trial.. 2022 ,	1
727	Differentiating Parkinson's Disease from Essential Tremor Using Transcranial Sonography: A Systematic Review and Meta-Analysis.. 2022 ,	0
726	A Randomized, Double-Blind, Controlled Phase II Study of Foliglurax in Parkinson's Disease.. 2022 ,	1
725	A replication study, systematic review and meta-analysis of automated image-based diagnosis in parkinsonism.. 2022 , 12, 2763	1
724	Effect of vitamin D and other indicators of phosphorus-calcium metabolism on cognitive functions and quality of life in patients with Parkinson's disease. 2022 , 14, 38-44	
723	Serum NfL and CHI3L1 for ALS and parkinsonian disorders in the process of diagnosis.. 2022 , 129, 301	
722	Multimodal Brain Connectomics-Based Prediction of Parkinson's Disease Using Graph Attention Networks.. 2021 , 15, 741489	1
721	Effectiveness of Different Methods for Baroreflex Sensitivity Assessment in Determining the Severity of Cardiovascular Autonomic Neuropathy in Patients With Parkinson's Disease.. 2022 , 16, 833344	0
720	Telling functional networks apart using ranked network features stability.. 2022 , 12, 2562	
719	Effect of Intensive Rehabilitation Program in Thermal Water on a Group of People with Parkinson's Disease: A Retrospective Longitudinal Study.. 2022 , 10,	0
718	A Panel of Plasma Biomarkers for Differential Diagnosis of Parkinsonian Syndromes.. 2022 , 16, 805953	1
717	Significant modulations of linc001128 and linc0938 with miR-24-3p and miR-30c-5p in Parkinson disease.. 2022 , 12, 2569	0
716	Altered Dynamic Functional Connectivity in Parkinson's Disease Patients With Depression.. 2021 , 13, 789785	0
715	Computer Aided Written Character Feature Extraction in Progressive Supranuclear Palsy and Parkinson's Disease.. 2022 , 22,	1
714	Profile of cognitive impairment in late-stage Parkinson's disease.. 2022 , e32537	0
713	Alterations in Proteostasis System Components in Peripheral Blood Mononuclear Cells in Parkinson Disease: Focusing on the HSP70 and p62 Levels.. 2022 , 12,	2
712	The Effects of Action Observation Therapy as a Rehabilitation Tool in Parkinson's Disease Patients: A Systematic Review.. 2022 , 19,	

- 711 Two-year longitudinal follow-up of visual illusions and hallucinations in Parkinson's disease.. **2022**, 1
- 710 Relationship between Plasma Level of Beta-amyloid, Alpha-synuclein, and Tau Protein with Cognitive Impairment in Parkinson Disease. **2022**, 10, 663-667
- 709 Altered Neural Network Connectivity Predicts Depression in Parkinson's Disease.. **2022**, 16, 828651 ○
- 708 The coin rotation test: a reliable and valid test in people with Parkinson's disease.. **2022**, 1-10 ○
- 707 Shared Molecular Targets in Parkinson's Disease and Arterial Hypertension: A Systematic Review.. **2022**, 10, ○
- 706 Novel insights into the effects of levodopa on the up- and downstrokes of writing sequences.. **2022**, 129, 379 ○
- 705 The incidence, baseline predictors, and outcomes of dementia in an incident cohort of Parkinson's disease and controls.. **2022**, 1 ○
- 704 Large-scale network dysfunction in α -Synucleinopathy: A meta-analysis of resting-state functional connectivity.. **2022**, 77, 103915 1
- 703 Gait-Related Metabolic Covariance Networks at Rest in Parkinson's Disease.. **2022**, ○
- 702 Fear of Falling Avoidance Behavior Assessment and Intervention in Parkinson's Disease: A Scoping Review. Volume 12, 1-17 ○
- 701 Characterization of advanced Parkinson's disease in Germany: results of the non-interventional OBSERVE-PD study.. **2022**, 4, 9 1
- 700 Evaluation of Brain SPECT with Tc-TRODAT-1 in the Differential Diagnosis of Parkinsonism.. **2022**, 2022, 1746540
- 699 Neuroinflammation Upregulated Neuronal Toll-Like Receptors 2 and 4 to Drive Synucleinopathy in Neurodegeneration.. **2022**, 13, 845930 2
- 698 Seed-Based Connectivity Prediction of Initial Outcome of Subthalamic Nuclei Deep Brain Stimulation.. **2022**, 1 ○
- 697 Adaptive and pathological connectivity responses in Parkinson's disease brain networks.. **2022**, ○
- 696 Amplitude setting and dopamine response of finger tapping and gait are related in Parkinson's disease.. **2022**, 12, 4180
- 695 Autoimmune Disease Associated Variants Convey Risk of Parkinson's Disease in Han Chinese.. **2022**, 13, 856493 ○
- 694 No Dopamine Agonist Modulation of Brain [F]FE0BV Binding in Parkinson's Disease.. **2022**,

693	RNA-seq analysis of gene expression profiles in posttraumatic stress disorder, Parkinson's disease and schizophrenia identifies roles for common and distinct biological pathways. 2022 , 2,	0
692	Opicapone Improves Global Non-Motor Symptoms Burden in Parkinson's Disease: An Open-Label Prospective Study.. 2022 , 12,	2
691	The Reliability and Validity of the Manual Ability Measure-36 in Patients with Parkinson's Disease.	0
690	Factors Contributing to Malnutrition in Parkinson's Disease Patients With Freezing of Gait.. 2022 , 13, 816315	
689	Reduced Norepinephrine Transporter Binding in Parkinson's disease with dopa Responsive Freezing Gait.	
688	Cortical oscillatory dysfunction in Parkinson disease during movement activation and inhibition.. 2022 , 17, e0257711	0
687	Role of Lysosomal Gene Variants in Modulating GBA-Associated Parkinson's Disease Risk.. 2022 ,	3
686	A Multimodal Omics Exploration of the Motor and Non-Motor Symptoms of Parkinson's Disease. 2022 , 2, 97-112	0
685	Does transcranial direct current stimulation enhance cognitive performance in Parkinson's disease mild cognitive impairment? An event-related potentials and neuropsychological assessment study.. 2022 , 1	
684	Automated Differentiation of Atypical Parkinsonian Syndromes Using Brain Iron Patterns in Susceptibility Weighted Imaging.. 2022 , 12,	
683	Crocin Protects Malathion-Induced Striatal Biochemical Deficits by Inhibiting Apoptosis and Increasing α -Synuclein in Rats' Striatum.. 2022 , 1	
682	Hyperhidrosis in Parkinson's disease: a 3-year prospective cohort study.. 2022 ,	1
681	Elevation of Plasma Homocysteine and Minor Hallucinations in Parkinson's Disease: A Cross-Sectional Study.. 2022 , 2022, 4797861	0
680	Characteristics of the Ontario Neurodegenerative Disease Research Initiative cohort.	1
679	The Effect of a Structured Medication Review on Quality of Life in Parkinson's Disease.. 2022 ,	0
678	Motion characteristics of subclinical tremors in Parkinson's disease and normal subjects.. 2022 , 12, 4021	2
677	Gamma Knife [®] stereotactic radiosurgery as a treatment for essential and parkinsonian tremor: long-term experience.. 2022 ,	1
676	A modified version of the interlocking finger test as a bedside screening test for visuospatial deficits and dementia in Parkinson's disease.. 2022 , e2516	

- 675 The Effects of Subthalamic Nucleus Deep Brain Stimulation in Parkinson's Disease on Associative Learning of Verbal and Non-Verbal Information by Trial and Error or with Corrective Feedback.. **2022**, 0
- 674 Striatal dopamine transporter imaging in Parkinson's disease drug-naïve patients: focus on sexual dysfunction.. **2022**, 1 0
- 673 Association Study of Variants in Parkinson's Disease.. **2022**, 16, 846095
- 672 Parkinson's Disease Progression and Statins: Hydrophobicity Matters.. **2021**, 0
- 671 Poly (ADP-Ribose) and Synuclein extracellular vesicles in patients with Parkinson disease: A possible biomarker of disease severity.. **2022**, 17, e0264446 0
- 670 Dopaminergic medication reduces interhemispheric hyper-synchronization in Parkinson's disease.. **2022**, 97, 39-46
- 669 A Novel Way of Measuring Dual-Task Interference: The Reliability and Construct Validity of the Dual-Task Effect Battery in Neurodegenerative Disease.. **2022**, 15459683221088864 2
- 668 Altered functional connectivity of ventral striatum subregions in de-novo parkinson's disease with depression.. **2022**, 0
- 667 Classification of healthy, Alzheimer and Parkinson populations with a multi-branch neural network. **2022**, 75, 103617 0
- 666 Effects on intermittent postural control in people with Parkinson's due to a dual task.. **2022**, 83, 102947
- 665 Dual tasking reduces gait asymmetry of trajectory deviation during obstacle circumvention in people with Parkinson's disease.. **2022**, 83, 102938 0
- 664 Utility of 18F FDG-PET in Parkinsonism in an African population.. **2022**, 27, 100399
- 663 Longitudinal White Matter Damage Evolution in Parkinson's Disease. **2021**, 0
- 662 Risk of falls using the Biodex Balance System in non-faller patients with Parkinson Disease.. **2021**, 1-5
- 661 Profiling the most elderly parkinson's disease patients: Does age or disease duration matter?. **2021**, 16, e0261302 0
- 660 Phosphorylated Synuclein in diluted human serum a biomarker for Parkinson's disease.. **2021**, 1 1
- 659 Identifying a whole-brain connectome-based model in drug-naïve Parkinson's disease for predicting motor impairment.. **2021**, 1 1
- 658 Cognitive correlates of visual and minor hallucinations in Parkinson's disease.. **2021**, 1-15 0

- 657 The Parkinson's Disease Progression Neuroimaging Initiative.. **2021**, 2021, 2230196 ○
- 656 Neuroimaging cerebrovascular biomarkers in Parkinson's disease. **2021**, 19714009211059118
- 655 Transcriptome deregulation of peripheral monocytes in GBA-related Parkinson's disease.
- 654 Akathisia in Parkinson's Disease: A Comparative Cross-Sectional Study.
- 653 Motor and non-motor circuit disturbances in early Parkinson disease: which happens first?. **2021**, 8
- 652 Prevalence and incidence of Parkinson's disease and other forms of parkinsonism in a cohort of elderly individuals in Southern Brazil: protocol for a population-based study.. **2021**, 11, e054423
- 651 Cognition and Driving Ability in Isolated and Symptomatic REM Sleep Behavior Disorder.. **2021**,
- 650 Alpha-synuclein oligomers and small nerve fiber pathology in skin are potential biomarkers of Parkinson's disease.. **2021**, 7, 119 2
- 649 Amphetamine-induced dopamine release and impulsivity in Parkinson disease.. **2021**,
- 648 Multimodality Anatomic and Molecular Imaging of Parkinson Disease and Atypical Parkinson Syndromes with MRI, Iodine 123 N-Fluoropropyl-2-(4-Iodophenyl) Nortropine SPECT (Dopamine Transporter SPECT), Iodine 123 Metaiodobenzylguanidine Cardiac Scintigraphy, and [18F] FDG-PET. **2021**, 11, 259-274
- 647 Transcriptome Analysis of Induced Pluripotent Stem Cells and Neuronal Progenitor Cells, Derived from Discordant Monozygotic Twins with Parkinson's Disease.. **2021**, 10, 1
- 646 Sleep Disturbances and Associated Factors in Drug-Naïve Patients with Parkinson's Disease. **2021**, 17, 3499-3508 ○
- 645 Low-Dose Niacin Supplementation Improves Motor Function in US Veterans with Parkinson's Disease: A Single-Center, Randomized, Placebo-Controlled Trial.. **2021**, 9, 1
- 644 The Hopkins Symptom Checklist (SCL-90-R): A Patient-Reported Outcome Measure in Parkinson's Disease.. **2021**, 8919887211060020
- 643 Associations between resting-state functional connectivity changes and prolonged benefits of writing training in Parkinson's disease.. **2022**, 1 ○
- 642 Structural Connectivity of Subthalamic Nucleus Stimulation for Improving Freezing of Gait.. **2022**, ○
- 641 Small and Large Magnetic Resonance Imaging-Visible Perivascular Spaces in the Basal Ganglia of Parkinson's Disease Patients.. **2022**, ○
- 640 Brain pathological changes during neurodegenerative diseases and their identification methods: How does QSM perform in detecting this process?. **2022**, 13, 74 ○

- 639 Proteinopathy and Longitudinal Cognitive Decline in Parkinson Disease.. **2022**, 0
- 638 Does Prefrontal Glutamate Index Cognitive Changes in Parkinson's Disease?. **2022**, 16, 809905 0
- 637 Impact of Visual Impairment on Vision-Related Quality of Life in Parkinson's Disease.. **2022**, 1
- 636 Prediction of Quality of Life in Patients With Parkinson's Disease With and Without Excessive Daytime Sleepiness: A Longitudinal Study.. **2022**, 14, 846563
- 635 Arterial spin labeling imaging for the detection of cerebral blood flow asymmetry in patients with corticobasal syndrome.. **2022**, 1 0
- 634 Continuous Dopaminergic Stimulation Improves Cortical Maladaptive Changes in Advanced Parkinson's Disease.. **2022**,
- 633 Gender gap in deep brain stimulation for Parkinson's disease.. **2022**, 8, 47 0
- 632 Intraoperative Quantification of MDS-UPDRS Tremor Measurements Using 3D Accelerometry: A Pilot Study.. **2022**, 11,
- 631 Differential diagnosis between Parkinson's disease and atypical parkinsonism based on gait and postural instability: Artificial intelligence using an enhanced weight voting ensemble model.. **2022**, 98, 32-37 0
- 630 Safety and efficacy of subcutaneous night-time only apomorphine infusion to treat insomnia in patients with Parkinson's disease (APOMORPHEE): a multicentre, randomised, controlled, double-blind crossover study.. **2022**, 21, 428-437 4
- 629 The association between LIN28A gene rare variants and Parkinson's disease in Chinese population.. **2022**, 829, 146515 0
- 628 Do P1 and N1 evoked by the ERP task reflect primary visual processing in Parkinson's disease?. **2001**, 102, 83-93 1
- 627 Image_1.PDF. **2018**,
- 626 Image_2.TIF. **2018**,
- 625 Image_3.TIF. **2018**,
- 624 Image_4.tif. **2018**,
- 623 Image_5.tif. **2018**,
- 622 Image_6.TIF. **2018**,

621 Table_1.docx. **2018,**

620 Table_1.DOCX. **2020,**

619 Table_2.DOCX. **2020,**

618 Table_3.DOCX. **2020,**

617 Table_4.DOCX. **2020,**

616 Table_5.DOCX. **2020,**

615 Data_Sheet_1.docx. **2020,**

614 DataSheet1.pdf. **2018,**

613 DataSheet2.xlsx. **2018,**

612 Image_1.JPEG. **2018,**

611 Image_2.JPEG. **2018,**

610 Image_3.JPEG. **2018,**

609 Image_4.JPEG. **2018,**

608 Image_5.JPEG. **2018,**

607 Table_1.DOCX. **2018,**

606 Data_Sheet_1.DOCX. **2018,**

605 Data_Sheet_2.docx. **2018,**

604 Video_1.MOV. **2020,**

603 Table_1.docx. **2017**,

602 Data_Sheet_1.ZIP. **2018**,

601 Table_1.DOCX. **2018**,

600 Image_1.PDF. **2018**,

599 Image_2.PDF. **2018**,

598 Image_3.pdf. **2018**,

597 Image_4.pdf. **2018**,

596 Table_1.DOCX. **2018**,

595 Table_2.DOCX. **2018**,

594 Table_3.DOCX. **2018**,

593 Table_4.DOCX. **2018**,

592 Table_1.docx. **2018**,

591 Image_1.TIF. **2019**,

590 Data_Sheet_1.docx. **2020**,

589 Data_Sheet_1.PDF. **2020**,

588 Data_Sheet_1.pdf. **2019**,

587 Data_Sheet_2.pdf. **2019**,

586 Table_1.DOCX. **2019**,

585 Table_2.DOCX. **2019**,

584 Table_3.DOCX. **2019**,

583 Data_Sheet_1.docx. **2020**,

582 Image1.PDF. **2017**,

581 Table1.docx. **2017**,

580 Data_Sheet_1.docx. **2019**,

579 Image_1.pdf. **2019**,

578 Data_Sheet_1.zip. **2020**,

577 Table_1.docx. **2020**,

576 Table_2.docx. **2020**,

575 Table_3.docx. **2020**,

574 Table_4.docx. **2020**,

573 Table_1.docx. **2018**,

572 Presentation1.PDF. **2018**,

571 Table_1.DOCX. **2019**,

570 Table_1.DOCX. **2018**,

569 Image_1.pdf. **2018**,

568 Data_Sheet_1.doc. **2018**,

567 Image_1.pdf. **2018,**

566 Presentation_1.zip. **2019,**

565 Table_1.docx. **2019,**

564 Table_2.DOCX. **2019,**

563 Table_1.docx. **2019,**

562 Data_Sheet_1.pdf. **2018,**

561 Data_Sheet_1.docx. **2018,**

560 Data_Sheet_1.xlsx. **2019,**

559 Data_Sheet_2.xlsx. **2019,**

558 Table1.DOCX. **2018,**

557 Data_Sheet_3.docx. **2019,**

556 Table2.DOCX. **2018,**

555 Table3.DOCX. **2018,**

554 Table4.DOCX. **2018,**

553 Table5.DOCX. **2018,**

552 Table6.DOCX. **2018,**

551 Table7.DOCX. **2018,**

550 Table8.DOCX. **2018,**

549 Data_Sheet_1.pdf. **2020,**

548 Presentation_1.pdf. **2020,**

547 Table_1.DOCX. **2020,**

546 Image_1.PDF. **2018,**

545 Image_2.PDF. **2018,**

544 Image_3.PDF. **2018,**

543 Image_4.PDF. **2018,**

542 Image_5.PDF. **2018,**

541 Image_6.PDF. **2018,**

540 Table_1.DOCX. **2018,**

539 Table_2.DOCX. **2018,**

538 Table_1.DOCX. **2020,**

537 Data_Sheet_1.docx. **2020,**

536 Data_Sheet_1.PDF. **2019,**

535 Data_Sheet_1.ZIP. **2020,**

534 Data_Sheet_2.XLSX. **2020,**

533 Data_Sheet_3.DOCX. **2020,**

532 Data_Sheet_4.XLSX. **2020,**

531 Image_1.JPEG. 2020,

530 Image_2.JPEG. 2020,

529 Table_1.docx. 2020,

528 Data_Sheet_1.pdf. 2020,

527 Table_1.DOCX. 2019,

526 Table_2.DOCX. 2019,

525 Table_1.DOCX. 2020,

524 Data_Sheet_1.pdf. 2018,

523 Video_1.mp4. 2018,

522 Video_1.WMV. 2018,

521 Video_2.WMV. 2018,

520 Table_1.docx. 2020,

519 Table_1.docx. 2020,

518 Image_1.pdf. 2020,

517 Table_1.DOCX. 2020,

516 Table_1.DOCX. 2020,

515 Table_2.DOCX. 2020,

514 Table_3.DOCX. 2020,

513 Data_Sheet_1.docx. **2020**,

512 Table_1.docx. **2020**,

511 Image_1.tif. **2019**,

510 Image_2.TIF. **2019**,

509 Table_1.docx. **2020**,

508 Table_1.DOCX. **2020**,

507 Table_2.DOCX. **2020**,

506 Table_3.DOCX. **2020**,

505 Table_4.DOCX. **2020**,

504 Data_Sheet_1.PDF. **2020**,

503 Table_1.pdf. **2020**,

502 Table_2.docx. **2020**,

501 Table_1.DOCX. **2020**,

500 Table_2.DOCX. **2020**,

499 Table_3.DOCX. **2020**,

498 Table_1.DOCX. **2019**,

497 Table_2.docx. **2019**,

496 Table_3.docx. **2019**,

495 Table_1.DOCX. 2020,

494 Image_1.tiff. 2020,

493 Image_2.tif. 2020,

492 Image_3.tif. 2020,

491 Image_4.tif. 2020,

490 Table_1.DOCX. 2020,

489 Data_Sheet_1.pdf. 2019,

488 Image_1.pdf. 2020,

487 Data_Sheet_1.docx. 2019,

486 Data_Sheet_1.xlsx. 2019,

485 Data_Sheet_1.docx. 2019,

484 Data_Sheet_1.PDF. 2019,

483 Image_1.JPEG. 2019,

482 Table_1.docx. 2019,

481 Table_2.docx. 2019,

480 Table_1.docx. 2020,

479 Data_Sheet_1.docx. 2019,

478 Table_1.docx. 2020,

477 Table_2.docx. **2020**,

476 Table_1.DOCX. **2020**,

475 Data_Sheet_1.docx. **2019**,

474 Table_1.DOCX. **2019**,

473 Data_Sheet_1.PDF. **2019**,

472 Data_Sheet_2.pdf. **2019**,

471 Image_1.TIF. **2019**,

470 Image_2.TIF. **2019**,

469 Image_3.TIF. **2019**,

468 Image_4.TIF. **2019**,

467 Image_5.TIF. **2019**,

466 Data_Sheet_1.PDF. **2020**,

465 Image_1.TIF. **2020**,

464 Table_1.DOC. **2020**,

463 Image_1.pdf. **2020**,

462 Table_1.pdf. **2020**,

461 Table_2.pdf. **2020**,

460 Table_3.pdf. **2020**,

459 Table_4.pdf. **2020**,

458 Table_5.pdf. **2020**,

457 Table_1.docx. **2018**,

456 Table_1.DOCX. **2020**,

455 Table_1.docx. **2018**,

454 Table_2.docx. **2018**,

453 Table_3.docx. **2018**,

452 Antagonistic network signature of motor function in Parkinson's disease revealed by connectome-based predictive modeling.. **2022**, 8, 49

1

451 Multicentre, randomised, single-blind, parallel group trial to compare the effectiveness of a Holter for Parkinson's symptoms against other clinical monitoring methods: study protocol. **2021**, 11, e045272

0

450 A composite clinical motor score as a comprehensive and sensitive outcome measure for Parkinson's disease.. *Journal of Neurology, Neurosurgery and Psychiatry*, **2022**,

5-5

449 Effect of Theta Burst Stimulation-Patterned rTMS on Motor and Nonmotor Dysfunction of Parkinson's Disease: A Systematic Review and Metaanalysis.. **2021**, 12, 762100

0

448 Subthalamic Beta Activity in Parkinson's Disease May Be Linked to Dorsal Striatum Gray Matter Volume and Prefrontal Cortical Thickness: A Pilot Study.. **2022**, 13, 799696

0

447 Advanced diffusion imaging to track progression in Parkinson's disease, multiple system atrophy, and progressive supranuclear palsy.. **2022**, 34, 103022

0

446 Effect of *Lacticaseibacillus Paracasei* Strain Shirota Supplementation on Clinical Responses, Gut Microbiota and Faecal Metabolites in Patients with Parkinson's Disease: A Randomized, Double-Blind, Placebo-Controlled Trial.

0

445 How does prosodic deficit impact naïve listeners recognition of emotion? An analysis with speakers affected by Parkinson's disease. **2022**, 26, 102-125

0

444 Elevated β -synuclein and NfL levels in tear fluids and decreased retinal microvascular densities in patients with Parkinson's disease.. **2022**, 1

0

443 Non-motor symptoms fluctuations in patients with Parkinson's disease at the Clinical Hospital of Salvador, Bahia.

442 The effects of an individualized smartphone-based exercise program on self-defined motor tasks in Parkinson's disease: A pilot study (Preprint).

- 441 Aberrant changes of dynamic global synchronization in patients with Parkinson's disease.. **2022**, 2841851221094967
- 440 Exploring Perceptions of Cross-Sectoral Data Sharing with People with Parkinson's Disease.. **2022**, 14, 888942 0
- 439 Free-water imaging of the cholinergic basal forebrain and pedunculopontine nucleus in Parkinson's disease.. **2022**, 14, 888942 0
- 438 Tau protein quantification in skin biopsies differentiates tauopathies from alpha-synucleinopathies.. **2022**, 14, 888942 0
- 437 Polymorphisms of Cytochromes P450 and Glutathione S-Transferases Synergistically Modulate Risk for Parkinson's Disease.. **2022**, 14, 888942 0
- 436 From Perceived Stress to Demoralization in Parkinson Disease: A Path Analysis. **2022**, 13, 14, 888942 0
- 435 Nutritional Intake and Gut Microbiome Composition Predict Parkinson's Disease. **2022**, 14, 888942 1
- 434 Success of home-to-home tele-neuropsychology (TeleNP) in deep brain stimulation (DBS) candidacy assessments: COVID-19 and beyond.. **2022**, 98, 56-61
- 433 The Atrophy of the Vagus Nerve Correlated With Gastrointestinal Non-Motor Symptoms Scores, in Parkinson's Disease: A Sonography Research Study. 875647932210970
- 432 Caregiving concerns and clinical characteristics across neurodegenerative and cerebrovascular disorders in the ONDRI study. 0
- 431 Pallidal Structural Changes Related to Levodopa-induced Dyskinesia in Parkinson's Disease. **2022**, 14, 888942
- 430 Deep Brain Stimulation and Levodopa Affect Gait Variability in Parkinson Disease Differently.. **2022**, 14, 888942 0
- 429 Deficits in Emotion Recognition and Theory of Mind in Parkinson's Disease Patients With and Without Cognitive Impairments. **2022**, 13, 14, 888942 0
- 428 Unilateral GPi-DBS Improves Ipsilateral and Axial Motor Symptoms in Parkinson's Disease as Evidenced by a Brain Perfusion Single Photon Emission Computed Tomography Study. **2022**, 16, 17, 888942
- 427 Sleep disturbance and health-related quality of life in Parkinson's disease: A clear correlation between health-related quality of life and subjective sleep quality.. **2022**, 98, 86-91 0
- 426 Machine Learning Approach to Support the Detection of Parkinson's Disease in IMU-Based Gait Analysis. **2022**, 22, 3700 2
- 425 Improving Upper Extremity Bradykinesia in Parkinson's Disease: A Randomized Clinical Trial on the Use of Gravity-Supporting Exoskeletons.. **2022**, 11, 12, 888942
- 424 EEG Abnormalities During Delirium as a Prodromal Feature of Dementia with Lewy Bodies: A Case Report. **2022**, 6, 223-228

- 423 Parkinson's disease clinical milestones and mortality.. **2022**, 8, 58 ○
- 422 Depotentiation of associative plasticity is intact in Parkinson's disease with mild dyskinesia.. **2022**, 99, 16-22
- 421 Abnormal metabolic covariance patterns associated with multiple system atrophy and progressive supranuclear palsy.. **2022**, 98, 131-138 ○
- 420 The Potential Circular RNAs Biomarker Panel and Regulatory Networks of Parkinson's Disease. **2022**, 16, ○
- 419 Uit de kliniek: De patiënt met de ziekte van Parkinson aan het werk. **2009**, 17, 116-119
- 418 Comparison of the Results of a Parkinson's Holter Monitor With Patient Diaries, in Real Conditions of Use: A Sub-analysis of the MoMoPa-EC Clinical Trial. **2022**, 13, 1
- 417 The Gut Microbiome in Parkinson's Disease: A Longitudinal Study of the Impacts on Disease Progression and the Use of Device-Assisted Therapies. **2022**, 14, 1
- 416 Parkinson's Disease-Specific Autoantibodies against the Neuroprotective Co-Chaperone STIP1. **2022**, 11, 1649
- 415 An antisense Alu transposon insertion/deletion polymorphism of ALDH1A1 may functionally associate with Parkinson's disease.. **2022**, 22, 427 ○
- 414 Predictors of the change in burden, strain, mood, and quality of life among caregivers of Parkinson's disease patients. 2
- 413 Evolution of Prodromal REM Sleep Behavior Disorder to Neurodegeneration: A Retrospective, Longitudinal Case-control Study.. **2022**, 1
- 412 Clinical Aspects of the Differential Diagnosis of Parkinson's Disease and Parkinsonism.. **2022**, 18, 259-270 ○
- 411 Association of white matter lesions with orthostatic hypotension.. **2022**, 14, 2410-2418
- 410 Genetic Determinants of Survival in Parkinson's Disease in the Asian Population. ○
- 409 Safety and feasibility of fecal microbiota transplantation for Parkinson's disease patients: a protocol for a self-controlled interventional donor-FMT pilot study. ○
- 408 Daily Exercise Patterns and Their Differences between Parkinson's Disease Patients with and without Postural Instability. **2022**, 2022, 1-6
- 407 Pilates method for low back pain in individuals with Parkinson's disease: A feasibility study. **2022**,
- 406 Erfassung exekutiver Funktionsstörungen mit dem KÖber-Exekutiv-Test. **2022**, 33, 71-83

- 405 Glutamate cycle changes in the putamen of patients with de novo Parkinson's disease using 1H MRS. **2022**, 99, 65-72 0
- 404 Implications of Parkinson's Disease-Associated Alterations in the Oral and Gut Microbiome on Vitamin B $\frac{12}{6}$; Biosynthesis and Levodopa Bioavailability.
- 403 Heart-brain synchronization breakdown in Parkinson's disease. **2022**, 8,
- 402 Use of levodopa-carbidopa intestinal gel to treat patients with multiple system atrophy. **2022**, 0
- 401 Impaired Interhemispheric Synchrony in Parkinson's Disease with Fatigue. **2022**, 12, 884 0
- 400 Heterogeneity of PD-MCI in Candidates to Subthalamic Deep Brain Stimulation: Associated Cortical and Subcortical Modifications. **2022**, 1-20
- 399 Penetrance of Parkinson's disease LRRK2 G2385R-associated variant in the Chinese population. 1
- 398 A Pilot Randomized Controlled Trial Investigating MBSR for Parkinson's Disease Patients and Their Caregiving Partners: Effects on Distress, Social support, Cortisol, and Inflammation.
- 397 Factors associated with mortality in early stages of parkinsonism. **2022**, 8, 0
- 396 Detection and differentiation of ataxic and hypokinetic dysarthria in cerebellar ataxia and parkinsonian disorders via wave splitting and integrating neural networks. **2022**, 17, e0268337 0
- 395 Circulating microRNAs as potential biomarkers for the diagnosis of Parkinson's disease: A meta-analysis. **2022**,
- 394 Safety and efficacy of melatonin, clonazepam, and trazodone in patients with Parkinson's disease and sleep disorders: a randomized, double-blind trial. 1
- 393 Leucine-rich repeat kinase 2 (LRRK2): an update on the potential therapeutic target for Parkinson's disease. 1-10 0
- 392 Relationship between motor learning and gambling propensity in Parkinson's disease. 1-12
- 391 Interactions Across Emotional, Cognitive and Subcortical Motor Networks Underlying Freezing of Gait.
- 390 Objective Quantification of Responses to the Clinical Pull-Test in People with Parkinson's Disease.
- 389 Which Test Is the Best to Assess Visuo-Cognitive Impairment in Patients with Parkinson's Disease with Mild Cognitive Impairment and Dementia? A Systematic Review and Meta-Analysis. **2022**, 1-34 0
- 388 Mass Spectrometry-Based Analysis of Serum N-Glycosylation Changes in Patients with Parkinson's Disease. **2022**, 13, 1719-1726 1

- 387 The Weekly Calendar Planning Activity to Assess Functional Cognition in Parkinson Disease. 1539449222110400
- 386 Interventions for preventing falls in Parkinson's disease. **2022**, 2022, 0
- 385 Association of Structural Measurements of Brain Reserve With Motor Progression in Patients With Parkinson Disease. 10.1212/WNL.0000000000200814 0
- 384 The Effect of Cannabidiol for Restless Legs Syndrome/Willis-Ekbom Disease in Parkinson's Disease Patients with REM Sleep Behavior Disorder: A Post Hoc Exploratory Analysis of Phase 2/3 Clinical Trial.
- 383 Identifying Depression in Parkinson's Disease by Using Combined Diffusion Tensor Imaging and Support Vector Machine. 13, 1
- 382 Gray and white matter alterations in different predominant side and type of motor symptom in Parkinson's disease. 1
- 381 GuitarPD: A Randomized Pilot Study on the Impact of Nontraditional Guitar Instruction on Functional Movement and Well-Being in Parkinson's Disease. **2022**, 2022, 1-12
- 380 Polymorphism of neurodegeneration-related genes associated with Parkinson's disease risk. 0
- 379 Deficiency in endocannabinoid synthase DAGLB contributes to early onset Parkinsonism and murine nigral dopaminergic neuron dysfunction. **2022**, 13, 0
- 378 Angiotensin type-1 receptor and ACE2 autoantibodies in Parkinson's disease. **2022**, 8, 2
- 377 The Instrumental Activities of Daily Living in Parkinson's Disease Patients Treated by Subthalamic Deep Brain Stimulation. 14,
- 376 Reference Values for Dopamine Transporter Imaging With ^{99m}Tc-TRODAT-1 in Healthy Subjects and Parkinson's Disease Patients. Publish Ahead of Print,
- 375 Life-space mobility, balance and self-efficacy in Parkinson's disease: a cross-sectional study.
- 374 Cerebral blood flow alterations specific to freezing of gait in Parkinson's disease.
- 373 A 10-Year Community-Based Study of Leucine-Rich Repeat Kinase 2 G2385R Carriers' Conversion to Parkinson's Disease. 0
- 372 Cerebrospinal fluid levels of proenkephalin and prodynorphin are differentially altered in Huntington's and Parkinson's disease.
- 371 Diagnostic Performance for Differential Diagnosis of Atypical Parkinsonian Syndromes from Parkinson's Disease Using Quantitative Indices of ¹⁸F-FP-CIT PET/CT. **2022**, 12, 1402
- 370 Attentional focus effect on dual-task walking in Parkinson's disease with and without freezing of gait.

- 369 Insulin-like growth factor in Parkinson's disease is related to nonmotor symptoms and the volume of specific brain areas. **2022**, 783, 136735 1
- 368 Ketogenic therapy for Parkinson's disease: A systematic review and synthesis without meta-analysis of animal and human trials. **2022**, 163, 46-61 0
- 367 Polysomnographic and Clinical Parameters before and after Zonisamide Therapy for Parkinson's Disease. **2022**,
- 366 Functional training versus Mat Pilates in motor and non-motor symptoms of individuals with Parkinson's disease: study protocol for a randomized controlled trial. 28,
- 365 Evaluation of the Dementia Apraxia Test in Parkinson's Disease Patients. **2022**, 51, 271-278 1
- 364 Neural correlates of working memory and compensation at different stages of cognitive impairment in Parkinson's disease. **2022**, 35, 103100
- 363 Simulating the progression of brain structural alterations in Parkinson's disease. **2022**, 8, 1
- 362 Parkinsonian Syndromes in Motor Neuron Disease: A Clinical Study. 14, 0
- 361 Documentation and Diagnosis of Delirium in Parkinson's Disease.
- 360 Yerbamate Tea Consumption: A Protective Factor in Parkinson Disease. **2022**, 45, 79-83
- 359 STN-DBS does not increase the risk of sialorrhea in patients with advanced Parkinson's disease. **2022**, 8,
- 358 Cholinergic brain network deficits associated with vestibular sensory conflict deficits in Parkinson's disease: correlation with postural and gait deficits. 0
- 357 Use of deep learning-based radiomics to differentiate Parkinson's disease patients from normal controls: a study based on [18F]FDG PET imaging.
- 356 Automated Volumetric Determination of High R² * Regions in Substantia Nigra (SN): A Feasibility Study of Quantifying SN Atrophy in PSP. 0
- 355 Oral and gut dysbiosis leads to functional alterations in Parkinson's disease. **2022**, 8, 1
- 354 Dual task effect on upper and lower extremity skills in different stages of Parkinson's disease. 0
- 353 Association between Baseline Cognitive Score and Postoperative Delirium in Parkinson's Disease Patients following Deep Brain Stimulation Surgery. **2022**, 2022, 1-8
- 352 Association of Plasma and Electroencephalography Markers With Motor Subtypes of Parkinson's Disease. 14,

- 351 Predictors of health-related quality of life in Parkinson's disease: the impact of overlap between health-related quality of life and clinical measures.
- 350 TGFB1 rs8179181 polymorphism is reproducibly associated with Parkinson's disease in a Spanish population.
- 349 The Role of Parkinson Nurses for Personalizing Care in Parkinson's Disease: A Systematic Review and Meta-Analysis. **2022**, 1-25
- 348 A Critical Analysis of Intestinal Enteric Neuron Loss and Constipation in Parkinson's Disease. **2022**, 1-21 ○
- 347 Novel inflammasome and oxidative modulators in Parkinson's disease: A prospective study. **2022**, 786, 136768 ○
- 346 Evaluation of iron overload in nigrosome 1 via quantitative susceptibility mapping as a progression biomarker in prodromal stages of synucleinopathies. **2022**, 260, 119454 ○
- 345 Identification of metabolic correlates of mild cognitive impairment in Parkinson's disease using magnetic resonance spectroscopic imaging and machine learning.
- 344 Evaluation of the visual system with visual evoked potential and optical coherence tomography in patients with idiopathic Parkinson's disease and with multiple system atrophy. 1
- 343 Rare variant screening and burden analysis of PLXNA1 in Parkinson's Disease.
- 342 Integrated multi-cohort analysis of the Parkinson's disease gut metagenome.
- 341 Harmonic ratio is the most responsive trunk-acceleration derived gait index to rehabilitation in people with Parkinson's disease at moderate disease stages. **2022**, 1
- 340 New Targets and New Technologies in the Treatment of Parkinson's Disease: A Narrative Review. **2022**, 19, 8799 ○
- 339 Intermediate and Expanded HTT Alleles and the Risk for Synucleinopathies. ○
- 338 A multiple domain postural control assessment in people with Parkinson's disease: traditional, non-linear, and rambling and trembling trajectories analysis. **2022**,
- 337 Sleep spindle and slow wave activity in Parkinson disease with excessive daytime sleepiness. 1
- 336 The structural changes of gray matter in Parkinson disease patients with mild cognitive impairments. **2022**, 17, e0269787 ○
- 335 Is peripheral alpha synuclein a marker for gait velocity in Parkinson's disease?. **2022**, 786, 136819
- 334 Differential diagnosis of secondary parkinsonism in a complex clinical case in the city of Vladikavkaz. **2022**, 535-538

- 333 Identifying and validating subtypes of Parkinson's disease based on multimodal MRI data via hierarchical clustering analysis. 16, 0
- 332 Assessment of Vestibular-Evoked Myogenic Potentials in Parkinson's Disease: A Systematic Review and Meta-Analysis. **2022**, 12, 956
- 331 Feasibility and positive effects of scalp acupuncture for modulating motor and cerebral activity in Parkinson's disease: A pilot study. **2022**, 1-13, 0
- 330 Evaluation of the PREDIGT score's performance in identifying newly diagnosed Parkinson's patients without motor examination. **2022**, 8,
- 329 Decreased soluble Nogo-B in serum as a promising biomarker for Parkinson's disease. 16, 0
- 328 Adverse effects of levodopa/carbidopa intrajejunal gel treatment: A single-center long-term follow-up study. 0
- 327 First Two-Year Observational Exploratory Real Life Clinical Phenotyping, and Societal Impact Study of Parkinson's Disease in Emiratis and Expatriate Population of United Arab Emirates 2019-2021: The EmPark Study. **2022**, 12, 1300
- 326 Essential tremor-Parkinson's disease syndrome: clinical characteristics and subtypes using cluster analysis. Publish Ahead of Print,
- 325 A Mini-Mental State Examination Formula May Help to Distinguish Alzheimer's Disease from Dementia with Lewy Bodies. **2022**, 1-11
- 324 Association between LAG3/CD4 gene variants and risk of Parkinson's disease.
- 323 CSF levels of SNAP-25 are increased early in Creutzfeldt-Jakob and Alzheimer's disease. jnp-2021-328646 1
- 322 Increased phospho-AKT in blood cells from LRRK2 G2019S mutation carriers.
- 321 Vestibular Sensory Conflict During Postural Control, Freezing of Gait, and Falls in Parkinson's Disease.
- 320 Continuous theta burst stimulation over left supplementary motor area facilitates auditory-vocal integration in individuals with Parkinson's disease. 14, 0
- 319 Usability of Two New Interactive Game Sensor-Based Hand Training Devices in Parkinson's Disease. **2022**, 22, 6278
- 318 Stereotyped Relationship Between Motor and Cognitive Metabolic Networks in Parkinson's Disease. 0
- 317 Astrogliosis in aging and Parkinson's disease dementia: a new clinical study with 11C-BU99008 Positron Emission Tomography. 1
- 316 Striatal Hand Deformities in Parkinson's Disease: Hand Surgical Perspectives.

- 315 Serum metabolomic characterization of PLA2G6-associated dystoniaâParkinsonism: A case-control biomarker study. 16, 0
- 314 Immediate Effect of Augmented Reality, Virtual Reality, and Neurofunctional Physiotherapy on Postural Control and Executive Function of Individuals with Parkinson's Disease. 0
- 313 A task-specific cognitive domain decline is correlated with plasma and neuroimaging markers in patients with Parkinsonâ disease. 0
- 312 Validation of STOP, STOP-BANG, STOP-BAG, STOP-B28 and GOAL screening tools for identification of obstructive sleep apnea in patients with Parkinson disease. 0
- 311 Epigenetic Clock Acceleration Is Linked to Age at Onset of Parkinson's Disease. 1
- 310 Seasonal variations of nonmotor symptoms in patients with Parkinson's disease in Southeast China. Publish Ahead of Print, 0
- 309 Phase 1/1b Studies of UCB0599 , an Oral Inhibitor of ðsynuclein Misfolding, Including a Randomized Study in Parkinson's Disease. 1
- 308 Predicting Impulse Control Disorders in Parkinsonâ disease through incentive biomarkers. 0
- 307 The mutation spectrum of Parkinson-disease -related genes in early-onset Parkinson's disease in ethnic Chinese. 0
- 306 Prediction of Cognitive Degeneration in Parkinsonâ Disease Patients Using a Machine Learning Method. **2022**, 12, 1048 0
- 305 A Remote Longitudinal Observational Study of Individuals at Genetic Risk for Parkinson Disease. **2022**, 8, e200008 1
- 304 Identification and prediction of Parkinsonâ disease subtypes and progression using machine learning in two cohorts. 0
- 303 Can the prediction model using regression with optimal scale improve the power to predict the Parkinson's dementia?. **2022**, 12, 1031-1043 1
- 302 Altered Medial Prefrontal Connectivity in Parkinson's Disease Patients with Somatic Symptoms. 0
- 301 Balance Training Modulates Cortical Inhibition in Individuals with Parkinsonâ Disease: A Randomized Controlled Trial. 154596832211197 0
- 300 Prospective predictors of care partner burden and depression in Parkinson's disease. **2022**, 37, 0
- 299 The ability of patients with Parkinsonâ disease to recognize masked faces during the COVID-19 pandemic. 0
- 298 Oculomotor deficits in Parkinson's disease: Increasing sensitivity using multivariate approaches. 4, 0

- 297 Transcriptome deregulation of peripheral monocytes and whole blood in GBA-related Parkinson’s disease. **2022**, 17, ○
- 296 IN-HOME-PD: The effects of longitudinal telehealth-enhanced interdisciplinary home visits on care and quality of life for homebound individuals with Parkinson’s disease. **2022**, 102, 68-76 1
- 295 Decreased vestibular efficacy contributes to abnormal balance in Parkinson’s disease. **2022**, 440, 120357 ○
- 294 Identifying the white matter structural network of motor reserve in early Parkinson’s disease. **2022**, 102, 108-114 ○
- 293 Finger dexterity measured by the Grooved Pegboard test indexes Parkinson’s motor severity in a tremor-independent manner. **2022**, 66, 102695
- 292 The effect of age and disease duration on the efficacy of subthalamic nuclei deep brain stimulation in Parkinson’s disease patients. ○
- 291 Alterations of structure and functional connectivity of visual brain network in patients with freezing of gait in Parkinson’s disease. 14, ○
- 290 Incidental neuroimaging findings in South African adult research participants with and without neuropsychiatric disorders. **2022**, 2, 100130 ○
- 289 Sex modulates the outcome of subthalamic nucleus deep brain stimulation in patients with Parkinson’s disease. **2023**, 18, 901 ○
- 288 Translation, Cross-Cultural Adaptation, and Validation of the Physical Activity Scale for Individuals With Physical Disabilities for Brazilian Individuals With Parkinson’s Disease. **2022**, 1-7 ○
- 287 Parkinson’s Disease Detection Using Smartphone Recorded Phonemes in Real World Conditions. **2022**, 10, 97600-97609 ○
- 286 Time Taken for and Causes of a Decline to Hoehn and Yahr Stage 5 in Patients with Parkinson’s Disease. **2022**, ○
- 285 Vitamin D and other indicators of calcium-phosphorus metabolism as possible predictors of Parkinson’s disease. **2022**, 122, 56 ○
- 284 Stress system and related biomarkers in Parkinson’s disease. **2022**, 1
- 283 Cognitive correlates of dual tasking costs on the timed up and go test in Parkinson disease. **2022**, 7, 100158 ○
- 282 Breathing disorders in neurodegenerative diseases. **2022**, 223-239 ○
- 281 Widening spectrum of neuroleptic malignant syndrome: Case series. **2022**, 38, 309 ○
- 280 Effects of Health Qigong Exercise on Depression and Anxiety in Patients with Parkinson’s Disease. **2022**, 24, 855-867 ○

- 279 Is fatigue associated with balance in Parkinson's disease?. 28, 0
- 278 The effects of an individualized smartphone-based exercise program on self-defined motor tasks in Parkinson's disease: A pilot interventional study
Bradykinesia and rigidity are prototypical motor impairments of Parkinson's disease (PD) highly influencing everyday life. Exercise training is an effective treatment alternative for motor symptoms, complementing dopaminergic medication. High frequency training is necessary to yield clinically relevant improvements. Exercise programs need to be tailored to individuals. 0
- 277 Predicting cognitive decline in Parkinson's disease using FDG-PET based supervised learning. 0
- 276 Effect of Opicapone on Levodopa Pharmacokinetics in Patients with Fluctuating Parkinson's Disease. 2
- 275 Correlation of Serum Uric Acid with Cognition, Severity, and Stage of Disease in Patients with Idiopathic Parkinson's Disease and Vascular Parkinsonism: A Cross-Sectional Study. 2022, 16, 0
- 274 Medication adversely impacts visually-guided eye movements in Parkinson's disease. 2022, 0
- 273 Diet quality, sleep and quality of life in Parkinson's disease: a cross-sectional study. 1
- 272 Prevalence of lower urinary tract symptoms, urinary incontinence and retention in Parkinson's disease: A systematic review and meta-analysis. 14, 1
- 271 The effects of surface electrical stimulation plus voice therapy in Parkinson disease. 1-24 0
- 270 Prevalence of axial postural abnormalities and their subtypes in Parkinson's disease: a systematic review and meta-analysis. 0
- 269 Aberrant gray matter volume and functional connectivity in Parkinson's disease with minor hallucination. 14, 0
- 268 Blood based biomarkers for movement disorders. 2022, 146, 353-361 0
- 267 Freezing of Gait in Parkinson's Disease Patients Treated with Bilateral Subthalamic Nucleus Deep Brain Stimulation: A Long-Term Overview. 2022, 10, 2214 0
- 266 Multimodal striatal neuromarkers in distinguishing parkinsonian variant of multiple system atrophy from idiopathic Parkinson's disease. 0
- 265 Abnormal Cross Frequency Coupling of Brain Electroencephalographic Oscillations Related to Visual Oddball Task in Parkinson's Disease with Mild Cognitive Impairment. 155005942211287 0
- 264 The Forward and Lateral Tilt Angle of the Neck and Trunk Measured by Three-Dimensional Gait and Motion Analysis as a Candidate for a Severity Index in Patients with Parkinson's Disease. 2022, 14, 727-737 0
- 263 Initiating dopamine agonists rather than levodopa in early Parkinson's disease does not delay the need for deep brain stimulation. 0
- 262 Combination of Quantitative Susceptibility Mapping and Diffusion Kurtosis Imaging Provides Potential Biomarkers for Early-Stage Parkinson's Disease. 2022, 13, 2699-2708 0

- 261 Survival in patients with Parkinson's disease: a ten-year follow-up study in northern China. **2022**, 22, 1
- 260 Global Alterations of Whole Brain Structural Connectome in Parkinson's Disease: A Meta-analysis. 1
- 259 Impaired dynamic cerebral autoregulation: A potential mechanism of orthostatic hypotension and dementia in Parkinson's disease. 14, 0
- 258 Brain and systemic inflammation in de novo Parkinson's disease. 0
- 257 Relationship between Substantia Nigra Neuromelanin Imaging and Dual Alpha-Synuclein Labeling of Labial Minor in Salivary Glands in Isolated Rapid Eye Movement Sleep Behavior Disorder and Parkinson's Disease. **2022**, 13, 1715 1
- 256 *Agathobaculum butyriciproducens* Shows Neuroprotective Effects in a 6-OHDA-Induced Mouse Model of Parkinson's Disease. **2022**, 32, 1168-1177 0
- 255 Parkinsonics: A Randomized, Blinded, Cross-Over Trial of Group Singing for Motor and Nonmotor Symptoms in Idiopathic Parkinson Disease. **2022**, 2022, 1-14 0
- 254 Effect of cerebral small vessel disease on cognitive impairment in Parkinson's disease. 0
- 253 Cognitive Performance and Learning Parameters Predict Response to Working Memory Training in Parkinson's Disease. **2022**, 1-13 0
- 252 A literature review of online handwriting analysis to detect Parkinson's disease at an early stage. 0
- 251 Serotonin Transporter Imaging in Multiple System Atrophy and Parkinson's Disease. 0
- 250 Effects of LSVT-BIG via telerehabilitation on non-motor and motor symptoms and quality of life in Parkinson's disease. 0
- 249 Early Dysbiosis and Dampened Gut Microbe Oscillation Precede Motor Dysfunction and Neuropathology in Animal Models of Parkinson's Disease. **2022**, 1-18 0
- 248 Action observation and motor imagery have no effect on balance and freezing of gait in Parkinson's disease: a randomized controlled trial. 0
- 247 Resistance Training Combined with Balance or Gait Training for Patients with Parkinson's Disease: A Randomized Controlled Pilot Study. **2022**, 2022, 1-7 0
- 246 From anticipation to impulsivity in Parkinson's disease. **2022**, 8, 0
- 245 Immune system disruptions implicated in whole blood epigenome-wide association study of depression among Parkinson's disease patients. **2022**, 100530 0
- 244 The prevalence and associated factors of dysphagia in Parkinson's disease: A systematic review and meta-analysis. 13, 0

- 243 A Pilot Study about the Effectiveness of High-Dose Donepezil in Cognitive Function and Neuropsychiatric Symptoms in Parkinson's disease with Cognitive Impairment. ○
- 242 Actigraphy enables home screening of REM behavior disorder in Parkinson disease. ○
- 241 Mild cognitive impairment is associated with poor gait performance in patients with Parkinson's disease. 14, ○
- 240 Attentional Demand of Motor Speech Encoding: Evidence From Parkinson's Disease. 1-18 ○
- 239 Physical activity intensity is associated with cognition and functional connectivity in Parkinson's disease. **2022**, 104, 7-14 ○
- 238 Computerized analysis of speech and voice for Parkinson's disease: A systematic review. **2022**, 226, 107133 ○
- 237 Analysis of rs34637584 polymorphism in the LRRK2 gene in patients with Parkinson's disease. **2022**, 73, 33-37 ○
- 236 NigraNet: An automatic framework to assess nigral neuromelanin content in early Parkinson's disease using convolutional neural network. **2022**, 36, 103250 ○
- 235 Encoding type, medication, and deep brain stimulation differentially affect memory-guided sequential reaching movements in Parkinson's disease. 13, ○
- 234 Relevance of plasma biomarkers to pathologies in Alzheimer's disease, Parkinson's disease and frontotemporal dementia. **2022**, 12, ○
- 233 Dual-phase FP-CIT-PET and Cardiac MIBG of Parkinson's disease patients with GBA mutations: Evidence of the body-first type?. ○
- 232 Surgical Therapies for Parkinson Disease. **2022**, 28, 1301-1313 ○
- 231 Topological patterns of motor networks in Parkinson's disease with different sides of onset: A resting-state-informed structural connectome study. 14, ○
- 230 Nigral Iron Deposition Influences Disease Severity by Modulating the Effect of Parkinson's Disease on Brain Networks. **2022**, 1-14 ○
- 229 Differential cholinergic systems' changes in progressive supranuclear palsy versus Parkinson's disease: an exploratory analysis. ○
- 228 Identification of cholinergic centro-cingulate topography as main contributor to cognitive functioning in Parkinson's disease: Results from a data-driven approach. 14, ○
- 227 REDUCED POWER AND PHASE-LOCKING VALUES WERE ACCOMPANIED BY THALAMUS, PUTAMEN AND HIPPOCAMPUS ATROPHY IN PARKINSON'S DISEASE WITH MILD COGNITIVE IMPAIRMENT: AN EVENT-RELATED OSCILLATION STUDY. **2022**, ○
- 226 Abnormal brain activities in multiple frequency bands in Parkinson's disease with apathy. 16, ○

- 225 Altered dynamic functional network connectivity in levodopa-induced dyskinesia of Parkinson's disease. 0
- 224 A pilot trial of dopamine replacement for dynamic facial expressions in Parkinson's disease. 0
- 223 Specific pattern of linguistic impairment in Parkinson's disease patients with subjective cognitive decline and mild cognitive impairment predicts dementia. 1-9 0
- 222 Disrupted topological organization of resting-state functional brain networks in Parkinson's disease patients with glucocerebrosidase gene mutations. 0
- 221 Activities of Daily Living in Parkinson Disease. **2022**, 38, 285-295 0
- 220 Shrinkage of olfactory amygdala connotes cognitive impairment in patients with Parkinson's disease. 0
- 219 Split-Belt Treadmill Training to Improve Gait Adaptation in Parkinson's Disease. 0
- 218 Telehealth Transdiagnostic Cognitive Behavioral Therapy for Depression in Parkinson's Disease: A Pilot Randomized Controlled Trial. 1
- 217 Motor progression marker for newly diagnosed drug-naïve patients with Parkinson's disease: A resting-state functional MRI study. 0
- 216 Reproductive Lifespan and Motor Progression of Parkinson's Disease. **2022**, 11, 6163 0
- 215 Global, in situ analysis of the structural proteome in individuals with Parkinson's disease to identify a new class of biomarker. **2022**, 29, 978-989 1
- 214 Levodopa alters resting-state functional connectivity more selectively in Parkinson's Disease with freezing of gait. 0
- 213 Retinal microvasculature damage associated with orthostatic hypotension in Parkinson's disease. 0
- 212 Human Induced Pluripotent Stem Cell Phenotyping and Preclinical Modeling of Familial Parkinson's Disease. **2022**, 13, 1937 2
- 211 An integrated biometric voice and facial features for early detection of Parkinson's disease. **2022**, 8, 0
- 210 High frequency of Depressive Disorders and Suicidal Phenomena in Late-Stage Parkinson's Disease – A Cross-Sectional Study. 089198872211355 0
- 209 Identification of Drugs Associated with Lower Risk of Parkinson's Disease Using a Systematic Screening Approach in a Nationwide Nested Case-Control Study. Volume 14, 1217-1227 0
- 208 The relationship between meaning in life and apathy in people with Parkinson's disease: a cross-sectional analysis. 0

- 207 Diagnostic value of β -synuclein seeding amplification assays in β -synucleinopathies: A systematic review and meta-analysis. **2022**, 2
- 206 Muscle Strength and Power in People With Parkinson Disease: A Systematic Review and Meta-analysis. Publish Ahead of Print, 0
- 205 Putamen Atrophy Is a Possible Clinical Evaluation Index for Parkinson's Disease Using Human Brain Magnetic Resonance Imaging. **2022**, 8, 299 0
- 204 Brain network characteristics and cognitive performance in motor subtypes of Parkinson's disease: A resting state fMRI study. **2022**, 105, 32-38 0
- 203 Altered brain iron depositions from aging to Parkinson's disease and Alzheimer's disease: A quantitative susceptibility mapping study. **2022**, 264, 119683 0
- 202 The c-Abl/p73 pathway induces neurodegeneration in a Parkinson's disease model. **2022**, 13, 378-387 0
- 201 Incidence of cataract surgeries in relation to diagnosis of Parkinson's disease. **2023**, 104, 104842 0
- 200 Treatment of Parkinson's Disease: Early, Late, and Combined. **2022**, 2891-2915 0
- 199 Pharmacotherapy of Psychosis in Parkinson's Disease. **2022**, 4231-4269 0
- 198 Objective and self-perceived lower limb weakness in Parkinson's disease. **2022**, 15, 175628642211369 0
- 197 Molecular imaging evidence in favor or against PDD and DLB overlap. **2023**, 275-295 0
- 196 Plasma p-tau181, neurofilament light chain and association with cognition in Parkinson's disease. **2022**, 8, 0
- 195 APDM gait and balance measures fail to predict symptom progression rate in Parkinson's disease. 13, 0
- 194 The mechanism of exercise for pain management in Parkinson's disease. 15, 0
- 193 APOE E4 is associated with impaired self-declared cognition but not disease risk or age of onset in Nigerians with Parkinson's disease. **2022**, 8, 0
- 192 Oral ENT-01 Targets Enteric Neurons to Treat Constipation in Parkinson Disease. 1 0
- 191 Correlation between serum IGF-1 and EGF levels and neuropsychiatric and cognitive in Parkinson's disease patients. 0
- 190 Multimodal visual system analysis as a biomarker of visual hallucinations in Parkinson's disease. 0

- 189 Attentional impairment in Parkinson's disease is modulated by side of onset: neurophysiological evidence. **2022**,
- 188 Socially Assistive Robots for Parkinson's Disease: Needs, Attitudes and Specific Applications as Identified by Healthcare Professionals.
- 187 Microstructural but not macrostructural cortical degeneration occurs in Parkinson's disease with mild cognitive impairment. **2022**, 8,
- 186 Quantitative Susceptibility Mapping and Free Water Imaging of Substantia Nigra in Parkinson's Disease. **2022**, 1-10
- 185 Cognitive Digital Intervention for Older Patients with Parkinson's Disease during COVID-19: A Mixed-Method Pilot Study. **2022**, 19, 14844
- 184 Machine learning based risk prediction for Parkinson's disease with nationwide health screening data. **2022**, 12,
- 183 Preliminary Effects of Osteopathic Manipulative Medicine on Reactive Oxygen Species in Parkinson's Disease: A Randomized Controlled Pilot Study. **2022**,
- 182 The Thr105Ile Variant (rs11558538) in the Histamine N-Methyltransferase Gene May Be Associated with Reduced Risk of Parkinson's Disease: A Meta-analysis.
- 181 Analysis of handgrip strength, pulling force using the upper limbs, and ground reaction forces in the task of boarding a bus between healthy elderly individuals and those with Parkinson's disease. 1-10
- 180 Dysphagia for medication in Parkinson's disease. **2022**, 8,
- 179 Deep learning signature of brain [18F]FDG PET associated with cognitive outcome of rapid eye movement sleep behavior disorder. **2022**, 12,
- 178 Mass Spectrometry-Based Proteomics Analysis of Human Substantia Nigra From Parkinson's Disease Patients Identifies Multiple Pathways Potentially Involved in the Disease. **2023**, 22, 100452
- 177 Speech temporal organization in three basal ganglia-related neurological conditions. **2022**, 38,
- 176 Severity of depressive and motor symptoms impacts quality of life in Parkinson's disease patients at an academic movement clinic: A cross-sectional study. **2023**, 8, 100180
- 175 Impact of long-term care insurance on medical costs and utilization by patients with Parkinson's disease. **2023**, 317, 115563
- 174 White matter hyperintensity presence, quantity, and location exhibits no association with motor and non-motor manifestations of PD. **2023**, 106, 105245
- 173 Proximity to residential and workplace pesticides application and the risk of progression of Parkinson's diseases in Central California. **2023**, 864, 160851
- 172 Parkinson's disease: Pathology and treatment. **2022**,

- 171 Tratamento da demência: recomendações do Departamento Científico de Neurologia Cognitiva e do Envelhecimento da Academia Brasileira de Neurologia. **2022**, 16, 88-100 ○
- 170 Diagnóstico e manejo da demência da doença de Parkinson e demência com corpos de Lewy: recomendações do Departamento Científico de Neurologia Cognitiva e do Envelhecimento da Academia Brasileira de Neurologia. **2022**, 16, 73-87 ○
- 169 Diagnosis and management of Parkinsonian disease dementia and dementia with Lewy bodies: recommendations of the Scientific Department of Cognitive Neurology and Aging of the Brazilian Academy of Neurology. **2022**, 16, 73-87 ○
- 168 Treatment of dementia: recommendations of the Scientific Department of Cognitive Neurology and Aging of the Brazilian Academy of Neurology. **2022**, 16, 88-100 ○
- 167 A Case Report of a Patient with Parkinsonian Disease Treated with Acupuncture and Exercise Therapy. **2022**, 43, 1018-1028 ○
- 166 Test-Retest Reliability and Criterion Validity of the Spanish Version of Two Motor Imagery Questionnaires in People With Parkinson Disease. **2023**, 47, 35-43 ○
- 165 Dual-task walking improvement with enhanced kinesthetic awareness in Parkinsonian disease with mild gait impairment: EEG connectivity and clinical implication. 14, ○
- 164 Progression of regional cortical cholinergic denervation in Parkinsonian disease. **2022**, 4, ○
- 163 Visinin-like protein 1 levels in blood and CSF as emerging markers for Alzheimerian and other neurodegenerative diseases. **2022**, 14, ○
- 162 Early Diagnosis of Parkinsonian Disease: Utility of Animal Models. ○
- 161 Transporter Single Photon Emission Computed Tomography (DaT-SPECT) use in The Diagnosis and Clinical Management of Parkinsonism: An Eight-Year Retrospective Study. ○
- 160 A Novel Trial of Mirabegron and Behavioral Modification Including Pelvic Floor Exercise for Overactive Bladder in Parkinson's Disease (MAESTRO). **2022**, ○
- 159 Technology assisted cognitive-motor dual-task rehabilitation in chronic age-related conditions: a systematic review (Preprint). ○
- 158 Mental imagery content is associated with disease severity and specific brain functional connectivity changes in patients with Parkinsonian disease. ○
- 157 A meta-analysis of the diagnostic utility of biomarkers in cerebrospinal fluid in Parkinsonian disease. **2022**, 8, ○
- 156 Particularités de la Maladie de Parkinson de la personne âgée : expérience du service de gériatrie de Fann ^ Dakar (Shgal). **2022**, ○
- 155 Impact of Gastrointestinal Symptoms on Health-Related Quality of Life in an Australian Parkinsonian Disease Cohort. **2022**, 2022, 1-8 ○
- 154 Detecting Parkinsonian disease and its cognitive phenotypes via automated semantic analyses of action stories. **2022**, 8, ○

- 153 Early-Onset Parkinson's Disease: Creating the Right Environment for a Genetic Disorder. **2022**, 12, 2353-2367 ○
- 152 Neural substrates in Parkinson's Disease psychosis: A systematic review. ○
- 151 Association of Depression With Early Occurrence of Postural Instability in Parkinson's Disease. ○
- 150 Genome-wide association study of REM sleep behavior disorder identifies polygenic risk and brain expression effects. **2022**, 13, 1 ○
- 149 Chronic Pain And Levodopa Therapy in Parkinson's Disease Patients. **2022**, 16, ○
- 148 Comparative efficacy and safety of monoamine oxidase type B inhibitors plus channel blockers and monoamine oxidase type B inhibitors as adjuvant therapy to levodopa in the treatment of Parkinson's disease: a network meta-analysis of randomized controlled trials. ○
- 147 Identification and prediction of Parkinson's disease subtypes and progression using machine learning in two cohorts. **2022**, 8, ○
- 146 Cortical and subcortical morphological alterations in motor subtypes of Parkinson's disease. **2022**, 8, ○
- 145 Feasibility of a Novel Therapist-Assisted Feedback System for Gait Training in Parkinson's Disease. **2023**, 23, 128 ○
- 144 Predictors of Falls with Injuries in People with Parkinson's Disease. ○
- 143 Alterations of Regional Homogeneity in Parkinson's Disease with Rapid Eye Movement Sleep Behavior Disorder. Volume 18, 2967-2978 ○
- 142 Hippocampal, basal ganglia and olfactory connectivity contribute to cognitive impairments in Parkinson's disease. ○
- 141 UQCRC1 variants in early-onset and familial Parkinson's disease in a Taiwanese cohort. 13, ○
- 140 Association between NOTCH3 gene and Parkinson's disease based on whole-exome sequencing. 14, ○
- 139 Recent hospitalization and risk of antidepressant initiation in people with Parkinson's disease. **2022**, 22, ○
- 138 Brain and Cerebrospinal Fluid α -Synuclein Real-Time Quaking-Induced Conversion Identifies Lewy Body Pathology in LRRK2-PD. ○
- 137 Telehealth For Individuals with Parkinson's Disease During Covid-19 In Brazil: A Prospective Case Series. **2022**, 14, ○
- 136 Experience of diagnosis and managements for patients with primary progressive freezing of gait. **2022**, 100039 ○

- 135 Telerehabilitation during social distancing for people with Parkinson's disease: a retrospective study. ○
- 134 Effect of Upper Limb Motor Rehabilitation on Cognition in Parkinson's Disease: An Observational Study. **2022**, 12, 1684 ○
- 133 The mortality of patients with Parkinson's disease with deep brain stimulation. 13, ○
- 132 Atrophy of the cholinergic basal forebrain can detect presynaptic cholinergic loss in Parkinson's disease. ○
- 131 Feasibility of a combined intermittent theta-burst stimulation and video game-based dexterity training in Parkinson's disease. **2023**, 20, ○
- 130 An explainable spatial-temporal graphical convolutional network to score freezing of gait in parkinsonian patients. 1
- 129 Clinical determinants of apathy and its impact on health-related quality of life in early Parkinson disease. **2023**, 102, e32674 ○
- 128 Faecal metabolite deficit, gut inflammation and diet in Parkinson's disease: Integrative analysis indicates inflammatory response syndrome. **2023**, 13, ○
- 127 Neuropsychological Changes in Isolated REM Sleep Behavior Disorder: A Systematic Review and Meta-analysis of Cross-sectional and Longitudinal Studies. ○
- 126 Physical exercise for people with Parkinson's disease: a systematic review and network meta-analysis. **2023**, 2023, 1
- 125 Ultrasound of the Biceps Muscle in Idiopathic Parkinson's Disease with Deep Brain Stimulation: Rigidity Can Be Quantified by Shear Wave Elastography. **2023**, 13, 213 ○
- 124 Role of serotonin in modulation of decision-making in Parkinson's disease. 026988112211446 ○
- 123 The effects of synbiotic supplementation on oxidative stress markers, mental status, and quality of life in patients with Parkinson's disease: A double-blind, placebo-controlled, randomized controlled trial. **2023**, 100, 105397 ○
- 122 Changes in Principal Caregiver Mood Affects the Mood of the Parkinson's Disease Patient: The Vicious Cycle of Illness. **2023**, 1-13 ○
- 121 Quality of life: Seasonal fluctuation in Parkinson's disease. 13, ○
- 120 Parkinson's Disease-Cognitive Rating Scale (PD-CRS): normative data and mild cognitive impairment assessment in Brazil. ○
- 119 Understanding the Impact of Occupational Stress on the Home Environment: Evidence from Oman. 231971452&11320
- 118 Effect of aquatic exercise programs according to the International Classification of Functionality, Disability and Health domains in individuals with Parkinson's disease: a systematic review and meta-analysis with GRADE quality assessment. 1-14 ○

- 117 Deep brain stimulation and dopamine medication enhance free choice preference in Parkinson's disease. ○
- 116 Electroacupuncture for motor dysfunction and constipation in patients with Parkinson's disease: a randomised controlled multi-centre trial. **2023**, 56, 101814 ○
- 115 Cross-sectional proteomic expression in Parkinson's disease-related proteins in drug-naïve patients vs healthy controls with longitudinal clinical follow-up. **2023**, 177, 105997 ○
- 114 Structural and metabolic correlates of neuropsychological profiles in multiple system atrophy and Parkinson's disease. **2023**, 107, 105277 ○
- 113 Linking acetylated α -tubulin redistribution to α -synuclein pathology in brain of Parkinson's disease patients. ○
- 112 Factors Influencing Driving following DBS Surgery in Parkinson's Disease: A Single UK Centre Experience and Review of the Literature. **2023**, 12, 166 ○
- 111 Impact of LSVT-BIG on functional mobility, walking, dexterity, and quality of life in Parkinson's disease. **2022**, 47, 1738-1745 ○
- 110 Cross-cultural validation of the Cebuano version of a screening questionnaire for Parkinson's disease. **2022**, 80, 1239-1245 ○
- 109 Striatal Dopaminergic Loss and Dysphagia in Parkinson Disease. **2023**, 48, 143-149 ○
- 108 Feasibility of Combining Disease-Specific and Balance-Related Measures as Risk Predictors of Future Falls in Patients with Parkinson's Disease. **2023**, 12, 127 ○
- 107 Parkinson's disease fluid biomarkers for differential diagnosis of atypical parkinsonian syndromes. **2023**, 3, 1
- 106 Parkinson disease. **2023**, 549-552 ○
- 105 Risk of Cognitive Impairment in Patients With Parkinson's Disease With Visual Hallucinations and Subjective Cognitive Complaints. 19, ○
- 104 The effect of whole body vibration on gait stability in individuals with Parkinson's disease: a preliminary study. **2023**, 30, 1-13 ○
- 103 Levodopa-induced Dyskinesia - Plausible Inflammatory and Oxidative Stress Biomarkers. 1-15 ○
- 102 ANXA1 mutation analysis in Italian patients with early onset PD. **2023**, ○
- 101 Interactions across emotional, cognitive and subcortical motor networks underlying freezing of gait. **2023**, 37, 103342 ○
- 100 Low Levels of Adenosine and GDNF Are Potential Risk Factors for Parkinson's Disease with Sleep Disorders. **2023**, 13, 200 ○

- 99 Dopamine transporter SPECT imaging in Parkinson's disease and atypical Parkinsonism: a study of 137 patients. ○
- 98 Altered gut microbiota in patients with idiopathic Parkinson's disease: an age-sex matched case-control study. ○
- 97 Characteristics of behavioural addiction in Parkinson's disease patients with self-reported impulse control disorder and controls matched for levodopa equivalent dose: a matched case-control study. **2023**, 130, 125-133 ○
- 96 Plasma extracellular vesicle tau, β amyloid, and β synuclein and the progression of Parkinson's disease: a follow-up study. **2023**, 16, 175628642211503 ○
- 95 Stroke in Parkinson's disease: a review of epidemiological studies and potential pathophysiological mechanisms. ○
- 94 Technology assisted cognitive-motor dual-task rehabilitation in chronic age-related conditions: a systematic review (Preprint). ○
- 93 Sequential production of motor-action verb subtypes in Parkinson's disease patients. 17, ○
- 92 The theoretical problems of "prodrome" and "phenconversion" in neurodegeneration. **2023**, 155-167 ○
- 91 Influence of cognitive reserve on cognitive and motor function in β synucleinopathies: A systematic review protocol. **2023**, 1522, 15-23 ○
- 90 Acute effects of transcranial direct current stimulation combined with physical therapy on the balance and gait in individuals with Parkinson's disease: A randomized controlled trial. **2023**, 226, 107604 ○
- 89 Transcranial direct current stimulation enhances motor learning in Parkinson's disease: a randomized controlled trial. ○
- 88 Brainstem neuromelanin and iron MRI reveals a precise signature for idiopathic and LRRK2 Parkinson's disease. **2023**, 9, ○
- 87 Non-motor effects of deep brain stimulation in Parkinson's disease motor subtypes. **2023**, 109, 105318 ○
- 86 Levodopa responsive freezing of gait is associated with reduced norepinephrine transporter binding in Parkinson's disease. **2023**, 179, 106048 ○
- 85 Presence but not the timing of onset of REM sleep behavior disorder distinguishes evolution patterns in Parkinson's disease. **2023**, 180, 106084 ○
- 84 (A)symmetry during gait initiation in people with Parkinson's disease: A motor and cortical activity exploratory study. 15, ○
- 83 Evoked resonant neural activity in subthalamic local field potentials reflects basal ganglia network dynamics. **2023**, 178, 106019 ○
- 82 Aberrant inter-network functional connectivity in drug-naive Parkinson's disease patients with tremor dominant and postural instability and gait difficulty. 17, ○

- 81 Differential serum microRNAs in premotor LRRK2 G2019S carriers from Parkinson's disease. **2023**, 9, ○
- 80 Fluphenazine-Induced Neurotoxicity with Acute Almost Transient Parkinsonism and Permanent Memory Loss: Lessons from a Case Report. **2023**, 24, 2968 ○
- 79 Safety and tolerability of adjunct non-invasive vagus nerve stimulation in people with parkinson's: a study protocol. **2023**, 23, ○
- 78 The Lived Experience of Caregiving and Perception of Service Provision among Family-Caregivers of People with Late-Stage Parkinson's: A Qualitative Study. **2023**, 2023, 1-12 ○
- 77 An Explainable Spatial-Temporal Graphical Convolutional Network to Score Freezing of Gait in Parkinsonian Patients. **2023**, 23, 1766 ○
- 76 Ambient Factors in Parkinson's Disease Progression: A Systematic Review. **2023**, 59, 294 1
- 75 At-home assessment of postural stability in parkinson's disease: a vision-based approach. ○
- 74 Gut microbiota of Parkinson's disease in an appendectomy cohort: a preliminary study. **2023**, 13, ○
- 73 Classification and staging of Parkinson's disease using video-based eye tracking. **2023**, 105316 ○
- 72 Orthostatic Hypotension Is a Predictor of Fatigue in Drug-Naïve Parkinson's Disease. **2023**, 2023, 1-6 ○
- 71 Genome-wide association study using whole-genome sequencing identifies risk loci for Parkinson's disease in Chinese population. **2023**, 9, ○
- 70 Quantifying Impairments in Swallowing Safety and Efficiency in Progressive Supranuclear Palsy and Parkinson's Disease. ○
- 69 Cerebral Small Vessel Disease Progression Increases Risk of Incident Parkinsonism. ○
- 68 Plasma GFAP in Parkinson's disease with cognitive impairment and its potential to predict conversion to dementia. **2023**, 9, ○
- 67 The challenging quest of neuroimaging: From clinical to molecular-based subtyping of Parkinson disease and atypical parkinsonisms. **2023**, 231-258 ○
- 66 Can we add whey protein supplementation in patients with Parkinson's disease without interfering with levodopa response?. 1-5 ○
- 65 Detection of ATXN2 Expansions in an Exome Dataset: An Underdiagnosed Cause of Parkinsonism. **2023**, 10, 664-669 ○
- 64 Healthy lifestyles and wellbeing reduce neuroinflammation and prevent neurodegenerative and psychiatric disorders. 17, ○

- 63 Dopamine transporter single photon emission computed tomography (DaT-SPECT) use in the diagnosis and clinical management of parkinsonism: an 8-year retrospective study. ○
- 62 Leveraging the regulatory framework to facilitate drug development in Parkinson's disease. **2023**, 347-360 ○
- 61 Quantitative Seed Amplification Assay: A Proof-of-Principle Study. **2023**, 127, 1735-1743 ○
- 60 Imaging in Movement Disorders. **2023**, 29, 194-218 ○
- 59 An open label, non-randomized study assessing a prebiotic fiber intervention in a small cohort of Parkinson's disease participants. **2023**, 14, ○
- 58 Differing Patterns of Diurnal Variation and Impact of Antacids on Levodopa Pharmacokinetics in Patients with Parkinson's Disease. **2023**, 54, 3-8 ○
- 57 Functional and structural alterations as diagnostic imaging markers for depression in de novo Parkinson's disease. 17, ○
- 56 The Relationship between Visual-Evoked Potential and Optic Coherence Tomography and Clinical Findings in Parkinson Patients. **2023**, 2023, 1-11 ○
- 55 Evaluating the association between DNM1L variants and Parkinson's disease in the Chinese population. 14, ○
- 54 Home calligraphic exercises as manual dexterity training in patients with Parkinson's disease: a pilot feasibility study. 1-5 ○
- 53 Is Disrupted Mitophagy a Central Player to Parkinson's Disease Pathology?. **2023**, ○
- 52 Relationship between [123I]FP-CIT SPECT data and peripheral CD4 + T cell profile in newly-diagnosed drug-naïve Parkinson's disease patients. ○
- 51 Multiple system atrophy. **2023**, 123, 144 ○
- 50 Efficacy of herbal medicine treatment based on syndrome differentiation for Parkinson's disease: A systematic review and meta-analysis of randomized placebo-controlled clinical trials. 14, ○
- 49 Brain and Systemic Inflammation in De Novo Parkinson's Disease. ○
- 48 The FACE test: a new neuropsychological task to assess the recognition of complex mental states from faces. ○
- 47 Sex differences in gastrointestinal dysfunction among patients with Parkinson's disease. ○
- 46 Comparative validation of AI and non-AI methods in MRI volumetry to diagnose Parkinsonian syndromes. **2023**, 13, ○

- 45 Fecal microbiota transplantation in Parkinson's disease—a randomized repeat-dose, placebo-controlled clinical pilot study. 14,
- 44 Synuclein Seed Amplification Assays in the Diagnosis of Synucleinopathies Using Cerebrospinal Fluid—a Systematic Review and Meta-Analysis.
- 43 Whole-genome sequencing reveals an association between small genomic deletions and an increased risk of developing Parkinson's disease. **2023**, 55, 555-564
- 42 Genetic impacts on nigral iron deposition in Parkinson's disease: A preliminary quantitative susceptibility mapping study.
- 41 Correlations between cerebrospinal fluid homovanillic acid and dopamine transporter SPECT in degenerative parkinsonian syndromes. **2023**, 130, 513-520
- 40 Quantitative and causal analysis for inflammatory genes and the risk of Parkinson's disease. 14,
- 39 Amplitude of low-frequency fluctuation-based regional radiomics similarity network: Biomarker for Parkinson's disease. **2023**, 9, e14325
- 38 Gene-wide significant association analyses of DNMT1 genetic variants with Parkinson's disease. 14,
- 37 Muscle shape changes in Parkinson's disease impair function during rapid contractions.
- 36 Staging Parkinson's Disease According to the MNCD (Motor/Non-motor/Cognition/Dependency) Classification Correlates with Disease Severity and Quality of Life. **2023**, 1-24
- 35 MerTK mediates the immunologically silent uptake of alpha-synuclein fibrils by human microglia.
- 34 Central retinal microvasculature damage is associated with orthostatic hypotension in Parkinson's disease. **2023**, 9,
- 33 Imagined Timed Up and Go test (iTUG) in people with Parkinson's Disease: test-retest reliability and validity. 1-11
- 32 Cytokine profiles of plasma extracellular vesicles as progression biomarkers in Parkinson's disease.
- 31 Incidence and outcomes of head injuries in people with and without Parkinson disease.
- 30 Low serum uric acid levels and levodopa-induced dyskinesia in Parkinson's disease. **2023**, 81, 040-046
- 29 Pharmacological and Behavioral Interventions for Fatigue in Parkinson's Disease: A Meta-Analysis of Randomized Controlled Trials. 089198872311632
- 28 The Assessment of the Diagnostic Delay in Japanese People with Parkinson's Disease Using a Web-based Survey of Patients and Physicians. **2023**, 62, 839-847

- 27 Mobile Applications for Resting Tremor Assessment in Parkinson's Disease: A Systematic Review. **2023**, 12, 2334 ○
- 26 Does one session of dry needling effect vital capacity in people with Parkinsons Disease?. ○
- 25 Clinical Utility of Plantar Pressure Measurements as Screening in Patients With Parkinson Disease With and Without Freezing of Gait History. **2023**, ○
- 24 Cognitive evaluation in Parkinson's disease: applying the Movement Disorder Society recommendations in a population with a low level of formal education. **2023**, 81, 119-127 ○
- 23 Long-Term Effects of Subthalamic Stimulation on Motor Symptoms and Quality of Life in Patients with Parkinson's Disease. **2023**, 11, 920 ○
- 22 Increased depressive symptoms in Parkinson's disease during the COVID-19 pandemic: Preliminary findings from longitudinal analysis of the PHASE study. **2023**, 8, 100194 ○
- 21 Quick computer aided differential diagnostics based on repetitive finger tapping in Parkinson's disease and atypical parkinsonisms. **2023**, 9, e14824 ○
- 20 Neuropsychological evaluation of phenoconversion risk in REM sleep behaviour disorder: A scoping review. ○
- 19 MAPTallele and haplotype frequencies in Nigerian Africans: population distribution and association with Parkinson's disease risk and age at onset. ○
- 18 The evolution of diagnosis from symptom onset to death in progressive supranuclear palsy (PSP) and corticobasal degeneration (CBD) compared to Parkinson's disease (PD). ○
- 17 Interplay between speech and gait variables in Parkinson's disease patients treated with subthalamic nucleus deep brain stimulation: A long-term instrumental assessment. ○
- 16 Severity of REM sleep without atonia correlates with measures of cognitive impairment and depressive symptoms in REM sleep behaviour disorder. ○
- 15 Circular RNAs in the human brain are tailored to neuron identity and neuropsychiatric disease. ○
- 14 Prevalence and Factors Associated with Drooling in Parkinson's Disease: Results from a Longitudinal Prospective Cohort and Comparison with a Control Group. **2023**, 2023, 1-18 ○
- 13 Association between Cognitive Impairment and Freezing of Gait in Patients with Parkinson's Disease. **2023**, 12, 2799 ○
- 12 Association of dysphagia with altered brain glucose metabolism in Parkinson's disease. ○
- 11 Upregulation of APAF1 and CSF1R in Peripheral Blood Mononuclear Cells of Parkinson's Disease. **2023**, 24, 7095 ○
- 10 The impact of the COVID-19 pandemic on neuropsychiatric and sleep disorders, and quality of life in individuals with neurodegenerative and demyelinating diseases: a systematic review and meta-analysis of observational studies. **2023**, 23, ○

- 9 Comparison of resting tremor at the upper limb joints between patients with Parkinson's disease and scans without evidence of dopaminergic deficit. **2023**, 1-9
- 8 The Clinical Diagnosis of Parkinson's Disease We Are Getting Better. **2023**, 38, 515-517
- 7 Automatic segmentation and quantification of nigrosome-1 neuromelanin and iron in MRI: a candidate biomarker for Parkinson's disease.
- 6 A non-expensive bidimensional assessment can detect subtle alterations in gait performance in people in the early stages of Parkinson's disease. 14,
- 5 Visual dysfunction is a better predictor than retinal thickness for dementia in Parkinson's disease. jnp-2023-381083
- 4 Effectiveness of Center of Pressure Trajectory as Anticipatory Postural Adjustment Measurement in Parkinson's Disease With Freezing of Gait History. 154596832311669
- 3 Validation of Commercial Activity Trackers in Everyday Life of People with Parkinson's Disease. **2023**, 23, 4156
- 2 Suicidal ideation among people with Parkinson's disease and comparison with a control group. **2023**, 38,
- 1 Genome-wide Association Identifies Novel Etiological Insights Associated with Parkinson's Disease in African and African Admixed Populations.